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Through the ages the viruses have plagued mankind claiming the lives of millions, pre-dating 
any advancements in the medicinal sciences.  One such pathogenic virus is influenza A, which 
has been implicated in the 1918-Spanish flu, the 2006-avian flu outbreak and the 2009-swine 
flu pandemic.  It is a highly sophisticated species, alluding efforts to thwart the spread of 
disease and infection.  One of the main reasons influenza has survived this long is simple 
evolution.  Natural mutation within the genome of virions expressed in proteins, enzymes or 
molecular structure render us unable to predict or take preventative measures against possible 
infection.  Thus, research efforts toward the competitive inhibition of biological pathways that 
lead to the spread of disease, have become attractive targets.   
The influenza A virus has a number of chemotherapeutic targets, such as:  
1) The surface antigens, hemagglutinin and neuraminidase,  
2) RNA-dependent RNA polymerase, and 
3) The M2 proton channel. 
Influenza RNA polymerase is composed of three large segments encoding polymerase acidic 
protein (PA), polymerase basic protein 1 (PB1) and polymerase basic protein 2 (PB2).  The  
PA protein is an N-terminal domain subunit which contains the endonuclease activity.  The 
influenza virus is incapable of synthesizing a 5’-mRNA cap, so it has adapted a cap-snatching 
mechanism whereby the PB2 subunit binds to the 5’-end of host mRNA, after which 10-14 
nucleotides downstream the PA-subunit (aka PAN) cleaves the strand forming a primer for viral 
mRNA synthesis which is catalysed by the PB1 subunit.  Influenza target identification is based 
primarily on evidence suggesting sequence conservation of each entity and its selective 
expression in the virus and not the host. 
In this thesis two enzymatic targets were investigated, the PA protein of RNA polymerase and 
neuraminidase.  The studies focussed on using computational tools to: 
1) provide insight into the mechanism of drug-resistance,  
2) describe the conformational structure of the protein in the presence of point mutations 
and in complex with an inhibitor, 




An array of computational techniques were employed in the studies, such as: molecular 
dynamics (MD) simulation, structure-based and ligand-based in silico screening, principal 
component analysis, radius of gyration analysis, binding free energy calculations and solvent-
accessible surface area analysis. 
The first study (Chapter 5) determined the mechanism of drug-resistance in influenza A 
neuraminidase as a consequence of antigenic variations.  Two distinct mutations in the enzyme 
sequence that were investigated are H274Y and I222K.  The active site residues of 
neuraminidase are conserved among the subtypes of influenza A.  However, it was discovered 
that the occurrence of resistance to the drug oseltamivir, in the H1N1 species was different to 
the H5N1 virus.  Although both systems shared a loss in hydrophobicity of the active site, the 
conformational distortion of the active site pocket distinguished the enzyme of the two viral 
entities, from one another. 
The discoveries made in the first study laid the foundation for the second study (Chapter 6), 
which was based on the in silico design and screen of potential neuraminidase inhibitors.  As 
a result 10 characteristic molecular scaffolds were suggested as potential inhibitors.  The 
pharmacophore design was constructed with consideration to the new conformational structure 
of the active site pocket. 
Chapter 7 is the third study of this thesis.  The active site pocket enclosing the endonuclease 
activity of the PA subunit was investigated.  Using molecular dynamics simulations and post-
dynamic analyses, a description of the protein conformation was offered.  Subsequently, a 
pharmacophore was proposed as a potential scaffold to which endonuclease inhibitors may be 
modelled upon. 
It is my belief that the impact of the results derived from the above mentioned studies would 
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1.1 Background and Rationale of Study 
 
The spread of seasonal influenza viral infections causes annual epidemics with more than 
20,000 reported deaths.  Recent outbreaks of the influenza A virus; subtype H5N1 and 
pandemic H1N1, have caused concern because of their higher mortality rates 1-5.  International 
health bodies have invested significant research in effective management strategies for the 
influenza virus which include: prevention strategies i.e. seasonal flu vaccinations 6 and curative 
chemoprophylaxis active against circulating subtypes of influenza- oseltamivir (Tamiflu®) 7, 
zanamivir (Relenza®) 8, laninamivir (Inavir®) 9 and peramivir (Rapivab®) 10.   
 
The influenza virus has demonstrated a remarkable ability to mutate rapidly.  Mutagenesis 
occurs by antigenic drifts and antigenic shifts.  In 2009, an H1N1 virus with a new combination 
of genes emerged with a rapid rate of infection, resulting in a pandemic claiming approximately 
284,500 lives.  The current drug treatments were ineffective against the outbreak.  The increase 
in reported incidences of resistance of H1N1 and H5N1 to current chemotherapies poses a 
threat to the human population, making us vulnerable to genetically divergent influenza A 
viruses 11-13. 
 
An extensive database of approximately 870 crystallised proteins (www.rcsb.org) or protein 
fragments of the influenza A virus 14-16, has assisted in isolating potential targets for the 
inhibition by a chemotherapeutic.  High profile targets include 16, 17:  
1. surface antigens: hemagglutinin (HA) and neuraminidase;  
2. RNA dependent RNA polymerase: polymerase acidic protein (PA), polymerase basic 
protein 1 (PB1) and polymerase basic protein 2 (PB2); and  
3. the M2 ion channel.  Our study focusses on the enzyme neuraminidase of H1N1 and 
H5N1 subtypes and the PA endonuclease fragment of the RNA polymerase of H1N1. 
 
Influenza A neuraminidase and endonuclease have been reported to have a high success rate of 
inhibition when treated with selective chemoprophylaxes.  Both enzymes, according to 
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literature have a largely conserved active site residue profile amongst the influenza A subtypes 
18, 19.  However, recent pandemics i.e. the 2009-pH1N1, expressed a genetic mutation at residue 
position 274 in the glycoprotein, neuraminidase.  The point mutation of histidine (H) to tyrosine 
(Y), observed a more potent and resilient H1N1 strain comparable to the 2006 highly 
pathogenic H5N1 avian flu 20, 21.  Resistance of pH1N1 and pathogenic H5N1 to the available 
drug therapies emphasizes the need for further research for new, innovative and effective drug 
treatments.   
 
Endonuclease, however, has been an untapped focal point.  The influenza virus requires 
transcription and replication mechanistic tools 22-24, by selectively inhibiting the PA subunit we 
prevent the propagation and spread of viral infection.  There are no current FDA-approved drug 
candidates targeting the heterotrimeric polymerase complex 17, 25.  The favourability and 
robustness of the PA subunit against evolutionary mutagenesis enable us to design and develop 
a potential chemotherapy 26.  This study embarks on investigation of the resistance mechanisms 
behind neuraminidase in the presence of evolutionary mutations as well as characterising the 
binding profile of endonuclease.  We propose potential new drug candidates for the inhibition 
of neuraminidase.   
 
This study utilises multidimensional computational techniques, such as: molecular dynamics 
(MD) simulations which is a useful tool in defining the ligand binding affinities and 
characterising the binding landscape, as well as in silico virtual screening methods to identify 
possible inhibitors 27.  Post-dynamic evaluations provide the insight into the mechanism of 
resistance and the specific binding mode of drug candidates.  The techniques combined in this 
thesis incorporate: root mean square deviation (RMSD), potential energy, root mean square 
fluctuation (RMSF), principal component analysis (PCA), residue interaction network (RIN) 
profiling, solvent accessible surface area (SASA), molecular mechanics generalised Born 
surface area (MM-GBSA), quasi-harmonic entropy estimations, estimation of total hydrogen 
bonds, radius of gyration (Rg), secondary structure analysis and average volume estimation of 






1.2 Aim and Objectives 
 
The primary focus of the thesis is to investigate specific classes of influenza virus glycosidase 
targets.  This includes the surface antigen neuraminidase and RNA dependent endonuclease.  
There are three critical goals: 
1. To determine, differentiate and distinguish the mechanism of resistance of 
neuraminidase in influenza A, 2009-pandemic H1N1 (2009-pH1N1) and H5N1 
subtypes in the presence of mutation/s H274Y and I222K. 
In order to accomplish this the following objectives were outlined: 
1.1 Estimation of the free binding energies of the drug-protein complexed of wild type 
and mutant 2009-pH1N1 and H5N1 enzyme species. 
1.2 Identify, characterise and compare the binding landscape of wild type and mutant 
2009-pH1N1 and H5N1 subtypes. 
2. To propose potential neuraminidase scaffolds for new and innovative prophylactic 
chemotherapies via the aid of in silico technique ligand-based virtual screening (LB-
VS) and structure-based virtual screening (SB-VS). 
The study was performed by focussing on the following objectives: 
2.1 Identify current active drug targets of influenza neuraminidase. 
2.2 Establish an average cumulative scaffold of current actives using just the ligand 
three-dimensional structure for LB-VS. 
2.3 Establish an average cumulative scaffold of current actives using the three-
dimensional spatial orientation of ligands in the protein active site for SB-VS. 
 
3. To identify the binding mode of the polymerase endonuclease of H1N1 and isolate 
potential drug therapies to selectively inhibit enzyme activity, using LB-VS and SB-
VS. 
This was achieved using the following objectives: 
3.1 Characterise the active site i.e. amino acid residues responsible for the 
endonuclease activity. 





1.3 Novelty and Significance of the Study 
 
Contributions have been made in isolating and characterising the protein structure of the 
influenza A neuraminidase 28-30 and the PA subunit 31, 32.  There have been no reported 
computational analyses which comparatively investigate the difference in the binding site of 
H1N1 and H5N1 neuraminidase to explain the contrast in susceptibility to the potent drug, 
oseltamivir.  Computational investigation of influenza A endonuclease is limited and remains 
largely underdeveloped.  There is minimal understanding with regard to the selective inhibition 
of the enzyme, the binding pocket responsible for enzyme activity and whether the presence of 
a single or multiple metal center/s is imperative to enzyme function.   
This study would provide insight into understanding the mechanism of resistance and relative 
susceptibilities of genetically diverse H1N1 and H5N1 neuraminidase to available drug 
therapies.  By characterising the altered active sites’ structural and functional composition, new 
inhibitors may be developed.  With the use of computational tools a refined perspective may 
be offered to highlight the endonuclease active site.  The study will characterise amino acid 
residues implicated in enzyme activity as well as the co-ordination profile of metal centres.  
Defining the binding landscape will offer prospective design of selective and unique inhibitors 
with critical pharmacophores features.   
 
1.4 Overview of the Thesis 
 
The thesis is divided into eight chapters, including this one: 
Chapter 1: Outlines briefly the rationale, aims and objectives of the study, the impact of the 
research and structure of the thesis. 
Chapter 2: Provides insight into the targets of influenza A virus, current drug therapies and 
the limitations due to resistance.  The chapter highlights the structure of neuraminidase and 
endonuclease, and the mode of action and inhibition of the enzymes. 
Chapter 3: This chapter offers a general insight into computational chemistry.  The specific 





Chapter 4: (Published work) 
Has been presented in the format requested by the journal. 
This is a review paper which initiated our investigation into influenza glycosidase enzymes.  
The paper is entitled “Anti-cancer Glycosidase Inhibitors from Natural Products: A 
Computational and Molecular Modelling Perspective”.  Published in the Journal of Anti-
Cancer Agents of Medicinal Chemistry (IF = 2.4).  The journal article specifically addresses 
natural products used in the treatment of glycosidase enzymes implicated in cancer.  During 
the research it was found that many of the enzymes and drugs expressed duality being linked 
to the influenza virus. 
Chapter 5: (Published work) 
Has been presented in the format requested by the journal. 
The research paper entitled “Understanding the cross-resistance of oseltamivir to H1N1 and 
H5N1 influenza A neuraminidase mutations using multidimensional computational analyses” 
addresses the objectives (1.1 and 1.2) outlined in section 1.2.  The journal article was 
submitted to Drug Design, Development and Therapy (IF = 3.0). 
Chapter 6: (Manuscript Submitted and under review) 
Has been presented in the format requested by the journal. 
The manuscript currently under review entitled “Per-residue Free Binding Energy Profiled 
Pharmacophore Modelling as an Enhanced Approach in Drug Discovery: A Case Study for in 
silico Screening and Validation of Potential Influenza A Neuraminidase Inhibitors” has been 
submitted to The Journal of Molecular Biosystems (IF = 3.2).  The paper addresses the 
objectives (2.1 – 2.3) outlined in section 1.2.  
Chapter 7: (Manuscript Submitted and under review) 
Has been presented in the format requested by the journal. 
The manuscript is currently under review entitled “A molecular dynamics description of the 
conformational binding of a potential influenza A endonuclease inhibitor and in silico screen 
of possible drug candidates” has been submitted to the European Journal of Medicinal 
Chemistry (IF = 3.4).  The paper addresses the objectives (3.1 and 3.2) outlined in section 
1.2. 
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2. Background on Influenza A virus 
 
2.1 History of Influenza A virus  
 
The influenza virus was first isolated scientifically in 1932.  However, the disease has plagued 
mankind for centuries, although 1173 was the first reported case of a pandemic 1.  There are 
two criteria that need to be met in order for an outbreak of influenza to be classed as a pandemic.  
Firstly, the influenza infection should be spread on a worldwide scale.  Secondly, a pandemic 
is caused by a new influenza virus A subtype.  The new virus subtype arises from antigenic 
shifts, resulting in a different glycoprotein, which should be resistant to immunity acquired 
from past seasonal influenza viruses 2. 
There have been several reports of influenza pandemics from the 14th and 15th centuries 3.  The 
1729 influenza outbreak lasted three years starting in Russia and claiming an undisclosed 
number of lives 1, 4-6.  Between 1781 - 1782, a singular strain stemming from China swept 
through Europe 7.  The peak of the pandemic observed a high incidence of infection in young 
adults.  St. Petersburg recorded an infection rate of 30,000 people per day, the disease infected 
approximately two-thirds of Rome’s population.  The greatest “medical holocaust” in history 
was the influenza pandemic of 1918 – 1920, which claimed approximately 39.3 million lives, 
impacting North America, India, Africa, Australia and Europe 8.  The most recent outbreak was 
the 2009-H1N1 influenza pandemic which affected 74 countries.  The novel H1N1 virus 
preferentially infected younger people below the age of 25 years, elderly people and 
immunocompromised individuals.  The estimated number of deaths ranged between 151,700 
and 575,400 in its first year of infection 9.  The spread of infection is eminent and from literature 
the frequency of influenza pandemics has increased.  Thus it is important to understand the 
mechanism for the propagation of disease 10, 11.  In doing so, specific biomolecular targets 
influencing viral maturation can be identified as potential inhibitory sites.  Inhibition of these 






2.2 Life cycle and mechanism of structural components of influenza A virus 
 
The basic life cycle of the virus occurs by attaching itself to the host cell surface receptors.  It 
then enters the cell with the subsequent uncoating of the viral nucleic acid.  At this point the 
host cellular machinery is “hijacked” into replicating the viral genome.  The new viral 
components synthesized are assembled into progeny virions which are released into the host.  
The sequential cellular functioning of the virus is governed by specialised protein species 
encapsulated within the virus structure 11. 
The influenza A virus is pleomorphic i.e. it is spherical or elongated in shape.    It contains 
three surface glycoproteins, embedded in a lipid bilayer, an artefact of the host cell (Figure 1).  
The glycoproteins are: 1) hemagglutinin (HA); 2) neuraminidase (NA); and 3) the M2 proton 
ion channel.  Virus replication is initiated by the binding of HA protein to sialic acid residue 
receptors contained on the host cell surface (Figure 2).  The binding of the entities mediates 
fusion of the viral envelope forming an endosome after receptor-mediated endocytosis.  The 
NA protein plays an integral role in the latter stages of infection.  Neuraminidase is responsible 
for the release of newly assembled viral progeny from the cell surface.  The enzyme cleaves 
the sialic acid residues from sialyloligosaccharides.  This process prevents self-aggregation of 
the virus particles.   The HA and NA proteins also serve as a characterisation tool for the 
subtypes of the influenza virus.  There are 17 genetically distinct subtypes for HA (i.e. H1 – 
H17) and nine for NA (i.e. N1 – N9), which differentiate influenza viral species (e.g. H1N1, 
H5N1, H3N2 and H7N9).   
 
Figure 1: Structure of influenza virus12 
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At the interface of the endosomal wall and the inside of the virus, beneath the bilipid layer lies 
a critical structural M1 matrix protein.  A ribonucleoprotein (RNP) complex lies inside the 
virus envelope.  This is typically characterised by eight segmented, negative-strand RNA 
genomes; the RNA-dependent RNA polymerase (PB1, PB2 and PA) and the nucleoprotein 
(NP).  The third glycoprotein, the M2 ion channel, promotes the influx of H+ ions into the virus.  
This lowers the internal pH of the virus which facilitates binding of the virus to the endosomal 
wall and the release of viral ribonucleoproteins into the host cell.  Once the viral RNPs have 
infiltrated the cell, they are immediately transported into the nucleus where viral protein 
synthesis takes place.  Because of the lack of self-checking systems during transcription of 
viral proteins, point mutations are prevalent.  Newly synthesized viral proteins are transported 
from the nucleus to a site in close proximity to the cell membrane for self-assembly.  The 
process of self-assembly has been termed “budding”, resulting in the formation of virions.  
These virions (as previously mentioned), are released into the host and allowed to infect new 




Figure 2: Influenza A life cycle (adapted from the work of Das et al. 16) 
Figure 2, description (a) Influenza A virus has a lipid bilayer envelope, within which are eight RNA genomic 
segments, each of which is associated with the trimeric viral RNA polymerase (PB1, PB2, PA) and coated with 
multiple nucleoproteins (NPs) to form the vRNPs. The outer layer of the lipid envelope is spiked with multiple 
copies of HA, NA and a small number of M2, whereas the M1 molecules keep vRNPs attached to the inner layer. 
(b) The viral surface glycoprotein HA binds to the host cell-surface sialic acid receptors, and the virus is 
transported into the cell in an endocytic vesicle. The low pH in the endosome triggers a conformational change in 
the HA protein that leads to fusion of the viral and endosomal membranes. The low pH also triggers the flow of 
protons into the virus via the M2 ion channel, thereby dissociating the vRNPs from M1 matrix proteins. The 
14 
 
vRNPs that are released into the cytoplasm are transported into the nucleus by recognition of the nuclear 
localization sequences (NLSs) on nucleoproteins17 only when the M1 molecules are dissociated. (c) In the nucleus, 
the viral polymerase initiates viral mRNA synthesis with 5′-capped RNA fragments cleaved from host pre-
mRNAs. The PB2 subunit binds the 5′ cap of host pre-mRNAs18, and the endonuclease domain in PA subunit 
cleaves the pre-mRNA 10–13 nucleotides downstream from the cap19. Viral mRNA transcription is subsequently 
initiated from the cleaved 3′ end of the capped RNA segment19,20. This 'cap snatching' occurs on nascent pre-
mRNAs. (d) Viral mRNAs are transported to the cytoplasm for translation into viral proteins. The surface proteins 
HA, M2 and NA are processed in the endoplasmic reticulum (ER), glycosylated in the Golgi apparatus and 
transported to the cell membrane. (e) The NS1 protein of influenza A virus serves a critical role in suppressing 
the production of host mRNAs by inhibiting the 3′-end processing of host pre-mRNAs 21, 22, consequently blocking 
the production of host mRNAs, including interferon-β mRNAs. Unlike host pre-mRNAs, the viral mRNAs do not 
require 3′-end processing by the host cell machinery. Therefore, the viral mRNAs are transported to the cytoplasm, 
whereas the host mRNA synthesis is predominantly blocked. (f) The viral polymerase is responsible for not only 
capped RNA-primed mRNA synthesis but also unprimed replication of vRNAs in steps (−) vRNA → (+) cRNA 
→ (−) vRNA. The nucleoprotein molecules are required for these two steps of replication and are deposited on 
the cRNA and vRNA during RNA synthesis23. The resulting vRNPs are subsequently transported to the cytoplasm, 
mediated by a M1–NS2 complex that is bound to the vRNPs; NS2 interacts with human CRM1 protein that exports 
the vRNPs from the nucleus24. (g) The vRNPs reach the cell membrane to be incorporated into new viruses 
(reviewed in ref.25) that are budded out. The HA and NA proteins in new viruses contain terminal sialic acids that 
would cause the viruses to clump together and adhere to the cell surface. The NA of newly formed viruses cleaves 
these sialic acid residues, thereby releasing the virus from the host cell. (Adapted from the work of Kaylan et al. 
16) 
 
2.3 Drug targets, prevention and treatment of infection 
 
Seasonal influenza infections occur as a result of antigenic drifts.  An antigenic drift is a small 
change in the genes of influenza viruses.  This occurs continually over time due to viral 
replication.  Thus, as a remedial therapy, vaccinations are used.  Unfortunately, this does not 
prevent infection by pandemic influenza strains and has no effect on those who have contracted 
a pandemic virus.  Influenza pandemics, as mentioned earlier, occur as a result of antigenic 
shifts.  Monitoring of antigenic variation/s in the influenza virus is imperative in preparing for 
an epidemic or a pandemic.  Due to the limitations in preventing potential influenza pandemics, 
anti-viral chemoprophylaxes offers an alternate method of treatment.   
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2.3.1 M2 ion channel 
 
The M2 protein is a small homotetrameric transmembrane (TM) protein (Figure 3).  The 
protein is comprised of three components: 
1) An N-terminal extracellular domain of 24 amino acid residues, 
2) A signal anchor transmembrane domain of approximately 19 residues in length, and 
3) A 54 residue cytoplasmic tail 26. 
The oligo-tetramers are stabilised by disulphide bonds.  Its primary function is to channel 
protons into the virion and host cell, to adjust the pH of intracellular compartments.  Little is 
known about the functional mechanism of the protein.  With the aid of computational 
techniques Sharma et al. 27, suggested that a cluster exists in the heart of the TM domain.  It 
comprises residues His to Trp41, and thought to chaperone the protons through the channel.  
This is achieved by hydrogen bond formation and breaking between the “His-Trp gate”.  
However, it was Wu and Voth 28, who initially suggested an open and closed state of the M2 
proton channel.  This phenomenon may explain the mechanism of conductance of protons.  
Thus, in the TM domain lies the channel pore, which is the site for inhibition by anti-influenza 
virus drugs   
FDA-approved anti-viral drugs amantadine (Figure 3) and rimantadine, function by blocking 
the M2 ion channel pore 29.  Co-workers Sansom and Kerr 30, designed a molecular model of 
the M2 channel.  By virtue of energy interaction profiles, they were able to describe the mode 
of inhibition of amantadine.  Two distinct residues S31 and I42, which are positioned at 
opposite ends of the pore, were implicated in facilitating the inhibition of the protein.  Inhibiting 
the activity of the M2 ion channel, impedes the transport of H+ ions into the endosome.  This 
affects the proteins ability to adjust the pH, required for the release of RNPs into the host cell 
which ultimately inhibits viral replication.  The activity of the modulator is regulated by 
changes in pH.   
Although these drugs have demonstrated their effectiveness, a major drawback is the severe 
side effects.  Because of these side effects, patients do not complete the prescribed dosages, 
leading to the emergence of drug resistant influenza viruses with increased virulence.  
Resistance is acquired by point mutations in the M2 protein.  Huang et al. 31 and Jing et al. 32, 
made significant contribution to the structural basis of drug-resistance of rimantadine and 
amantadine, using high resolution NMR studies.  They characterised the mechanism of action 
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of point mutations: D44N, D44A, N44D and R45A; in the TM domain.  It was elucidated that 
mutation R45A specifically interferes with the binding of rimantadine, whilst mutation D44A 
partially inhibits the binding of amantadine and rimantadine.  The presence of the point 
mutation exerted a conformational stress on the pore preventing either drug from binding inside 
the channel pore 32. 
 
Figure 3: Crystal structure of the transmembrane domain (orange) of the M2 protein 




Hemagglutinin (HA), is a trimeric, rod shaped glycoprotein which comprises the envelope 
surrounding the influenza virus 34.  The abundancy of HA on the surface membrane is four 
times that of neuraminidase, thus making HA an appealing therapeutic target.  The glycoprotein 
is synthesised as a single polypeptide chain (HA0), by post-translational modification the 
protein is cleaved into two subunits, HA1 and HA2 (Figure 4).  These subunits are linked 
covalently by a disulphide bridge.  The HA protein facilitates a pH dependent fusion of the 
endosome to the host cell surface and the release of the viral RNPs into the host cell.   
The HA1 protein subunit forms the base of the structure i.e. the globular domain.  It is 
responsible for the binding of the virus to the sialic acid receptors.  HA1 is the primary antigenic 
determinant recognised to elicit an immune response.  The HA2 protein, is characterised by the 
fibrous stem.  The N-terminus of the HA2 subunit anchors the glycoprotein into the bilipid 
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layer.  This feature is distinguished by 20 consecutive, hydrophobic residues and is essential 
for membrane fusion. 
 
Figure 4: Crystal structure of influenza A hemagglutinin (HA0); A) the HA2 protein (fibrous 
stem) and B) the HA1 protein (globular head)  (PDB code: 2VIU) 34 
(Sa site-green); (Sb site-red); (Ca1 site-orange); (Ca2 site-purple) and (Cb site-yellow) 
Viral replication occurs at a high rate, which compromises the accuracy in which proteins are 
transcripted and translated.  The lack of proofreading mechanisms allows antigenic variations 
of HA to emerge.  Therefore unravelling the efforts of vaccinations and antibodies created from 
immune memory.  A variety of HA proteins exists (i.e. H1 – H17), each surface antigen is 
conformationally unique.  However, only H1, H2 and H5 subtypes affect the human population.   
Analysis of HA sequence variations of isolates causing epidemics have resulted in the 
identification of five antigenic sites, categorised as being strain specific (S) or common (C).  
There are two strain specific, the Sa and Sb sites (Figure 4) 35.  These antigenic sites are 
positioned near the tip of HA protein at residues co-ordinates: 128 – 129, 156 – 160, 162 – 167 
and 187-198.  Three common sites have been isolated: Ca1, Ca2 and Cb.  The Ca1 and Ca2 
sites are located between adjacent HA monomers mid-way down the globular base.  The 
residue co-ordinates of the Ca1 are: 169 - 173, 206 - 208 and 238 - 240; whilst the Ca2 sites 
resides within residues 140 - 145 and 224 - 225.  The Cb antigenic site resides in the base of 
the HA1 protein at residue co-ordinate 74 - 79.  The vast combinations of antigenic variants 
imposes great difficulty in the discovery of new drug.   
The FDA have approved the administration of the HA protein vaccine FluBlok, in the 
prevention of infection.  However, there are no clinical therapeutic agents that inhibit HA 




been dedicated to discovery of potential inhibitors.  A series of serine protease inhibitors have 
been identified as potential HA inhibitors.  Important inhibitors include:  
1. ε-aminocaproic acid 36,  
2. Nafamostat 37,  
3. pulmonary surfactant (lipoprotein complex) 38, and  
4. mucous protease inhibitors 39, have been implicated in inhibiting the cleavage of HA 
precursors.   
Other drug candidates have been identified as promising inhibitors.  However, none have yet 




Neuraminidase is a tetrameric enzyme (Figure 5).  Each monomer has a molecular mass of 
~60 kDa and comprises three domains: 
1) a cytoplasmic head (resides on the virion surface), 
2) a transmembrane stem, and 
3) a cytoplasmic tail.   
Neuraminidases’ enzyme activity lies in its cytoplasmic head.  The residues implicated in the 
catalytic site include: Arg118, Asp151, Arg152, Arg224, Glu276, Arg292, Arg371 and Tyr406.  
The listed residues of various influenza A virus subtypes is largely conserved.  This feature 
only enhances the attractiveness of neuraminidase as target for the treatment of influenza.  A 
calcium binding site is present near the catalytic domain.  It serves to stabilise the enzyme 
structure at low pH.  The calcium domain is enclosed within residues 293, 347, 111 - 115 and 
139 - 143.  This pocket is held together by the interaction of carbonyl oxygens of the αC 
backbone, specifically residues 297, 345 and 348; as well as the oxygen of Asp324’s carboxyl 
group.  Information regarding the three-dimensional structure of the cytoplasmic tail and 
transmembrane stem is limited.  This is further incentive to investigate neuraminidase as a 




       
Figure 5: Crystal structure of neuraminidase N1; (A) tetramer with oseltamivir bound, and 
(B) monomer highlighting active site residues (orange) (PDB code: 2HU4) 44 
As previously mentioned, the catalytic site of influenza A subtypes share a conversed active 
site profile.  As a result, current and potential anti-viral drugs may exert a broader spectrum of 
inhibition.  Inhibition of the NA protein impedes the proliferation of new virions into the host.  
Prominent researcher Mark von Itzstein, made one the first attempts of using molecular 
modelling tools in understanding the binding landscape of neuraminidase 45.  With the aid of 
co-worker, he proposed the rational design of novel anti-influenza drugs 46, 47.  The principles 
outlining the design of inhibitors are still employed in the discovery of new and improved drug 
therapies.  Von Itzstein et al., described the structural and energetic aspects of the substrate and 
potential NA inhibitor binding and mechanism of action of influenza neuraminidase.  It was 
found that the two potential NA inhibitors: 
1) DANA (2-deoxy-2,3-didehydro-N-acetylneuramicnic acid), and  
2) an N-trifluoroacetyl analogue of FANA,  
demonstrated good activity in vitro but lacked clinical efficacy 13, 45.  However, these were 
essential discoveries as they served as leads in the development of FDA-approved drugs: 
oseltamivir (Tamiflu), and zanamivir (Relenza) 15.  During the 2006 virulent strain of H5N1- 
avian influenza, the chemotherapeutic agent, oseltamivir, failed to treat the virus.  A similar 
scenario was observed in 2009, with the pandemic strain of H1N1, a point mutation of H274Y 







viruses of the N1 subtype, placed the human population at risk of future pandemics.  Hence, 
the design of new inhibitors peramivir, which, was made available in the United States by 
Emergency Use Authorisation (EUA) 48, as well as laninamivir. 
There have been accounts of computational investigations performed: 
1) to understand the drug resistance mechanisms 49, 50,  
2) to determine the point mutations inflicting resistance 50, 51, and 
3) investigate the development of enhanced anti-viral agents 52, 53. 
However, none have comparatively and comprehensively identified the structural and 
conformational impact of specific point mutations.  With subsequent proposal of compound 
scaffolds able to bind to the newly evolved active site of neuraminidase. 
 
2.3.4 RNA-dependent RNA polymerase 
 
The viral RNA polymerase enzyme is a heterotrimer of ~250 kDa.  It is characterised by eight 
negative-sense single-stranded RNA segments which encode 10 essential proteins.  The 
enzyme is solely responsible for catalysing RNA replication and viral protein transcription in 
the infected nuclei of host cells 54.  The three largest RNA segments encode the RNA-dependent 
RNA polymerase protein subunits:  
1) polymerase acidic protein (PA);  
2) polymerase basic protein 1 (PB1); and  
3) polymerase basic protein 2 (PB2).   
The three medium sized RNA segments, when translated reveal the nucleoprotein (NP).  The 
NP coupled with the polymerase subunits and viral RNA segments (vRNA), form the 
ribonucleoprotein (RNP).  RNPs are released into the host cytoplasm once fusion of the viral 
and endosomal membranes, occurs.  The two remain short vRNA segments encode: 
1) the matrix protein (M1) that lines the inner membrane surface of the viral bilipid layer, 
2) the NS1 protein which participates in evading the innate immune response of the host, 
and 
3) the NS2 or nuclear export protein responsible for chaperoning RNPs from the nucleus 
into the cytoplasm. 
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There are no proofreading mechanisms available during RNA polymerase activity.  As a result, 
the antigenic variants of the encoded proteins, occurs at a rate nearly equivalent to the rate of 
viral replication.  A statistical evaluation of this process estimated approximately 10,000 
potentially new viral mutants can be produced to infect healthy cells.  Viral RNA polymerase 
is pivotal to viral evolution, inhibition of the enzymes catalytic activity will threaten the 
survival of the influenza virus.  The distinct structure and activity of the enzyme is exclusive 
to the influenza virus composition and cannot be found in the human genome.  The selectivity 
and promise of the complete extinction of the viral infection emphasizes the RNA polymerase 
as a crucial target for new anti-viral drugs 54.  
The PA subunit has been benchmarked as the primary target of inhibition.  This is attributed to 
the N-terminal domain of PA encompassing the endonuclease activity of RNA polymerase.   
The PA and PB2 protein subunits compose the cap-binding domain, which is involved in the 
transcription cap-snatching process. Each subunit projects inwardly toward one another across 
a solvent channel.  The 5’ terminal of the polymerase enzyme folds over to form ‘hook’.  The 
hook-like structure creates a second highly conserved binding pocket between residues PB1 
and PA 55.  The arrangement of the active site and folding of the PA domain resembles the 
architecture of the PD-(D/E)XK family of nucleases 56.   
The endonuclease activity of the PA subunit is responsible for the cleavage of a phosphodiester 
bond 10 – 13 nucleotides downstream of the cap.  The process of cleaving the ‘cap’ is mediated 
by divalent metal centers.  The metal serves as a thermal stabiliser and shields the enzyme 
against fluctuations in pH.  Structure-based mutagenesis studies have been performed to 
determine the impact of induced point mutations in the PA active site, on the endonuclease 
activity.  It was established that the endonuclease-independent RNA replication function 
remained intact, whilst the endonuclease-dependent transcription was inhibited  57.   There have 
been reports of anti-cancer agents demonstrating dual activity by inhibiting the endonuclease 
activity of influenza A virus RNA polymerase 58.  A known inhibitor of the influenza 
endonuclease is 2,4-dioxo-4-phenylbutanoic acid (Figure 6) 59, 60.  However, to date there have 
been no clinically approved chemotherapeutic agents.  Thus the need for new drug therapies is 




Figure 6: Crystal structure of Influenza A PA endonuclease subunit in complex with 2,4-
dioxo-4-phenylbutanoic acid (green) (PDB code: 4AWF) 60 
The active site residues have been highlighted in red and Mn2+ metal centers coloured purple. 
 
2.4 Current Limitations 
 
The first 21st century influenza pandemic originated from a genetically divergent form of the 
H1N1 virus.  Since 2009, there have been an estimated 42 – 86 million cases of infection 
worldwide.  Highly pathogenic avian H5N1 influenza A viruses have become transmissible in 
humans by overcoming species barriers.  There have been reported infections in Asia, Europe 
and Africa, many with fatal outcomes.  Despite the availability of and treatment with current 
drug therapies, the H1N1 virus (including pandemic 2009 H1N1) and H5N1 maintain virulence 
and have developed resistance toward active inhibitors.  This is of growing concern and 
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3. Theoretical and Computational Methods 
3.1 Introduction to Computational Chemistry 
 
Computational chemistry (also referred to as molecular modelling), is the amalgamation of 
science and art.  It is a technique that combines computational investigation and design, as well 
as the fundamentals of chemistry from an atomistic and molecular perspective; to generate 
realistic molecular models.  Molecular modelling has been an essential tool in drug design and 
understanding the biology of biomolecules 1.    It investigates methodically: 
1) the three-dimensional molecular structure; 
2) molecular dynamics and flexibility; 
3) physical properties; 
4) biological activities such as protein folding, stability and conformation. 
This is achieved by the using the theoretically principles of physics, mathematics and 
chemistry; to describe the energetics of a three-dimensional biomolecular system. 
There are three basic components of used to describe molecular modelling:  
1) Molecular Mechanics (MM);  
2) Quantum Mechanics (QM); and  
3) Molecular dynamics simulation.   
Quantum mechanics is a technique based on first principles used to describe the behaviour of 
photons, electrons and other particles that compose the universe.  The Born-Oppenheimer 
approximation is used to solve the innate characteristics and mechanistic reactions of 
biomolecular systems.   
Molecular mechanics apply Newtonian mechanics to model molecular systems.  The potential 
energy of the system is estimated by using force fields.  Unlike QM, MM ignores the electrons 
and computes the energy of the system as a function of nuclear positions i.e. an implicit method 
of parameterisation for potential energy approximations.  This serves as a useful tool for 
biochemical and biomedical analyses.  Hybrid QM/MM techniques have been employed to 
reduce computational resources in which biomolecular mechanism models are built. 
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Molecular dynamics (MD) simulations are trajectory-based methods, designed to be less 
computationally expensive.  MD simulations offer a visual aspect to the motions of atoms using 
the classical laws of physics.  
In this thesis MD simulations were primarily used to: 
1) study the conformational changes of proteins,  
2) the impact of point mutations in a protein, and 
3) propose reasonable explanations for drug resistance. 
The three concepts of computational chemistry are further explained, so as to give insight into 
the relatedness of the energy descriptors. 
 
3.2 Quantum Mechanics  
Quantum mechanics is a branch of classical physics.  The first version of quantum mechanics 
was initiated by Werner Heisenberg, Max Born and Pascal Jordan who discovered matrix 
mechanics.  The invention of quantum theory was, however, not single handedly begotten.  It 
was through the great efforts and contributions of principal researchers: Max Planck, Wolfgang 
Pauli, Heisenberg, Born, Jordan, Erwin Schrödinger, Niels Bohr, Paul Dirac and Albert 
Einstein 2. 
The atomic particles (electrons of an atom) are treated as little packets of energy i.e. quantum 
particles.  The energy state of the different atomic particles are associated with unique quantum 
numbers. The assignment of quantum numbers to the atomic particles are governed by particle 
characteristics such as; the spin of particle (i.e. the intrinsic angular momentum) and molecular 
electronic states.  The change in energy either by release or addition, occurs in the form of a 
photon which is computed into a wave. 
Analysis of a biomolecule by QM involves the arrangement of nuclei and corresponding 
electrons, in a three-dimensional space.  The electrons are mapped using the continuous 
electronic density method, and the energetics measured are solved by the Schrödinger equation.  
For larger molecular systems the Born-Oppenheimer approximation coupled with the Hartree-
Fock self-consistent field which maps the electron density of the system. 
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3.2.1 The Schrödinger equation 
In 1925 Erwin Schrödinger described the evolution of wave functions by a differential 
equation3.  There are two derivative of the Schrödinger equation they are: 





𝜓(𝑟, 𝑡) =  ?̂?𝜓(𝑟, 𝑡)                   𝑒𝑞𝑛. 1 
Where i is the imaginary unit, ℏ is Planck’s constant divided 2π, 
𝜕
𝜕𝑡
 represents the partial 
derivative with respect to time, Ψ (psi) represents the wave function of the quantum 
system, and ?̂? is the Hamiltonian operator which characterises the total energy and is 
dependent on the wave function and form of the system. 
 
2) The time-independent Schrödinger equation which predicts standing waves which 
translate to atomic and molecular orbitals, 
𝐸Ψ =  ΗΨ̂                    𝑒𝑞𝑛. 2 
 
The term E, represents the energy of state.  The Hamiltonian operator is governed by a 
specific wave function. 
When using either equation the solution remains ambiguous, thus certain assumptions are 
required to obtain an approximate answer.  
 
3.2.2 Born-Oppenheimer approximation 
The Born-Oppenheimer approximation is one of the most important approximations in 
molecular QM.  It was developed in 1927 by Max Born and J. Robert Oppenheimer.  The basis 
of the approximation is built on the assumption that the motion of electrons and nuclei can be 
separated 4. 
The theory is derived from the consideration of the mass of atomic particles and the influence 
they have on one another.  There exists an interaction between the electron and nucleus, this 
interaction constitutes the fundamental character of an atom.  Supposing one component either 
the electron or nucleus, was by mass heavier than the other.  The motion of the lighter particle 
would thus be dominated and steered by the heavier particle 5.  Translating this phenomenon 
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into a wave function, the heavier particle would exert and interaction force on the lighter 
particle causing it to oscillate more rapidly around the heavier particle, in order to stay with the 
sphere of interaction.  This can be a considered a compensatory effect of the lighter particle.  
Electrons naturally have a higher diffusion constant which make them lighter than the nucleus.  
Thus in the Born-Oppenheimer approximation the nuclear positions are fixed.  The 
approximation is as follows 4: 
Ψ(𝑚𝑜𝑙)(𝑥, 𝑅) =  Ψ(𝑒𝑙𝑒𝑐)(𝑥, 𝑅)Ψ(𝑛𝑢𝑐)(𝑅)                  𝑒𝑞𝑛. 3 
R represents the nuclear position, and Ψ(𝑒𝑙𝑒𝑐)(𝑥, 𝑅) the electronic wave function solved by the 
nuclear position. 
The total classical energy of the molecule is calculated as follows: 
𝐾𝑒  + 𝐾𝑛  +  𝑉𝑒𝑒(𝑟) + 𝑉𝑒𝑛(𝑟, 𝑅)  + 𝑉𝑛𝑛(𝑅) = 𝐸                   𝑒𝑞𝑛. 4 
Ke and Kn measure the electronic and nuclear kinetic energies.  The symbol V is representative 
of the potential energy.  It must be noted that the Born-Oppenheimer approximation is 
dependent on the nuclear wave function and not the velocity. 
 
3.3 Molecular Mechanics 
Molecular mechanics (also known as force field calculations), is designed to compute large 
datasets.  It has been the preferred method for the estimation of energies of biomolecules.  As 
a result it used to elucidate structural details of the MD ensembles.  The mathematical model 
analyses the nuclear position of atoms whilst ignoring the electronic contribution.  Based on 
the previous discussion regarding the Born-Oppenheimer approximation, the nuclear position 
is regarded as fixed due to mass differentials.  In order for the electron approximations to be 
ignored, the model has to recognise the electronic component as one unit.  The unit sum of the 
electrons can be compensated for in the potential energy function 6. 
Molecular mechanics is a classical approach to molecular modelling.  The atoms in this 
approach are represented as balls and the bonds elastic sticks.  Structures acquired from x-ray 
crystal data or NMR studies, requires refinement by energy minimisation.  The atoms with a 
molecule are not static, they are in constant motion due to the bond type.  As a result 
biomolecules may adopt a many conformations of differing energies.  In some instances, the 
protein may have an average of its conformations at a local or global energy minimum, which 
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are separated by activation energy barriers.  There are different forces which act upon the 
system when being prepared.  Force fields are used to solve the energy equation 7, 8. 
 
3.3.1 MM Potential energy function 
 
The potential energy (PE) function is a mathematical characterisation of the molecules’ 
geometry by minimisation, and the nuclear probability distribution by solving the nuclear 
Schrodinger equation.  It is capable of determining nuclear dynamics, with the aid of solving 
the time-dependent Schrodinger equation.  A solid understanding of the distribution of 
electrons in molecules is essential.  An additional approximation derived from the PE function, 
involves the treatment of nuclei as classical particles with a potential energy.  Using the 
description of Newton’s Second Law, the nuclei would move as a classic point particle 9. 
The potential energy function is thus described as follows 10: 
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Where, Ubond measures the oscillations about the equilibrium, Uangle defines the 
oscillations of three atoms about an equilibrium bond angle, Udihedral expresses the 
torsional rotation of four atoms about a central bond and Unonbond is the descriptor of all 








3.3.2 Force Fields 
There are a variety of biomolecular system force fields available.  A few examples include: 
1) AMBER 11, 
2) CHARMM 12, 
3) GROMOS 13, 
4) OPLS-AA 14, 
In each of the aforementioned force fields, the biomolecule is characterised as a collective mass 
interacting with one another through harmonic forces.  The atoms in the molecule are depicted 
as balls of differing sizes joined together by springs i.e. bonds, of variable strength, length and 
angular distances.  In the studies conducted, the AMBER force field was implemented to 
characterise the enzymes, whilst GAFF was used to interpret the ligands.   
This AMBER force field provides a favourable balance in energy between the helical and 
extended regions of the peptide and protein backbones with improved dihedral torsions 15.  
Further to this the parameter set achieves better agreement of the dihedral contributions of the 
conformational model and experimental NMR data.  
 
Figure 7: A diagrammatic representation expressing the summation of total energy in a 
molecule 6 
Bonding terms: (1) bond stretching, (2) bond bending, (3) bond dihedrals.  Non-bonding terms: (4) electrostatic, and (5) van 
der Waals interactions 
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The total energy (Etot), of a molecule is computed from the deviation in energy contributions 
of different bond types (eqn. 1), i.e. bonding and non-bonding interactions (Figure 7) 16, 17.  
The harmonic bond type terms include: 
1) bond stretching energy (Estr)- describes the energy change as bonds stretch and contract 
2) angle-bending energy (Ebend)- describes the energy change of ‘spring-like’ or ‘scissor-
like’ bond harmonic  
3) torsional energy (Etors)- is a measure of the dihedral potential energy 
4) van der Waals energy (Evdw)- is the energetic contributions of van der Waals 
interactions 
5) electrostatic energy (Eelec)- is the energetic characterisation of the Coulombic charges 
E𝑡𝑜𝑡  =  𝐸𝑠𝑡𝑟  + E 𝑏𝑒𝑛𝑑 + 𝐸𝑡𝑜𝑟𝑠  +  𝐸𝑣𝑑𝑤  +  𝐸𝑒𝑙𝑒𝑐…                      𝑒𝑞𝑛. 5      
 
Total energy can be described as “a measure of intramolecular strain” of a three-dimensional 
biomolecular model in equilibrium, which is useful when comparing different conformations.   
 
3.4 Molecular dynamics (MD) simulation 
MD simulations estimate the correlated motions of a protein during a trajectory.  A single 
trajectory is capable of generating three ensembles of which the conformations extracted are 
closer to the x-ray crystal structure.  Molecular dynamics simulations were predominantly used 
in this study due to their excellent approximation of biomolecular systems 7, 18, 19. 
Classical molecular dynamics (MD), is an integrated computed algorithm system which 
incorporates Newton’s equations of motion.  Molecular dynamic simulation can provide high 
probability real-time view of many chemical reactions and/or biological systems.  Based on 
highly-evolved mathematical and physical criteria, the technique proposes possible 
conformations or mechanisms of action of systems on an atomic and molecular scale. 
Unlike other 2D analyses such as NMR and X-ray, MD is not a static technique and the 
resulting data is a snapshot of its motion at that moment.  However, MD simulation has proven 
an accurate and incomparable tool in estimating phenomena or unique occurrences. The 
importance of understanding the three-dimensional nature of a bound and unbound protein 
structures would prove invaluable. 
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MD simulation allows us to study a complex environment to predict the time evolution of a 
system of interacting particles (atoms, molecules, granules, etc.) with the aid of manipulating 
parameters such as temperature, velocity, flexibility of molecule and runtime.  The essence of 
the technique is to solve classical equations in an attempt to understand the energies and 
molecular mechanics of a particular network.  We are able to specify the initial velocity, 
conformation or positioning of our system, as well as we can direct the interaction potential.  





                    𝑒𝑞𝑛. 6 
Where ri(t) represents the co-ordinate of the particle position vector (i), t = time, mi is the mass 
of the particle and Fi depicts the force acting on (i) particle at a specific t and mi. 
There are advantages of running MD simulations, as all the inputs of a particular model are 
derived from crystal structures or well-constructed homology models which provide a 
description of the interatomic and intermolecular interactions.  Further to this, the results 
derived from the simulation are predominantly unbiased and made to mimic a real-time system 
with no assumptions.  Critical information can be extracted from the MD ensembles generated, 
with regards to the atomic and molecular interactions 21. 
3.4.1 Molecular dynamics solvent parameters 
 
Solvated biomolecular systems are best parameterised using the Particle-Mesh Ewald method 
(PME).  When using this method the protein is embedded in an explicit solvent which leads to 
stable trajectories.  The method has proven to be an accurate and efficient computational tool, 
used to calculate the three-dimensional Coulomb interactions with two-dimensional periodicity 
22-24.  The PME method separates the potential energy into Ewald’s standard direct (Ur) and the 
reciprocal sums (Um).  Conventional Gaussian charge distributions are used to describe the 
electrostatic potential.  The direct evaluation of the sum of point charges i.e. Ur is measured 
explicitly using cut-offs, whilst Um term is calculated using the Fast Fourier Transform (FFT), 
which solves the three-dimensional Coulombic charges into a two-dimensional grid.  This 
process reduces the memory and time required for PME estimation, whereby the differentiation 




3.4.2 Post-dynamics Analysis 
 
The post-dynamics techniques and calculations, discussed in this section have been used to 
describe the protein features in the studies of this thesis.  Post-dynamics analysis of trajectories 
obtained from the MD simulation is imperative in determining the: 
1) relative binding free energies,  
2) three-dimensional conformations and configurations, and  
3) to determine the state of thermodynamic equilibrium of the biomolecular system 25. 
3.4.2.1 Convergence 
 
Convergence is an empirical description of protein dynamics.  It is based on the fluctuations of 
bond type and bond angle vibrations, such that time magnitude and time range (from angstroms 
to a femto second to seconds) during the unfolding of a protein 26.  The point of convergence 
is often regarded as the stage at which the system enters a state of equilibrium such that in a 
graphical representation the curve is reported to plateau.  It is the point at which optimum 
distance from the reference structure is reached exhibiting the most energetically stable 
conformations of our protein-ligand system. 
The root mean square deviation (RMSD), provides invaluable information about the structural 
equilibrium of a simulated system.  Essential information derived from RMSD calculations, 
related to how long the system took to equilibrate can determine the number of conformations 
that exist for the biomolecule 27.  It may highlight biomolecules with ‘open’ and ‘closed’ 
conformations.  RMSD values may also shed light on the type of sampling of a structure 
whether it be extensive or non-convergent.  It can also aid in monitoring the atoms in the 
backbone and identifying the evolution of trajectories.  RMSD of a trajectory is calculated by 
continual measurement of the spatial difference between two static structures, i.e. a reference 
structure and the structure at that point in time of simulation 28. 
The evaluation of a systems potential energy (PE), during an MD simulation, confers 
information about the stability and functional motions of the structure.  Due to potential energy 
being quantised by velocity and time, a biomolecule takes to reach a state of equilibrium, 




3.4.2.2 Conformational and structural analysis 
The manner in which a protein folds influences the conformational freedom of that protein.  
Thus it is important to evaluate the secondary structure of protein.  These determinations can 
be achieved by the following approximations:  
1) RMSF  
The root mean square fluctuation (RMSF) captures, for each atom, the fluctuation about its 
average position.  Providing insight into the flexibility of regions of the protein that corresponds 
to the crystallographic β-factors (temperature factors) 27. 
2) PCA  
Principal component analysis (PCA), is a technique which is based on the reduction of size or 
dimensionality of a data set, which originally consists of a large number of interrelated 
variables whilst retaining as much of the variation as possible.  Reduction in the sample size is 
achieved by transforming a new set of variables, i.e. the principal components, which are 
marked as uncorrelated 30, 31.  However, they are ordered in such a way that the first few 
components retain most of the variation present in all original variables.  Thus for the purposes 
of our study a restricted analysis to the first two modes was instituted.  A useful tool in 
acquiring information with regards to the conformational freedom of proteins is covariance.  
Conformational freedom implicates the potential energy in the stability and functional motions 
of proteins.  Equations 7 and 8 below, offer a classical means for the numerical diagnosis of 
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)                              (𝑒𝑞𝑛. 8) 
Covariance is denoted as, 𝑐𝑜𝑣(𝑋, 𝑌); and defined by the size of the data set (𝑛), the mean of X 
and Y values (?̅??̅?), and the sum product of data values X and Y (∑ 𝑋𝑖𝑌𝑖)
𝑛
𝑖 .  An additional 
feature which allows the identification and fair comparison of protein during a trajectory is 
correlation.  Correlation (eqn. 9), concatenates the strength of linear association between two 
variables, which are quantified as being independent of one another.  Correlation (𝑟𝑋𝑌), is not 
governed by any measure or unit inflicted by the system.  This is accomplished by relating the 






                                                        (𝑒𝑞𝑛. 9) 
 
3) Solvent accessible surface area  
The solvent accessible surface area (SASA), is a derivative of the area over which absolute 
contact between the proteins’ Van der Waals surface and the solvent, arises.  This feature 
imparts information relative to the compactness of the structure as well as the extent of 
hydrophobicity in the interior of the folded protein 34. 
4) Radius of gyration   
The radius of gyration (Rg) is defined as the root mean square distance from each atom of the 
protein to their centroid.  It is classed as a qualitative assurance technique of MD simulations 
providing an understanding of the compactness of a biomolecule.  The compactness has been 
defined as the ratio of the accessible surface area of a protein to the surface area of an ideal 
sphere of the same volume 35.  The Rg is independent of the protein size.  The Rg and folding 
rate of a protein, share an inversely proportional relationship, e.g. A high radius of gyration 
value indicates a loosely-packed structure.   
 
3.4.2.3 Binding free energy calculations 
The binding free energy of MD ensembles can be calculated using different algorithmic 
approaches.  Some examples include: 
1) The free energy perturbation estimation, 
2) The Thermodynamic integration, 
3) The Linear interaction energy calculation,  
4) The Molecular Mechanics/Generalised Born Surface Area (MM/GBSA) calculation, 
5) The Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) calculation, 
and 
6) The Molecular docking calculation. 
The MM/GBSA and MM/PBSA free energy calculations infer information based on 
protein structure determinations.  The techniques employ the principles of molecular 
mechanics, by using an implicit solvent model to solve the binding free energy 
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computation.  Evaluation of ligand-protein complexes using MM/GBSA or MM/PBSA, 
provides a quantitative analysis of the binding affinity of the ligand to the protein.  The use 
of MM in these approaches, allows for averaged energy estimations to be made over certain 
frames from the MD trajectory to derive an estimate of the absolute binding free energy.  
The total binding free energy (ΔGbind), in equations 10 and 11, is defined by the collective 
contributions of: 
7) the gas-phase energy (Egas) term,  
8) the solvation free energy (Gsol) term, and 
9) multiple of the temperature (T) in Kelvins and entropy (S) approximation 
∆𝐺𝑏𝑖𝑛𝑑 = 𝐺𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐺𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 − 𝐺𝑙𝑖𝑔𝑎𝑛𝑑                    (𝑒𝑞𝑛. 10) 
∆𝐺𝑏𝑖𝑛𝑑 = 𝐸𝑔𝑎𝑠 + 𝐺𝑠𝑜𝑙 − 𝑇𝑆                                              (𝑒𝑞𝑛. 11) 
𝐸𝑔𝑎𝑠 = 𝐸𝑖𝑛𝑡 + 𝐸𝑣𝑑𝑤 + 𝐸𝑒𝑙𝑒                                               (𝑒𝑞𝑛. 12) 
𝐺𝑠𝑜𝑙 = 𝐺𝐺𝐵/𝑃𝐵 + 𝐺𝑆𝐴                                                               (𝑒𝑞𝑛. 13) 
𝐺𝑆𝐴 = 𝛾𝑆𝐴𝑆𝐴                                                                       (𝑒𝑞𝑛. 14) 
GSA, represents the non-polar solvation energy term and GGB describes the polar solvation 
energy.  Internal potential terms such as bond types, bond angles, torsional stresses and 
dihedral angles, influence the potential energy stability of the protein complex, which 
ultimately affect the binding free energy value.   
From the two methods MM/GBSA has better accuracy and determination capability of the 
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Abstract: The implementation of computational tools in pharmaceutics has proven an effectual 
strategy in creating harmony between the physical and chemical aspects of proteins and 
potential inhibitors.  This is achieved by bringing to life the three dimensional retrospect of 
biological systems, which takes into consideration computational approaches such as quantum 
mechanics and molecular dynamics to facilitate drug design and discovery.  In this work, we 
aim to provide a summary of the computational aspects of naturally derived anti-cancer 
inhibitors targeting the enzyme family of glucosidase’s.  Our study offers insight into the 
evolution of drug discovery, molecular modelling and molecular binding modes of natural 
product inhibitors associated with glycosidase enzymes.   
Keywords: Anti-cancer inhibitors, glycosidase, molecular modelling, natural product. 
 
INTRODUCTION 
Natural Products in Drug Discovery 
Since the beginning of time man has exploited the use of plant and animal based products for 
their medicinal application.  Ancient Eastern traditional healers have documented the healing 
properties of roots, bulbs, flowers and other herbs like ginseng, for at least 4,500 years [1].  
European healers dating back to the 10th century used foxglove (Digitalis purpurea L.), which 
was found to contain the active ingredient digitoxin which is effective in the management of 
congestive heart failure, along with its many structure based analogues [2].  The 
pharmacological use of natural products was, however, only established in Western culture by 
the 19th century the most famous being the synthesis of the anti-inflammatory, aspirin, derived 
from salicin, isolated from the bark of the willow tree (Salix alba L.).  By 1803 the alkaloid 
morphine was isolated from opium poppy (Papaver somniferum L.) which had been used by 
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the Sumerians and Ancient Greeks, and dubbed by the Arabs as being addictive.  Later during 
the 1870’s crude morphine treated with acetic anhydride yielded heroin, which was found to 
readily convert to codeine, a painkiller [2, 3].  The track record of nature lending itself as a 
curative, preventative or symptomatic treatment has been our only saving grace in eradicating 
infection and alleviating disease and other syndromes.  The current status of pharmaceutics 
worldwide indicates that approximately 40% of all dispensable medicines are either natural or 
semi-synthetic analogues of natural derivatives [4].  We are only at the precipice in drug 
discovery in terms of natural products and have yet to uncover and explore hidden secrets in 
different species genome using genome sequencing or single molecule real-time methods.  
Such discovery would allow new introspection in our management of disease, how some 
organisms remain immune to certain infections, as well as it would provide a new mechanism 
by which alternate biocatalysts and natural products may be identified.   The bulk of natural 
product derivatives currently in clinical study are dedicated to the treatment of cancer [5].  
There are a multitude of natural products sanctioned as leads in anticancer, there exists four 
main plant based drug classes, these include: 1) vinca alkaloids, 2) epipodophyllotoxins, 3) 
taxanes, and 4) camptothecines.  Each class targets different stages or pathways of the cell 
cycle of cancerous cells.  The alkaloids vinblastine and vincristine (Fig.  1), block mitosis with 
metaphase arrest by binding to tubulin resulting in its depolymerisation.  In combination with 
other cancer chemotherapeutic drugs the alkaloids can be used in the treatment of a variety of 
cancers including leukaemia’s, lymphomas, advanced testicular cancer, breast and lung cancer, 
and Kaposi’s sarcoma.  Podophyllotoxin derivatives etoposide and teniposide (Fig.  2), bind to 
tubulin, leading to DNA strand degradation irreversibly inhibiting topoisomerase II.  These two 
derivatives are used in the treatment of lymphomas, as well as bronchial and testicular cancers.  
The class of taxane, which include paclitaxel (taxol®) and other like derivatives act by 
disrupting the assembly of tubulin, they show specific activity in patients diagnosed with 
breast, ovarian and non-small cell lung cancer.   Camptothecin analogues selectively inhibit 
topoisomerase I.  The more effective and safer analogues being topotecan, an ovarian and small 
cell lung cancer chemotherapy and irinotecan, used in patients with colorectal cancer (Fig.  3).  
There exists many other natural products implicated in the treatment of different cancers, which 
only amplifies the cause for continued research efforts toward investigating natural products 
































































































































































Figure 3: Camptothecins; topotecan and irinotecan cancer inhibitors [7] 
 
 
Cancer and the Role of Glycosylation 
Cancer has been deemed one of the world’s major causes of mortality.  Characterised by the 
out-of-growth” cell growth, prohibiting normal bodily functions depending on the type of cell 
infected.  Cancer is a disease instigated by the function or dysfunction of catalytic pathways or 
cellular proteins.  Being a heterogeneous disease there are a number of biological therapies 
available to patients, which target specific genetic markers or enzymes relevant to the 
development and growth of the condition.   Through high through-put screening/dock it has 
been established that carbohydrates play an important role in cancer; and circulating or cell 
surface tumour-associated carbohydrate antigens serve as diagnostic markers [9-11].  Cell 
surface glycosylation is universal to all living cells reflecting their physiological state, and are 
perfectly positioned to mediate adhesion and motility.  A shift from the normal glycosylation 
pathway leads to altered glycan expression due to one or more of the following changes: (1) 
under- or overexpression of glycosyltransferases deregulated at the level of epigenetics [12, 
13], transcription [14-16], post-transcription [17], and/or chaperone [18]; (2) altered 
glycosidase activity [19-21]; (3) altered expression of glycoconjugate acceptor together with 
availability and abundance of the sugar nucleotide donor [22]; (4) modified sugar nucleotide 
transporter activity [23]; and (5) malfunction of the Golgi structure, the warehouse of 
48 
 
glycosyltransferases [9, 24, 25].  Abundant literature has suggested aberrant glycosylation 
contributes to various aspects of cancer development and progression, including proliferation, 
invasion, angiogenesis, metastasis and immunity [9, 26, and 27].   Fig.  4, depicts the N-
glycosylation pathway on the surface of the Golgi apparatus.  Overall the biosynthesis of N-
glycan’s have been deemed an expensive process in terms of the number of actively 
participating enzymes in the synthesis and trimming of N-glycan’s.  Structural diversity of N-
glycan’s in mature proteins in the cell surface are introduced by glycosyltransferases in the 
Golgi complex as a terminal step.  The core glycan’s in the endoplasmic reticulum are universal 
from yeast to mammal and are considered intermediates [28].   
 
Figure 4: Diagram of N-glycosylation pathway in human Golgi complex [29] 
 
Glycosidases are a vast class of enzymes designated to cleave glycosidic bonds of 
carbohydrates or polysaccharides to essentially assist in biochemical processes such as protein 
folding in living cells [27, 29].  Vocadlo and Davies provided insight into the mechanistic 
behaviour of glycosidase enzymes by understanding the enzyme reaction co-ordinates, through 
collective works in computational and structural studies [27].  The fundamental function of 
these enzymes is to hydrolyse glucose residues from glucosides.  Their specificity originates at 
a structural level, in terms of their α- and/or β- configurations as well as the configuration of 
its particular substrate.  The inability of a glycosidase to function correctly or expressions of 
the enzyme have been implicated as a cause of cancer.  Related cancers include: breast cancer 
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[30], brain tumours [31], prostate [32], lung, gastric, bone and ovarian [33].  The glycosylation 
pathway is an imperative target in the prevention of development of cancer or further spread 
of the disease [34].  There are an estimated 16 enzymes steam rolling the glycosylation pathway 
within the cellular framework.  These sites include the endoplasmic reticulum, golgi apparatus, 
cytosol and nucleus.  Each of the glycosidase enzymes, based on tissue loci and organism, 
exists in either an α- and/or β-configuration and are governed by the structural feature of the 
bond on which they exert themselves [35].  A prime example of the uniqueness of this class of 
enzyme is glucosidase.  The α-glucosidase depicted in Fig.  5, is derived from sugar beet and 
classified as an endoplasmic reticulum inner membrane bound protein, which is responsible 
for the cleavage of α-(1,2)- linked glucose units from amylose to extended carbohydrate chains 
[36].   
 
Figure 5: Crystal structure of sugar beet α-glucosidase (PDB code: 3WEO) [37] 
 
Fig.  6, highlights the covalent intermediate of human cytosolic β-glucosidase.  This enzyme 
has been associated with essential organs of the human metabolism such as the small intestine, 
kidneys and liver.  It is thought to play a role in the detoxification of xenobiotics (foreign 
chemical compounds which pose a toxic threat to the healthy cells), by hydrolysing β-glucoside 
moiety providing a site for conjugation which would lead to rapid excretion in the bile and 







Figure 6: Crystal structure of the covalent intermediate of human cytosolic β-glucosidase (PDB code: 
2ZOX) [40] 
 
A vast array of natural product glycosidase inhibitors have been explored due to their extensive 
ability in the treatment of cancer.  These include but are not limited to: castanospermine and 
deoxynojirimycin (glucosidase I & II and lysosomal α-glucosidase inhibitors), swainsonine 
(lysosomal and aryl-mannosidases inhibitor, and a potent mannosidase II inhibitor), 
kifunensine (potent mannosidase I inhibitor), allosamidin, salacinol, nojirimycin, mannostatin 
A & B, isogaomine, kojibiose, sophorose, nigerose, trehalose and xanthone derivatives. 
 
Evolution of Computational Techniques to Present Day 
By the 1950’s much improvement had been made in the way of instrumental techniques 
developed to analyse chemical reactions and molecular structures.  However, the lack of 
understanding in terms of kinetic models, visualisation of dynamic interactions as well as how 
and what the conformations, transition states and reaction intermediates look like and existence 
in their natural systems, left many an unanswered question.  It was not until 1957 when 
researchers Alder and Wainwright, reported the first successful molecular dynamic (MD) 
simulation.  Even in its infancy the pair brought to life phase transition.  Their investigation 
was based on a solid-fluid system evolution comprised of rigid spheres colliding 
instantaneously.  With limited computing, a 500-particle system was designed, emulating 
collisions between particles with a duration of one hour on an IBM 704 computer [41].  This 
sparked a ripple effect where in 1960, Gibson and colleagues implemented the first continuous 
repulsive Born-Mayer interaction potential in MD simulation.  This attempt may have been the 
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first recorded MD method in materials science.  Their study was based on the radiation damage 
in a copper (Cu) target.  This was performed by applying a constant force towards each atom 
on the boundary of the crystallite to account for the attractive part of the interatomic interaction 
[42].  In 1964 Aneesur Rahman described the attractive and repulsive forces in an 864 argon 
atom system using the Lennard-Jones potential [43].  The computational methods applied in 
his study, such as pair correlation function, velocity autocorrelation function and mean square 
displacement calculated for liquid Argon, are still relevant in current studies.  Current studies 
have observed the evolution of MD simulation and the vast approaches and information that 
can be derived from such analysis.  MD studies have offered a remarkable platform in the field 
of pharmaceutics; with regards to design and discovery of new and effective drug therapies for 
a multitude of diseases [44].  Nobel prize winner Richard Feynman described the motion of 
atoms being governed by probability functions, where chemical bonds are not formed 
mechanically but rather by the shifting of electron clouds which act as both waves and particles 
[45].  Thus the standard of the ‘lock and key’ theory has been set aside to accommodate the 
new age of binding models which accounts for conformational changes as well as the random 
motions of receptors and ligands.  This seemingly minor difference allows molecular dynamic 
simulations to stand apart from other static two dimensional models, thus playing an important 
role in drug discovery.  With the ability to analyse a three dimensional (3D) crystal structure 
of protein or target, we may gain perspective into the key features that enable such structures 
to function and possibly enhance or inhibit the expression of the protein species.  Such 
techniques which exploit these attributes are molecular dynamics and quantum mechanics, 
homology modelling and virtual screening.  Each of which offers different introspection into 
the specific aim of study [46]. 
 
COMPUTATIONAL APPROACHES ON NATURAL AGENTS AGAINST CANCER 
Homology Modelling 
Homology modelling is a technique applied in the prediction of protein structure based on the 
act that proteins of similar sequences bear similar structures.  The technique has promoted the 
identification of protein function and mechanism, drug binding to specific sites and 
rationalisation of select amino acids in the discovery of pertinent biological function ascribable 
to mutagenesis.  Due to computational methods being economically viable high throughput 
docking is an ideal method to select promissory compounds of appropriate chemical nature 
from extensive virtual chemical libraries, since they incur minor errors.  Lead optimisation 
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is a monotonous process of modifying the chemical structure of a known hit by modifying its 
physico-chemical and pharmacological properties to improve bioavailability, minimize 
unwanted toxicity and obtain the admissible drug profile appropriate for animal model studies 
and clinical trials [47].  Protein-ligand interaction comprehension is crucial in homology-based 
lead optimization, since the character of the structure obtained can steer ligand optimization 
towards enhanced pharmacological profiles.  Homology modelling has a significant 
contribution to structure-based drug discovery through prediction and generation of rational 
3D models for drug targets.  It generates plausible protein structures by presenting a 3D model 
from a protein template sequence subject to previously reported homologous protein structures.  
When building a homology model for proteins, the following typical procedure should be 
adhered to: 1) 3D protein structures with ~30% primary sequence similarity over the protein of 
unknown structure should be used [46, 48]; 2) the alignment of template and target protein 
sequences; 3) identification of variable and structurally conserved regions; 4) generation of 
structurally conserved residues of the unknown structure from template structure(s); 5) 
generation of loop conformations for the unknown structure; 6) generation of side chain 
conformations for the modelled protein; 7) refinement and evaluation of the generated 
unknown structure.  The RMSD (root of mean square deviation distance between Cα atoms) of 
the homology model is compared to that of the experimental structure, which should be ~ 1-2 
Å, to verify the accuracy of the homology model [49].  The accuracy of a homology model is 
defined by the template of choice, alignment accuracy and application of efficient refinement 
methods [47].  Homology models generated with over 50% sequence identity have satisfactory 
accuracy for drug discovery applications; whereas models of sequence identities of 25% to 
50% can be applied in target druggability assessment and design mutagenesis.  Homology 
models have proven invaluable as a rationalising tool of SAR data and the prediction of binding 
modes of experimental compounds [50, 51].  Heparanase is an endo-β-D-glucuronidase, which 
has been reported as a target for antimetastatic agents.  Its unique function in degrading heparin 
sulphate glycosaminoglycans in mammalian tissue has highlighted the enzyme.  Over 
expression would result in invasive normal and malignant cells such as; immune cells, 
lymphoma, melanoma, and carcinoma cells as well as human head and neck tumours.  Ishida 
et al., had proposed the design of selective inhibitors of heparanase by using a homology model 
of the enzyme.  The homology modelled enzyme was based on the sequence alignment of 
human heparanase and 1,4-β-xylanase from Penicillium simplicissimum.  Based on this model 
it was identified that the interaction between inhibitor and heparanase enzyme was stabilised 
by arylalkylation [52].  Glucosidases are last stage carbohydrate digestive enzymes.  They are 
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responsible for hydrolysing the glycosidic bond of oligosachharides.  Park et al., wished to 
design new inhibitors derived from structure based virtual screening.  In order to accomplish 
this they were required to obtain a high quality amino acid sequence of the enzyme.  This was 
achieved by the alignment of sequence from baker’s yeast α-glucosidase and oligo-1,6- 
glucosidase from Bacillus cereus.  Such that these sequences shared an amino acid identity and 
similarity of 38.5% and 58.4% respectively.  The homology model was sufficient to perform 
docking studies.  It was observed that the target and the template displayed highly similar 
folding structures, whereby the catalytic residues were conserved in terms of position in the 
active site when compared to the x-ray crystal structure of oligo-1,6-glucosidase (Figs.  7 & 8) 
[53].   
 
Figure 7: Comparative view of (a) homology modelled structure of α-glucosidase and (b) the x-ray 
crystal structure of oligo-1,6-glucosidase [53] 
 
Figure 8: Comparison of the ProSa energy profiles of the homology modelled structure of α-
glucosidase (red) and the x-ray crystal structure of oligo-1,6-glucosidase (green) [53] 
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Researchers Moorthy, Ramos and Fernandes conducted homology modelling of an α-
glucosidase enzyme which was later used in a quantitative structure activity relationship study 
of xanthone derivatives.  They had deduced that the active site of the model retained residues 
aspartic acid, histidine and glutamic acid, which contributed to the specific structural features 
of potential inhibitors [54].  Human glycan’s which include N-linked glycan’s, ABO blood 
group and Lewis antigens have prominent structural moieties of α-L-fucose a residue by-
product of reaction catalysed by α-L-fucosidase [55, 56].  Many cancers are associated with 
the high levels of fucosylation which increases with expression of the enzyme [57, 58].  Bueren 
et al., analysed the reaction co-ordinate of α-L-fucosidases by combining structural and 
quantum mechanical approaches.  They were able to interpret inhibitor binding by deriving a 
homology model of enzyme from B.  thetaiotaomicron as the sequence identity was in high 
correlation with that of the human enzyme [59]. 
 
Qualitative Structure Activity Relationship (QSAR) 
QSAR is a technique that has infiltrated the scene of drug design and discovery as an invaluable 
tool.  It has been implemented to identify ligands with high affinities for specific 
macromolecular targets, by screening drugs and providing potential outcomes of synthesis and 
testing.  It has also been applied in extended research in predicting adsorption, distribution, 
metabolism, elimination, toxicity properties as well as bioavailability of compounds.  Such 
studies can be undertaken on different dimensions ranging from 1D-QSAR, where only a single 
property of the ligand is exploited correlating to its activity; to 6D-QSAR which involves the 
ligand being represented as an ensemble of configurations with the explicit representation of 
different induced fit models and the representation of different solvation scenarios [60].  
Glycosidases have evolved finely tuned active site configurations for the specific hydrolysis of 
glycosidic bonds.  The inhibition of glucosidases has offered a noteworthy effect on the glycon 
structure ultimately affecting the maturation, transport, secretion and function of glycoproteins.  
Thus this could potentially have an altered recognition of cell-cell processes.  Moorthy et al., 
attempted QSAR studies on associated xanthone derivatives based on the data set published by 
Yan et al., as inhibitors of α-glucosidase.  Xanthones are natural derivatives extracted from 
different medicinal plant material (Fig.  9) [61, 62].  Due to the limited information presented 
from current literature, they decided to delve into the link of biological activity data and 
physiochemical descriptors of molecules.  By exploring structural features which have a 
determining effect on the binding affinity, mechanism of inhibition, topology and 
hydrophobicity.  It was established that heteroatoms such as; oxygen bonded to carbon, are 
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favourable features for enzyme inhibition.  Using an E-state count descriptor, the most 
favourable framework for inhibition of enzyme activity is a carbon atom linked with three 
aromatic bonds and hydrogen or other atoms [54, 63, and 64].  Moorthy and colleagues 
performed additional studies on the α-glucosidase enzyme of B.  Stearothermophilus and S.  











1: R = CH3
2: R = CH2CH3
Xanthonoxypropanolamines  
Figure 9: Xanthone and subsequent xanthone derivatives 
 
Virtual Screening 
Virtual screening has offered a cost effective method by which we may search for lead 
structures for further development as therapeutic agents in different biological systems and 
against a multitude of targets.  An advantage of this technique is the resulting computational 
prediction of binding affinity, which contributes to bottlenecking and reduces the number of 
compounds required for testing.  In terms of drug design, a range of computational methods 
are employed at distinctive stages of the procedure.  As previously mentioned, high through-
put screening of large compound libraries focuses on decreasing the number of potential 
ligands.  Post lead optimization, reduction of experimental costs and time is emphasized.  
Molecular dynamic simulations have improved docking procedures in terms of Molecular 
Mechanics Poison-Boltzmann/ Generalised Born Surface Area (MM/PBSA or MM/GBSA), 
Free Energy Perturbation (FEP), Thermodynamic Integration (TI) and Linear Interaction 
Energy (LIE) approaches [66-69].  They add invaluable insight into the dynamic behaviour of 
proteins at various time-frames, from speedy internal motions to steady conformational 
changes or even protein folding processes.  Studying of the explicit solvent molecule effect 
[70] on protein structure and stability to characterise a biomolecular system is plausible.  Such 
system characteristics include density, conductivity, dipolar moment and thermodynamic 
parameters inclusive of interaction energies as well as entropies [71, 72].  Several MD-based 
in silico methods for binding energy predictions have been extensively applied in drug design 
as they provide statistically meaningful conformational ensembles for thermodynamic 
calculations at a reasonable computational cost.  MM/PBSA and MM/GBSA are considered 
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more computationally efficient calculations as opposed to FEP/TI.  This is attributed to the 
former free binding energy calculations having fewer constraint rules to obey, as well as their 
capability to dissect total binding free energy into different interaction terms [73].  MM-
PBSA/GBSA are, however, theoretically more rigorous as such calculations take into 
consideration the conformation of free ligand, receptor and ligand-receptor complex.  The FEP 
theory was initially introduced by Zwanzig in 1954, where he correlated the free energy 
distinction between reference and target state of a system to its average function of energy 
estimated by sampling initial states [74].  Since then much improvement has been made by way 
of calculating free energy differences using this technique.  These include coupling the 
mathematical algorithm with advanced molecular dynamics and Monte Carlo sampling to 
elucidate respective solvation free energies, pKa values, medium-effects on conformational 
equilibria, host-guest binding affinities, organic and biochemical reactions free energy surfaces 
[75].  Alternatively, binding energies can be calculated by scoring functions as they compute 
results faster than the MM-GB/PBSA models.  However, scoring functions lack precision, with 
an average error of ~2.5 kcal/mol [69].  In 2008 Park and colleagues suggested discovering 
novel inhibitors of α-glucosidase through virtual screening encouraged by a homology-
modelled protein structure [53].  The technique allowed the screening of a library estimating 
85,000 compounds, resulting in the reduction of sample size to 200 of the highest scoring 
compounds.  It was later established that only 13 of these suggested agents presented a 50% 
inhibition at a concentration range between 0 μM and 50 μM [53].  Figs.  10, 11, are 
representative inhibitors, their scaffolds now form the templates for further development and 


















































































































Figure 11: Chemical structures 9 - 13 of newly identified α-glucosidase inhibitors [53] 
 
Molecular Modelling and Binding Modes 
Molecular modelling is a fusion of structure and function of molecules in the form of proteins, 
ligands and cellular entities.  The manipulation of chemistry and laws of protein folding allows 
scientists to seek understanding of physiology of disease.  The essence of the technology 
utilises molecular biology, x-ray crystallography and quantum mechanics [71, 76, and 77].  The 
allure of molecular modelling techniques lies in the atomistic level description of molecular 
systems.  There are three common stages involved in molecular modelling studies.  The first 
stage is a selection process whereby a model is chosen to best describe the intra- and inter- 
molecular interactions in a system.  The two most frequently used models are quantum 
mechanics and molecular mechanics, both follow the fundamentals of the energy associated 
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with the arrangement of atoms and molecules within the system.  The second stage 
encompasses the actual mathematical calculation of the system, this includes energy 
minimisation, molecular dynamic or Monte Carlo simulations or a conformational search.  This 
leads directly into the final stage of post-analysis of the calculations carried out in stage two.  
It is no small wonder that from these stages computational chemistry or molecular modelling 
is regarded as a classical example of scientific art [78].  From the post-analysis of calculations 
performed a multitude of information may be generated with respect to molecular geometry, 
energies, electronic properties, spectroscopic properties and bulk properties [78, 79].  
Allosamidin has been classified as a pseudo-trisaccharide (Fig.  12), isolated from the mycelia 




















Figure 12: 2D structure of allosamidin 
Germer and colleagues performed molecular modelling studies on the allosamidin and six 
additional analogues based on the allosamidin framework in an effort to validate 
conformational information extracted from 2D NMR studies.  Of which it was concluded that 
the results of each method were aligned.  Proving once again that computational approaches to 
scientific investigations can act both as a tool of diagnosis and validation [81].  Kara et al., 
proposed a mechanism of action of allosamidin in chitinase, which is regarded as a type of 
glycohydrolase enzyme.  With modelling, Kara and colleagues suggested that mechanism of 
action of the enzyme involves the bending of acetalamido group to oxygen of the substrate ring 
which subsequently neutralises the charge.  Allosamidin mimics the transition state of the 
catalytic reaction and thus perpetuates competitive and selective inhibition of the enzyme [82].  
α-Mannosidase is a class II enzyme partaking in the N-glycosylation reaction, with a function 
to link oligosaccharides to distinct asparagine amino acids in incipient proteins.  Thus 
subsequent inhibitors show radical antitumour and antimetastatic activity.  Such inhibitors 
include kifunensine an alkaloid derived from actinomycete Kitasatosporia kifunense, salacinol 
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extracted from Salacia reticulata and swainsonine [83-85].  Shah et al., compared the binding 




















Kifunensine Swainsonine 1-Deoxymannojirimycin  
Figure 13: 2D structure of α-mannosidase inhibitors kifunensine, swainsonine and 1-
deoxymannojirimycin [88] 
 
1-Deoxymannojirimycin, once thought only a derivative of the natural inhibitor nojirimycin a 
piperidine alkaloid isolated from Streptomyces sp., was found naturally occurring from the 
extract of mulberry leaves, Bacillus and Streptomyces sp.  as well as Micronesian marine 
sponge [5, 86, 87].  However, both entities proved viable inhibitors of glycosidases and thus 
exerted an effective activity as antitumor and anticancer agents.  Shah and colleagues 
performed energy directed studies which proposed kifunensine inferring moderate inhibition 
to class II mannosidase as compared to being more potent against class I mannosidase.  With 
kifunensine maintaining a 1C4 conformation in each of the different active sites.  1-
Deoxymannojirimycin being a smaller inhibitor observed a 4C1 conformation in the class I 
mannosidase active site but a 1C4 conformation in the class II mannosidase active site [88].  
Wen et al., investigated the binding mode off the previously mentioned inhibitors docked in 
the glycosidase enzyme.  The study revealed that the five membered ring of kifunensine is 
planar.  There exists three distinct binding modes differing by the distance between zinc and 
hydroxyl polar groups.  In mode I the distance was estimated to 2.3 Å, mode II 3.31 Å, whereas 
with mode III the ligand appeared to turn completely within the active site and thus the distance 
was of polar group to zinc was too far.  With respect to salacinol the inflexibility of its five 
membered ring offered pseudo rotation (Fig.  14).  The three distinct binding modes of this 
system reasoned that the relative conformations are independent of the interaction between the 
polar species of the ligand and active site interactive moieties.  In conclusion these findings 













Figure 14: 2D structure of salacinol 
Mannostatin A and B (Fig.  15), were discovered by Aoyagi and collaborators in 1989 from 
isolates of Streptoverticilliu verticillus variation quantum.  Classed as novel 
aminocylcopentitol structures they were found to be active inhibitors of α-mannosidase and α-
glucosidase [90].  Kawatkar et al., explored the ligand-protein interactions of mannostatin A 
and α-mannosidase II.  Their research team had elucidated that mannostatin A mimicked 
covalently linked mannosyl intermediate which adopts a 1S5 skew boat conformation.  It was 
established that the thiomethyl group is required for high affinity binding, which was reported 
to have good overlay with the C-6 hydroxyl of the covalently linked intermediate [91].  Kuntz 
et al., had performed binding mode studies on a similar system.  Their findings were in cognito 
with corresponding literature, that inhibition sees crucial contribution of zinc interactions, 
interactions with Asp341 and Asp472, as well as hydrophobic interactions with Phe206 of the 





















Figure 15: 2D structure of mannostatin A and B with corresponding inhibition values [92] 
 
Cardona et al., conducted molecular dynamic simulations on glucoamylase II from Aspergillus 
awamori with natural inhibitors 1-deoxynojirimycin and lentiginosine (Fig.  16) in an attempt 
to understand binding for further investigation in the design of new inhibitors in human systems 
as antitumour agents.  It was then determined that lentiginosine observed optimal conformation 
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in the enzyme cavity when hydrogen bonding to residues Arg54 and Arg55.  As well as 
inhibition was dominated by the interaction of hydroxyl groups of the substrate with key 
enzyme residues [93].  Zhou et al., performed similar simulations, however, the system 
involved comprised of 1-deoxynojirimycin and isogaomine.  They showed that 1-
deoxynojirimycin bound to glucosidase in a protonated chair conformation with a binding 
energy value of -46.76 kJ/mol. 
Major thermodynamic contributions implying favourable enthalpy of binding were attributed 






Figure 16: 2D structure if lentiginosine 
 
Pereira et al., performed a conformational and dynamical study on disaccharides in water using 
explicit-solvent molecular dynamic simulations [95, 96].  They analysed eight reducing 
disaccharides of β-anomeric configuration isolated from honey: kojibiose, sophorose and 
nigerose (Fig 17), as well as laminarabiose, maltose, cellobiose, isomaltose and gentiobiose.  
In current literature most of the disaccharides have been characterised and theoretically 
investigated using MD simulations, molecular mechanics calculations or quantum mechanics 
calculations.  In the study a continuous 50 ns run time was performed, during which time it 
was concluded that the preference of dihedral angles which dictates that polar substituents are 






































Kräutler et al., explored conformation, dynamic, solvation and respective stabilities of specific 
β-hexopyranoses in water using a molecular dynamic platform.  Four β-D-aldohexopyranoses 
monosaccharides were studied, namely: β-D-glucose, β-D-mannose, β-D-galactose and β-D-
talose; which were simulated in a series of 200 ns timescale.  During the simulation the latter 
three substrates maintained a 4C1 chair conformation, unlike glucose which has evolving boat 
and twisted configurations.  Kräutler et al., described the intramolecular hydrogen-bonding 
pattern with each substrate, and were deemed opportunistic contributors to the relative 
conformation and stability of the structure.  They had ranked the estimated epimerisation 
energies in order of decreasing stability, with talose exhibiting the least stability superseded by 
galactose and mannose in turn, with glucose registered as most stable.  This confirmed results 
obtained from intramolecular effects and hydrophilicity investigations [98].  Trehalose (Fig.  
18), a sugar extract from yeast, exists as a naturally occurring disaccharide in mushrooms and 
other fungi.  This unique combination of α-D-glucopyranosyl-α-D-glucopyranoside has been 
implicated as prominent inhibitor of the glucosidase enzyme [99].  The dysfunction of the 
enzyme has proven a target in the prevention of growth and development of metastatic cancer.  
Trehalose has been shown to form direct hydrogen bonds to proteins which endure the ligand 
requiring occupation of specific active site in a specific orientation [100].  There have been a 
number of reported simulations investigating the structural dynamics of binary sugar/water 
solution in an attempt to elucidate physical properties [101-111].  Sum et al.  [112] and Pereira 
et al.  [113, 114] had conducted a simulation of a lipid membrane in the presence of sugars.  
They discovered that specific hydrogen bonding governed the interaction between sugar and 
lipid molecules.  Lerbret et al.  had decided to simulate a lysozyme in aqueous solution of 
trehalose, sucrose and maltose.  It was suggested that trehalose was the most hydrated of all 













Figure 18: 2D structure of trehalose 
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Park and collaborators, took their study of novel α-glucosidase inhibitors a step further by 
exploiting the binding modes of the 13, then, newly identified molecules in the active site of 
the enzyme during which they noticed that the phenolic oxygen of the select inhibitor was a 
key feature in the migration of a hydrogen bond from His348 to Asp349, essentially translating 
to the phenol moiety playing a pivotal role for binding to the active site.  It was also established 
that the stabilisation of docked ligands can be attained by inducing hydrophobic interactions at 
across from the active site [53]. Pistarà et al., had provided in silico characterisation of 
cyclitols, inosose the ketone structure of inositols found in mammalian tissues and 
Streptomyces griseus.  The inosose molecules were docked in human maltase-glucoamylase 
which has been crystallised with miglitol (Fig.  19).  It was determined that nitrogen that 
engages in a hydrogen bond with Asp443 in the catalytic residue is an essential entity for 
inhibitory activity.  Additional structural components such as benzyl have the ability of filling 
the active site [116].  The binding free energy of compound 1 was calculated to be -6.0 kcal/mol 
















Figure 19: (left) 2D structure of miglitol and (right) 2D structure of compound 1 
CONCLUSION 
From the topics described above, it is evident that there exist considerable gaps in the way of 
computational studies performed on the natural element inhibitors of glycosidase enzymes.  
These include the understanding of kinetic mechanisms of inhibitor enzyme interaction, 
conformational support within active site, effects of mutagenesis, selective and competitive 
inhibition of enzyme species; and many more.  Thus, there is great opportunity for continued 
research toward answering many of these essential components by way of a computational 
approach.  Additional research toward understanding the reaction kinetics and mechanism of 
glycosidase enzymes in their natural biological system, would be imperative in our quest to 
discover and design innovative anticancer inhibitors.  Despite the large array of high resolution 
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crystal structures available within the protein databank, much effort is required in acquiring 
crystal structures of human glycosidase.  Such that accurate study may be performed to 
investigate possible inhibitors.  Intensive molecular dynamic study encompassing molecular 
biology techniques would aid research in determining critical enzyme reactions that perpetuate 
cancerous species.  Thus by isolating specific drug targets, it would allow us to build into the 
inhibitor, selective drug delivery systems exerting a specialised response.  An attractive feature 
of obtaining refined crystal structures of human glycosidase enzymes, offers insight into the 
active site residues.  Thus accurate binding modes may be established as well as chemical 
structuring of potential inhibitors may be designed according to supported conformational and 
steric properties.  Despite limitations of the crystal library with the aid of computational tools 
we may continue studies in this field by accurately constructing best-fit homology models of 
associated enzymes.  Extensive studies based on QSAR and QM/MM of biological systems 
will dramatically improve our understanding of the influence of glycosidase enzymes in cancer 
development.  As well as it could bridge the gap between theoretical and experimental studies, 
by economising on time, cost of study and prioritising higher possibility enzyme structure and 
mechanistic predictions.  The above mentioned attributes contribute to the design and 
development of new drugs as anticancer agents as well as provides pivotal information with 
regards to the specific enzyme pathways implicated in cancer.  Molecular dynamic studies 
present an opportunistic methodology whereby we may unlock and unveil the mystery 
underlying the disease thus unleashing great strides in our fight against cancer.  Computational 
techniques boast an arsenal to unravel and offer a broad introspection into the molecular 
dynamics of glycosidase enzymes.  Thus the study of this family is not exclusive or restricted 
to its effect on cancer but rather a multi-dimensional study on other congenital disorders of 
glycosylation may be investigated.  Armed with computational tools the study of glycosidase 
enzymes remains limitless, and with the limited literature available within this topic much 
research is yet to be done in this field. 
 
CONFLICT OF INTEREST 









[1] Wong, K.C., Wang, C.; Wu, L.  History of Chinese medicine: Being a chronicle of medical 
happenings in china from ancient times to the present period 1936: Tientsin Press. 
[2] Dias, D.A.; Urban, S.; Roessner, U.  A historical overview of natural products in drug 
discovery.  Metabolites, 2012, 2(2), 303-336. 
[3] Balunas, M.J.  Kinghorn, A.D.  Drug discovery from medicinal plants.  Life Sci., 2005.  
78(5), 431-441. 
[4] Li, J.W.; Vederas, J.C.  Drug discovery and natural products: End of an era or an endless 
frontier? Science, 2009, 325(5937), 161-165. 
[5] Cragg, G.M.; Newman, D.J.  Plants as a source of anti-cancer agents.  J.  Ethnopharmacol., 
2005, 100(1-2), 72-79. 
[6] Srivastava, V.  Plant-based anticancer molecules: A chemical and biological profile of some 
important leads.  Bioorg.  Med.  Chem., 2005, 13(21), 5892-5908. 
[7] Newman, D.J.; Giddings, L.A.  Natural products as leads to antitumor drugs.  Phytochem.  
Rev., 2013, 13(1), 123-137. 
[8] Gordaliza, M.  Natural products as leads to anticancer drugs.  Clin.Trans.  Oncol., 2008, 
9(12), 767-776. 
[9] Padler-Karavani, V.  Aiming at the sweet side of cancer: Aberrant glycosylation as possible 
target for personalized-medicine.  Cancer Lett., 2013. 
[10] Dube, D.H.; Bertozzi, C.R.  Glycans in cancer and inflammation [mdash] potential for 
therapeutics and diagnostics.  Nat.  Rev.  Drug Discov., 2005, 4(6), 477-488. 
[11] Ludwig, J.A.; Weinstein, J.N.  Biomarkers in cancer staging, prognosis and treatment 
selection.  Nat.  Rev.  Cancer, 2005, 5(11),845-856. 
[12] Kannagi, R.;Yin, J.; Miyazaki, K.; Izawa, M.  Current relevance of incomplete synthesis 
and neo-synthesis for cancer-associated alteration of carbohydrate determinants—Hakomori's 
concepts revisited.  Biochimica.  Biophysica.  Acta, 2008, 1780(3), 525-531. 
[13] Miyazaki, K.; Ohmori, K.; Izawa, M.; Koike, T.; Kumamoto, K.; Furukawa, K.; Ando, T.; 
Kiso, M.; Yamaji, T.; Hashimoto, Y.; Suzuki, A.; Yoshida, A.; Takeuchi, M.; Kannagi, R.  Loss 
of disialyl lewisa, the ligand for lymphocyte inhibitory receptor sialic acid-binding 
immunoglobulin-like lectin-7 (siglec-7) associated with increased sialyl lewisa expression on 
human colon cancers. Cancer Res., 2004, 64(13), 4498-4505. 
[14] Buckhaults, P.; Chen, L.; Fregien, N.; Pierce, M.Transcriptional regulation of N-




[15] Le Marer, N.; Laudet, V.; Svensson, E.C.; Cazlaris, H.; Van Hille, B.; Lagrou, C.; Stehelin, 
D.; Montreuil, J.; Verbert, A.; Delannoy, P.  The c-Ha-ras oncogene induces increased 
expression of β-galactoside α-2,6-sialyltransferase in rat fibroblast (FR3T3) cells. 
Glycobiology, 1992, 2(1), 49-56. 
[16] Hatano, K.; Miyamoto, Y.; Mori, M.; Nimura, K.; Nakai, Y.; Nonomura, N.; Kaneda, Y.  
Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cells.  PLoS 
One, 2012, 7(2), e31234. 
[17] Kim, J.K.; Noh, J.H.; Jung, K.H.; Eun, J.W.; Bae, H.J.; Kim, M.G.; Chang, Y.G.; Shen, 
Q.; Park, W.S.; Lee, J.Y.; Borlak, J.; Nam, S.W.  Sirtuin7 Oncogenic Potential in Human 
Hepatocellular Carcinoma and its regulation by the tumour suppressors MiR-125a-5p nd MiR-
125b.  Hepatology, 2013, 57(3), 1055-1067. 
[18] Schietinger, A.; Philip, M.; Yoshida, B.A.; Azadi, P.; Liu, H.; Meredith, S.C.; Schreiber, 
H.  A mutant chaperone converts a wildtype protein into a tumor-specific antigen.  Science, 
2006, 314(5797), 304-308. 
[19] Miyagi, T.  Aberrant expression of sialidase and cancer progression. Proc.  JPN.  Acad.  
Ser.  B.  Phys.  Biol.  Sci., 2008, 84(10), 407-418. 
[20] Miyagi, T.; Wada, T.; Yamaguchi, K.; Hata, K.  Sialidase and malignancy: A minireview.  
Glycoconj.  J., 2003, 20(3), 189-198. 
[21] Kakugawa, Y.; Wada, T.; Yamaguchi, K.; Yamanami, H.; Ouchi, K.; Sato, I.; Miyagi, T.  
Up-regulation of plasma membrane associated ganglioside sialidase (Neu3) in human colon 
cancer and its involvement in apoptosis suppression.  Proc.  Nat.  Acad.  Sci., 2002, 99(16), 
10718-10723. 
[22] Dennis, J.W.; Laferté, S.; Waghorne, C.; Breitman, M.L.; Kerbel, R.S.  Beta 1-6 branching 
of Asn-linked oligosaccharides is directly associated with metastasis.  Science, 1987, 
236(4801), 582-585. 
[23] Kumamoto, K.; Goto, Y.; Sekikawa, K.; Takenoshita, S.; Ishida, N.; Kawakita, M.; 
Kannagi, R.  Increased expression of udp galactose transporter messenger rna in human colon 
cancer tissues and its implication in synthesis of thomsen-friedenreich antigen and sialyl lewis 
a/x determinants.  Cancer Res., 2001, 61(11), 4620-4627. 
[24] Kellokumpu, S.; Sormunen, R.; Kellokumpu, I.  Abnormal glycosylation and altered Golgi 
structure in colorectal cancer: Dependence on intra-Golgi pH.  FEBS Lett., 2002, 516(1-3), 
217-224. 
[25] Moremen, K.W.; Tiemeyer, M.; Nairn, A.V.  Vertebrate protein glycosylation: Diversity, 
synthesis and function.  Nat.  Rev.  Mol. Cell Biol., 2012, 13(7), 448-462. 
68 
 
[26] Meany, D.L.; Chan, D.W.  Aberrant glycosylation associated with enzymes as cancer 
biomarkers.  Clin.  Proteomics, 2011, 8(1), 7. 
[27] Vocadlo, D.J.; Davies, G.J.  Mechanistic insights into glycosidase chemistry.  Curr.  Opin.  
Chem.  Biol., 2008, 12(5), 539-555. 
[28] Gramatikoff, K.  Steps in the glycosylation of mammalian n-linked oligosaccarides.  
Pathways [cited 2014 02 September]; Available at: 
http://www.biocarta.com/pathfiles/h_aMANPathway.asp#contributors. 
[29] Divakar, S.; Glycosidases, Enzymatic Transforation, 2013, 5-21. 
[30] Kushen Ramessur, P.G.A.M.D.  Glycosidases and breast cancer cell migration through 
the extracellular matrix.  The Biomed.  Scient., 2010. 
[31] Prabha, M.N.R.S.; Ravi, V.  Specific activity of glycosidases in brain tumors and their 
expression in primary explants culture.  J. Biochem.  Technol., 2013, 5(1), 654-665. 
[32] Bellezza, I.; Aisa, M.C.; Palazzo, R.; Costanzi, E.; Mearini, E.;  Minelli, A.  Extracellular 
marix degrading enzymes at the prostasome surface.  Prostate Cancer Prost.  Dis, 2005, 8, 
344-348. 
[33] Niedbala, M.J.; Madiyalakan, R.; Matta, K.; Crickard, K.; Sharma, M.; Bernacki, R.J.  
Role of glycosidases in human ovarian carcinoma cell mediated degradation of subendothelial 
extracellular matrix.  Cancer Res., 1987, 47, 4634-4641. 
[34] Yarema, K.J., Bertozzi, C.R.  Characterizing glycosylation pathways.  Genome Biol, 2001, 
2(5). 
[35] Gerber-Lemaire, S.; Juillerat-Jeanneret, L.  Glycosylation pathways as drug targets for 
cancer: Glycosidase Inhibitors.  Mini-Rev.  Med. Chem., 2006, 6(9), 1043-1052. 
[36] Yamasaki, Y.; Konno, H.  Purification and properties of alphaglucosidase from 
suspension-cultures sugar-beet cells. Phytochemistry, 1991, 30(9).  2861-2863. 
[37] Tagami, T.; Yamashita, K.; Okuyama, M.; Mori, H.; Yao, M.; Kimura, A.  Sugar beet 
alpha-glucosidase with acarviosylmaltohexaose. [cited 2014 02 September]; Available at: 
http://www.rcsb.org/pdb/explore/explore.do?structureId=3weo. 
[38] Day, A.J.; DuPont, M.S.; Ridley, S.; Rhodes, M.; Rhodes, M.J.; Morgan, M.R.; 
Williamson, G.  Deglycosylation of flavonoid and isoflavonoid glycosides by human small 
intestine and liver β-glucosidase activity.  FEBS Lett., 1998.  436(1), 71-75. 
[39] Pelkonen, O.; Jorma, T.A.; Jukka, H.; Miia, T.  Consideration of metabolism in in vitro 
cellular systems, in In Vitro toxicology Systems, Meth.  Pharmacol.  Toxicol., 2014, 501-519. 
69 
 
[40] Noguchi, J.; Hayashi, Y.; Baba, Y.; Okino, N.; Kimura, M.; Ito, M.; Kakuta, Y.  Crystal 
structure of the covalent intermediate of human cytosolic beta-glucosidase.  Biochem.  Biophys.  
Res. Commun., 2008, 374(3), 549-552. 
[41] Alder, B.J.; Wainwright, T.E.  Studies in molecular dynamics.  I. general method.  J.  
Chem.  Phys., 1959, 31(2), 459-466. 
[42] Gibson, J.B.; Dynamics of radiation damage.  Phys.  Rev., 1960, 120(4), 1229-1253. 
[43] Rahman, A.  Normalization of diffraction data from liquids.  J. Chem.  Phys., 1965, 42(10), 
3540-3542. 
[44] Karplus, M.; McCammon, J.A.  Molecular dynamics simulations of biomolecules.  Nat.  
Struct.  Biol., 2002, 9(9), 646-652. 
[45] Durrant, J.; McCammon, J.A.  Molecular dynamics simulations and drug discovery.  BMC 
Biol., 2011, 9(1), 71. 
[46] Honarparvar, B.; Govender, T.; Maguire, G.E.; Soliman, M.E.; Kruger, H.G.  Integrated 
approach to structure-based enzymatic drug design: Molecular modeling, spectroscopy, and 
experimental bioactivity.  Chem.  Rev., 2013, 114(1), 493-537. 
[47] Cavasotto, C.N.; Phatak, S.S.  Homology modeling in drug discovery: Current trends and 
applications.  Drug Disc.  Today, 2009, 14(13), 676-683. 
[48] Power, T.D.; Ivanciuc, O.; Schein, C.H.; Braun, W.Assessment of 3D models for allergen 
research.  Proteins, 2013, 81(4), 545-554. 
[49] Rodrigues, J.P.; Melquiond, A.S.; Karaca, E.; Trellet, M.; Van Dijk M.; Van Zundert G.C.; 
Schmitz, C.; De Vries S.J.; Bordogna, A.; Bonati, L.; Kastritis, P.L.; Bonvin, A.M.  Defining 
the limits of homology modeling in information-driven protein docking.  Proteins, 2013, 
81(12), 2119-2128. 
[50] Schmidt, T.; Bergner, A.; Schwede, T.  Modelling threedimensional protein structures for 
applications in drug design.  Drug Discov.  Today, 2014, 19(7), 890-897. 
[51] Nakamura, S.  Homology modeling of human alpha-glucosidase catalytic domains and sar 
study of salacinol derivatives.  Open J. Med.  Chem.; 2012, 2(03), 50-60. 
[52] Ishida, K.; Hirai, G.; Murakami, K.; Teruya, T.; Simizu, S.; Sodeoka, M.; Osada, H.  
Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.  Mol.  
Cancer Therapeut., 2004, 3(9). 
[53] Park, H.; Hwang, K.Y.; Oh, K.H.; Kim, Y.H.; Lee, J.Y.; Kim, K. Discovery of novel α-
glucosidase inhibitors based on the virtual screening with the homology-modeled protein 
structure.  Bioorg.  Med. Chem., 2008, 16(1) 284-292. 
70 
 
[54] Moorthy, N.S.; Ramos, M.J.; Fernandes, P.A.  Topological, hydrophobicity, and other 
descriptors on alpha-glucosidase inhibition: A QSAR study on xanthone derivatives.  J.  
Enzyme Inhib.  Med.  Chem., 2011, 26(6), 755-766. 
[55] Liu, T.W.; Ho, C.W.; Huang, H.H.; Chang, S.M.; Popat, S.D.; Wang, Y.T.; Wu, M.S, 
Chen, Y.J.; Lin, C.H.  Role for alpha-Lfucosidase in the control of Helicobacter pylori-infected 
gastric cancer cells.  Proc.  Natl.  Acad.  Sci.  USA, 2009, 106(34), 14581-14586. 
[56] Liu, T.W.; Ho, C.W.; Huang, H.H.; Chang, S.M.; Popat, S.D.; Wang, Y.T.; Wu, M.S.; 
Chen, Y.J.; Lin, C.H.  Identification of essential residues of human α-l-fucosidase and tests of 
its mechanism.  Biochemistry, 2008, 48(1), 110-120. 
[57] Patrick, J.; Willems, H.C.S.; Paul, C.  Rossana tonlorenzi and john s o'brien, spectrum of 
mutations in fucosidosis.  Eur.  J.  Human Genet., 1999, 7(1), 60-67. 
[58] Yuan, K.; Kucik, D.; Singh, R.K.; Listinsky, C.M.; Listinsky, J.J.; Siegal, G.P.  Alterations 
in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins 
displaying alpha-L-fucose moieties.  Int.  J.  Oncol, 2008, 32(4), 797-807. 
[59] Lammerts van Bueren, A.; Ardèvol, A.; Fayers-Kerr, J.; Luo, B.; Zhang, Y.; Sollogoub, 
M.; Blériot, Y.; Rovira, C.; Davies, G.J. Analysis of the reaction coordinate of α-l-fucosidases: 
A combined structural and quantum mechanical approach.  J.  Am.  Chem.  Soc., 2010, 132(6), 
1804-1806. 
[60] Lill, M.A.  Multi-dimensional QSAR in drug discovery.  Drug Discov.  Today, 2007, 
12(23-24), 1013-1017. 
[61] Pinto, M.M.; Sousa, M.E.; Nascimento, M.S.  Xanthone Derivatives: New insights in 
biological activities.  Curr.  Med. Chem., 2005, 12, 2517-2538. 
[62] Negi, J.S.; Singh, V.K.B.P.; Rawat, M.S.M.; Joshi, G.P.  Naturally occurring xanthones: 
Chemistry and biology.  J.  App.  Chem., 2013. 
[63] Liu, Y.; Ke, Z.; Cui, J.; Chen, W.H.; Ma, L.; Wang, B.  Synthesis, inhibitory activities, 
and QSAR study of xanthone derivatives as α- glucosidase inhibitors.  Bioorg.  Med.  Chem., 
2008, 16(15) 7185-7192. 
[64] Liu, Y.; Zou, L.; Ma, L.; Chen, W.H.; Wang, B.; Xu, Z.L. Synthesis and pharmacological 
activities of xanthone derivatives as α-glucosidase inhibitors.  Bioorg.  Med.  Chem., 2006, 
14(16), 5683-5690. 
[65] Narayana Moorthy N.S.; Ramos, M.J.; Fernandes, P.A. Comparative structural analysis 
of alpha-glucosidase inhibitors on difference species: A computational study.  Arch.  Pharm.  
Chem. Life Sci., 2012, 345, 265-274. 
71 
 
[66] Yang, Y.; Qin, J.; Liu, H.; Yao, X.  Molecular dynamics simulation, free energy 
calculation and structure-based 3d-qsar studies of b-raf kinase inhibitors.  J.  Chem.  Inform.  
Mod., 2011, 51(3), 680-692. 
[67] Xue, Q.; Zhang, J.L.; Zheng, Q.C.; Cui, Y.L.; Chen, L.; Chu, W.T.; Zhang, H.X.  
Exploring the molecular basis of dsRNA recognition by Mss116p using molecular dynamics 
simulations and free-energy calculations.  Langmuir, 2013, 29(35), 11135-11144. 
[68] Cui, Y.L.; Zheng, Q.C.; Zhang, J.L.; Xue, Q.; Wang, Y.; Zhang H.X.  Molecular dynamic 
investigations of the mutational effects on structural characteristics and tunnel geometry in 
CYP17A1.  J. Chem.  Inform.  Mod, 2013, 53(12), 3308-3317. 
[69] Xu, L.; Sun, H.; Li, Y.; Wang, J.; Hou, T.  Assessing the performance of MM/PBSA and 
MM/GBSA methods.  3.  The impact of force fields and ligand charge models.  J.  Phys.  Chem.  
B, 2013, 117(28), 8408-8421. 
[70] Pang, X.; Zhou, H.X.  Poisson-Boltzmann Calculations: Van der waals or molecular 
surface? Commun.  Comput.  Phys., 2013, 13(1), 1-12. 
[71] Alonso, H.; Bliznyuk, A.A.; Gready, J.E.  Combining docking and molecular dynamic 
simulations in drug design.  Med.  Res.  Rev., 2006, 26(5), 531-568. 
[72] McInnes, C.  Virtual screening strategies in drug discovery.  Curr. Opin.  Chem.  Biol., 
2007, 11(5), 494-502. 
[73] Sun, H.; Li, Y.; Tian, S.; Xu, L.; Hou, T.  Assessing the performance of MM/PBSA and 
MM/GBSA methods.  4.  Accuracies of MM/PBSA and MM/GBSA methodologies evaluated 
by various simulation protocols using PDBbind data set.  Phys.  Chem.  Chem. Phys., 2014, 
16(31) 16719-16729. 
[74] Jorgensen, W.L.; Thomas, L.L.  Perspective on free-energy perturbation calculations for 
chemical equilibria.  J.  Chem.  Theory Comput., 2008, 4(6), 869-876. 
[75] Chipot, C.  Frontiers in free-energy calculations of biological systems.  Wiley 
Interdisciplinary Reviews: Comput.  Mol.  Sci., 2014, 4(1), 71-89. 
[76] Meyer, E.F.; Swanson, S.M.; Williams, J.A.  Molecular modelling and drug design.  
Pharmacology & Therapeutics, 2000, 85(3), 113-121. 
[77] Caflisch, A.  Focal Point: Medicinal Chemistry.  Chimia, 1999.  50, 35-36. 
[78] Redhu, S.; Jindal, A.  Molecular modelling: A new scaffolding for drug design.  Int.  J.  
Pharm.  Pharmaceut.  Sci., 2013, 5(1). 
[79] Friedman, R.; Boye, K.; Flatmark, K.  Molecular modelling and simulations in cancer 
research.  Biochim.  Biophys.  Acta, 2013, 1836(1), 1-14. 
72 
 
[80] Berecibar, A.; Grandjean, C.; Siriwardena, A.  Synthesis and biological activity of natural 
aminocyclopentitol glycosidase inhibitors: Mannostatins, trehazolin, allosamidins, and their 
analogues.  Chem.  Rev., 1999.  99, 779-844. 
[81] Germer, A.; Peter, M.G.; Kleinpeter, E.  Solution-State conformational study of the 
hevamine inhibitor allosamidin and six potential inhibitor analogues by NMR spectroscopy 
and molecular modeling.  J.  Org.  Chem., 2002, 67(18), 6328-6338. 
[82] Bortone, K.; Monzingo, A.F.; Ernst, S.; Robertus, J.D.  The Structure of an allosamidin 
complex with the coccidioides immitis chitinase defines a role for a second acid residue in 
substrate assisted mechanism.  J.  Mol.  Biol., 2002, 320(2), 293-302. 
[83] Kawatkar, S.P.  Molecular modeling insights into the inhibition and catalytic mechanism 
of golgi alpha-mannosidase II, 2006, University of Georgia Athens, Georgia. 
[84] Elbein, A.D.; Tropea, J.E.; Mitchell, M.; Kaushal, G.P. Kifunensine, a potent inhibitor of 
the glycoprotein processing mannosidase I.  J.  Biol.  Chem., 1990, 265(26), 15599-15605. 
[85] Michael, J.P.  Indolizidine and quinolizidine alkaloids.  Nat.  Prod. Rep., 2004, 21(5), 625-
649. 
[86] Borges de Melo, E.; Da Silveira Gomes, A.; Carvalho, I.  α- and β- Glucosidase inhibitors: 
Chemical structure and biological activity. Tetrahedron, 2006, 62(44), 10277-10302. 
[87] Da Rocha A.B.; Lopes, R.M.; Schwartsmann, G.  Natural products in anticancer therapy.  
Curr.  Opin.  Pharmacol., 2001, 1, 364-369. 
[88] Shah, N.; Kuntz, D.A.; Rose, D.R.  Comparison of kifunensine and 1-
deoxymannojirimycin binding to class I and II alphamannosidases demonstrates different 
saccharide distortions in inverting and retaining catalytic mechanisms.  Biochemistry, 2003, 
42(47), 13812-13816. 
[89] Wen, X.; Yuan, Y.; Kuntz, D.A.; Rose, D.R.; Pinto, B.M.  A combined STD-
NMR/molecular modeling protocol for predicting the binding modes of the glycosidase 
inhibitors kifunensine and salacinol to Golgi alpha-mannosidase II.  Biochemistry, 2005, 
44(18), 6729-6737. 
[90] Nobili, S.; Lippi, D.; Witort, E.; Donnini, M.; Bausi, L.; Mini, E.; Capaccioli, S.  Natural 
compounds for cancer treatment and prevention.  Pharmacol.  Res., 2009, 59(6), 365-378. 
[91] Kawatkar, S.P.; Kuntz, D.A.; Woods, R.J.; Rose, D.R.; Boons GJ. Structural basis of the 
inhibiton of golgi alpha-mannosidase II by Mannostatin A and the role of the thiomethyl moiety 
in ligandprotein interactions.  2006. 
73 
 
[92] Kuntz, D.A.; Zhong, W.; Guo, J.; Rose, D.R.; Boons, G.J.  The molecular basis of 
inhibition of Golgi alpha-mannosidase II by mannostatin A.  Chem.Bio.Chem., 2009, 10(2) 
268-277. 
[93] Francesca, C.; Andrea, G.; Alberto, B.; Maria, S.; Neri, N.; Stefano, M.  Molecular 
dynamics simulations on the complexes of Glucoamylase II (471) from Aspergillus awamori 
var.  X100 with 1-Deoxynojirimycin and lentiginosine.  Mol.  Mod.  Ann., 1997, 3(7), 
249-260. 
[94] Jin-Ming, Z.; Jun-Hong, Z.; Yi, M.; Min-Bo, C.  Molecular dynamics simulation of 
iminosugar inhibitor−glycosidase complex: insight into the binding mechanism of 1-
deoxynojirimycin and isofagomine toward β-Glucosidase.  J.  Chem.  Theor.  Comput., 2005, 
2(1), 157-165. 
[95] Karplus, M.; Kushick, J.N.  Method for estimating the configurational entropy of 
macromolecules.  Macromolecules, 1981, 14(2) 325-332. 
[96] Ilario, G.T.; René, S.; Paul, E.S.; Wilfred, F.; Van, G.  A generalized reaction field method 
for molecular dynamics simulations.  J.  Chemi.  Phys., 1995, 102(13), 5451-5459. 
[97] Pereira, C.S.; Kony, D.; Baron, R.; Müller, M.; Van Gunsteren, W.F.; Hünenberger, 
PH.Conformational and dynamical properties of disaccharides in water: A molecular dynamics 
study.  Biophys.  J., 2006, 90(12), 4337-4344. 
[98] Kräutler, V.M.; Müller, M.; Hünenberger, P.H.  Conformation, dynamics, solvation and 
relative stabilities of selected β-hexopyranoses in water: a molecular dynamics study with the 
gromos 45A4 forcefield.  Carbohydrate Res., 2007, 342(14), 2097-2124. 
[99] Lerbret, A.; Bordat, P.; Affouard, F.; Descamps, M.; Migliardo, F. How homogeneous are 
the trehalose, maltose, and sucrose water solutions? An insight from molecular dynamics 
simulations.  J. Phys.  Chem.  B, 2005, 109(21), 11046-11057. 
[100] Sastry, G.M.; Agmon, N.  Trehalose prevents myoglobin collapse and preserves its 
internal mobility.  Biochemistry, 1997.  36(23), 7097-7108. 
[101] Brady, J.W.; Schmidt, R.K.  The role of hydrogen bonding in carbohydrates: Molecular 
dynamics simulations of maltose in aqueous solution.  J.  Phys.  Chem., 1993, 97(4), 958-966. 
[102] Qiang, L.; Schmidt, R.K.; Teo, B.; Karplus, P.A.; Brady, J.W. Molecular dynamics 
studies of the hydration of α,α-Trehalose.  J. Am.  Chem.  Soc., 1997, 119(33), 7851-7862. 
[103] Minoru, S.; Masashi, M.; Yoshio, I.; Akihiro, H.; Syouichi, K. Molecular-dynamics study 
of aqueous solution of trehalose and maltose: Implication for the biological function of 
trehalose.  Bull. Chem.  Society Japan, 1997, 70(4), 847-858. 
74 
 
[104] Roberts, C.J.; Debenedetti, P.G.  Structure and dynamics in concentrated, amorphous 
carbohydrate−water systems by molecular dynamics simulation.  J.  Physical Chem.  B, 1999, 
103(34), 7308-7318. 
[105] Conrad, P.B.; De Pablo, J.J.  Computer simulation of the cryoprotectant disaccharide α,α-
Trehalose in aqueous solution.  J. Physical Chem.  A, 1999, 103(20), 4049-4055. 
[106] Bonanno, G.; Noto, R.; Fornili, S.L.  Water interaction with [small alpha],[small alpha]-
trehalose: Molecular dynamics simulation.  J. Chem.  Soc, Faraday Trans., 1998, 94(18), 2755-
2762. 
[107] Naidoo, K.J.; Kuttel, M.  Water structure about the dimer and hexamer repeat units of 
amylose from molecular dynamics computer simulations.  J.  Comput.  Chem., 2001, 22(4), 
445-456. 
[108] Engelsen, S.B.; Monteiro, C.; Hervé de Penhoat, C.; Pérez, S.  The diluted aqueous 
solvation of carbohydrates as inferred from molecular dynamics simulations and NMR 
spectroscopy.  Biophys. Chem., 2001, 93(2-3),103-127. 
[109] Ekdawi-Sever, N.  Diffusion of Sucrose and α,α-Trehalose in Aqueous Solutions.  J.  
Phy.  Chem.  A, 2003, 107(6), 936-943. 
[110] Molinero, V.; Çaǧın, T.; Goddard Iii, W.A.  Sugar, water and free volume networks in 
concentrated sucrose solutions.  Chem.  Phy. Lett., 2003, 377(3-4), 469-474. 
[111] Bordat, P.; Lerbret, A.; Demaret, J.P.; Affouard, F.; Descamps, M. Comparative study 
of trehalose, sucrose and maltose in water solutions by molecular modelling.  Euro.Phys.  Lett., 
2004, 65(47). 
[112] Sum, A.K.; Faller, R.; Pablo, J.J.D.  Molecular simulation study of phospholipid bilayers 
and insights of the interactions with disaccharides.  Biophys.  J.; 2003, 85(5), 2830-2844. 
[113] Pereira, C.S.; Lins, R.D.; Chandrasekhar, I.; Freitas, L.C Hünenberger, P.H.  Interaction 
of the disaccharide trehalose with a phospholipid bilayer: A molecular dynamics study.  
Biophys.  J., 2004.  86(4), 2273-2285. 
[114] Pereira, C.S.; Hünenberger, P.H.  Interaction of the Sugars trehalose, Maltose and 
glucose with a phospholipid bilayer: A comparative molecular dynamics study.  J.  Phys.  
Chem.  B, 2006, 110(31), 15572-15581. 
[115] Lerbret, A.  Molecular dynamics simulations of lysozyme in water/sugar solutions.  
Chem.  Phys., 2008, 345(2-3), 267-274. 
[116] Venerando, P.; Giuseppe, M.L.; Antonio, R.; Alessia, B.; Felicia D’, A.; Francesco, P.  
Experimental and in silico characterization of a biologically active inosose.  Struct.  Chem., 





Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A 
neuraminidase mutations using multidimensional computational analyses 
Ashona Singh, Mahmoud E Soliman 
School of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa 
Correspondence: Mahmoud E Soliman 
School of Health Sciences, University of KwaZulu-Natal, Westville, Campus, Private Bag 
X54001, Durban 4000, South Africa 
Tel +27 31 260 7413, Fax +27 31 260 7413, Email soliman@ukzn.ac.za 
 
 Abstract: This study embarks on a comprehensive description of the conformational 
contributions to resistance of neuraminidase (N1) in H1N1 and H5N1 to oseltamivir, using 
comparative multiple molecular dynamic simulations.   The available data with regard to 
elucidation of the mechanism of resistance as a result of mutations in H1N1 and H5N1 
neuraminidases is not well established.   Enhanced post-dynamic analysis, such as principal 
component analysis, solvent accessible surface area, free binding energy calculations, and 
radius of gyration were performed to gain a precise insight into the binding mode and origin of 
resistance of oseltamivir in H1N1 and H5N1 mutants.   Three significant features reflecting 
resistance in the presence of mutations H274Y and I222K, of the protein complexed with the 
inhibitor are: reduced flexibility of the α-carbon backbone; an improved ΔEele of ~15 (kcal/mol) 
for H1N1 coupled with an increase in ΔGsol(~13 kcal/mol) from wild-type to mutation; a low 
binding affinity in comparison with the wild-type of ~2 (kcal/mol) and ~7 (kcal/mol) with 
respect to each mutation for the H5N1 systems; and reduced hydrophobicity of the overall 
surface structure due to an impaired hydrogen bonding network.   We believe the results of this 
study will ultimately provide a useful insight into the structural landscape of neuraminidase-
associated binding of oseltamivir.   Furthermore, the results can be used in the design and 
development of potent inhibitors of neuraminidases. 







The rapid evolution of highly pathogenic and resistant variants of influenza A viruses, H5N1 
and H1N1, takes us to the precipice of a possible new-age influenza pandemic.   The first 
human influenza pandemic documented in the 20th century was the 1918–1919 “Spanish flu”, 
which claimed the lives of approximately 50 million people worldwide.1–4  Since 1997, the 
highly pathogenic avian influenza A (H5N1) has had a detrimental effect on the socioeconomic 
development in countries across Africa, Asia, and the Middle East.   Pharmacological advances 
in viable influenza chemotherapeutics and vaccines could not have predicted the influenza A 
(H1N1) virus outbreak in 2009–2010, which claimed an estimated 284,500 lives.   The viruses 
H5N1 and H1N1 display similar pathogenesis of respiratory tract infection in humans.   
However, statistically H5N1 has a higher mortality rate.5 
Influenza virus A is highly communicable.   H1N1 is easily transmissible between humans, 
while avian influenza has not yet adapted sufficiently to facilitate human-human spread; the 
spread of H5N1 is largely dependent on close avian-human contact.   Based on the research, 
the H1N1 and H5N1 viruses can both trace their lineage back to pigs as potential intermediate 
hosts.   Both viruses can undergo reassortment in the intermediate host prior to infection in the 
new host.6,7  This raises the concern that more virulent and highly transmissible influenza virus 
strains may infect humans.8 
Both the H1N1 and H5N1 viruses express two main surface antigens, H5/H1 (hemagglutinin 
type 5/1, respectively) and N1 (neuraminidase type 1).9–11  Neuraminidase has been the main 
target for potential pharmacological interventions.12 It plays a vital role in the spread of 
infection through cleavage of the viral receptor, sialic acid, from both viral and host proteins.   
This results in the release of newly replicated virus from an infected cell.12,13  The active site 
residues of the neuraminidase enzyme are highly conserved within all virus types and subtypes, 
ie, designed neuraminidase inhibitors may be effective against types A and B of the influenza 
virus.14–17 
There are four effective neuraminidase inhibitors currently available: zanamivir,18 
laninamivir,19 peramivir,20 and oseltamivir.21  Zanamivir is commercially known as Relenza® 
and is administered as an aerosol into the nasal cavity.   Zanamivir has been approved in many 
countries since 1999/2000.   Laninamivir is administered in the form of an inhaler and was 
made available to the Japanese market in 2010 (under the trade name Inavir®).   Peramivir, 
commercially known as PeramiFlu®, is administered by intravenous drip and is approved in 
Japan, the Republic of Korea, and the People’s Republic of China.   Oseltamivir commercially 
known as Tamiflu® (Figure 1), has long been the “drug of choice” due to ease of oral 
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administration, improved bioavailability, and easy accessibility.   There has been an increase 
in the number of reports describing oseltamivir resistance in H1N1 and H5N1, and the rapid 
development of resistance toward the drug poses a threat in the event of an outbreak.22,23 
 
Figure 1: Structure of drug oseltamivir 
Research directed toward gaining an insight into the mechanism of resistance of influenza 
viruses is imperative in the future design of drugs as well as in the development of pre-emptive 
measures against possible mutations.   The comparative multiple molecular dynamic (MD) 
simulations conducted in this study offer an atomistic perspective into the complex nature of 
protein motions as a function of time.24,25  Due to H5N1 virus sharing a 91.47% sequence 
identity and a conserved binding site with the 2009 H1N1, the results of molecular simulation 
may apply to both viruses.26 
Several computational approaches have been used in an attempt to understand the impact of 
mutations on oseltamivir resistance to neuraminidase.   Karthick et al initiated one of the first 
MD studies, which was based solely on the natural mutation H274Y of H1N1 isolated during 
the 2007–2008 Eurasia influenza season.27,28  Malaisree et al refined the source of oseltamivir 
resistance in avian influenza H5N1 virus with the H274Y mutation using MD simulation.29,30 
Wang and Zheng performed a similar study that incorporated the mutations N294S and 
E119G.31  In the above studies, it was found that although residue 274 is a framework residue 
in the active site,21 the mutation of histidine (His) to tyrosine (Tyr) significantly impaired the 
binding of oseltamivir because the binding pocket could not accommodate the steric bulk of 
the drug.   Further to this, the presence of additional mutations was found to amplify resistance 
of the neuraminidase enzyme to oseltamivir.   A large database of crystallized glycoprotein of 
influenza virus A and B exists, each with a different mutation in the neuraminidase amino acid 
sequence.26,27,32–34  The MD studies for each mutation revealed enhanced surface expression of 
oseltamivir-resistant influenza neuraminidase.35 In many instances, these included zanamivir 
and peramivir resistance.36 
Nguyen et al37 and Huang et al38 identified a mutation at position 222 from isoleucine to lysine 
(Lys) in strains of wild-type (WT) and H274Y mutants of H1N1 and H5N1.   The point 






















































residue I222 of H1N1 and H5N1 neuraminidase offered stability to oseltamivir binding.39,40  
Structure stability was reinforced by the presence of the hydrophobic pocket created by E276 
and R224, which in turn supported a seven hydrogen bond interaction between the active site 
residues and the drug.30,36 
Insufficient information about the origin of resistance of oseltamivir against neuraminidase 
H1N1 and H5N1 mutations, I222K and H274Y (Figure 2) prompted us to perform a 
comprehensive multidimensional analysis using a multiple MD approach.   Multiple MD 
simulations have demonstrated better sampling efficiency.41 Multiple trajectories with different 
initial conditions improved the conformational sampling of MD simulations in proteins.42,43 
Several post-dynamic analyses, such as root mean square fluctuation (RMSF), root mean 
square deviation (RMSD), free binding energy calculations, radius of gyration, solvent 
accessible surface area (SASA), and principal component analysis (PCA) were performed in 
order to gain a comprehensive understanding of the impact of mutations on binding and the 
conformational landscape of the oseltamivir–protein complex.   Our research should contribute 










Figure 2: Three dimensional structure of H5N1 and H1N1 neuraminidase, A and B, 










The X-ray crystal structures of H1N1 and H5N1 WT and mutant neuraminidase were extracted 
from Protein Data Bank (PDB) codes 4B7R (WT-H1N1),44 2HU4 (WT-H5N1),15 and 3CL0 
(H274Y mutation-H5N1)45 complexed with oseltamivir, obtained from the Research 
Collaboratory for Structural Bioinformatics.   Neuraminidase is a tetrameric enzyme, using the 
Chimera software package46 a single subunit was selected with the inclusion of an active site 
drug complex to reduce computational cost.   Influenza virus, H1N1 PDB code 4B7R, formed 
the WT sequence with a His274 residue.   Using Chimera, point mutations were introduced at 
positions 222 (from I to K) and 274 (from H to Y).   Table 1 lists the three enzymes with 
relevant mutations resulting in eight simulations. 
Table 1: The crystal structure of the simulated systems, PDB codes and abbreviations 
Simulated system PDB code Abbreviation*  
H1N1 wild-type 4B7R WTH1N1 
H1N1 I222K 4B7R I222KH1N1 
H1N1 H274Y 4B7R H274YH1N1 
H1N1 H274Y-I222K 4B7R H274Y-I222KH1N1 
H5N1 wild-type 2HU4 WTH5N1 
H5N1 I222K 2HU4 I222KH5N1 
H5N1 H274Y 3CL0 H274YH5N1 
H5N1 H274Y-I222K 3CL0 H274Y-I222KH5N1 
* These abbreviations are used throughout the manuscript 
MD simulation 
Multiple MD simulations were performed to establish the impact of mutation I222K on the 
binding of oseltamivir to the WT enzyme and in the presence of mutation H274Y of H1N1 and 
H5N1.   A long continuous MD trajectory may incur greater statistical errors as the protein 
denatures and evolves from one conformation to another during the time of the simulation.47 
Thus, a multiple MD approach was undertaken.   This method in turn reduced the force field 
artefacts, statistical bias, and computational time.   A total simulation time of 100 ns partitioned 
in five distinct 20 ns MD runs was executed, with each trajectory having a different initial 




Figure 3: Multiple MD trajectory approach adopted in this report 
MD simulation set-up and parameters 
The MD simulation was performed using the graphics processing unit version of the PMEMD 
engine provided with the Amber 12 and 14 package.48,49  The FF99SB variant of the Amber 
force field50 was used to describe the protein.   The LEAP module of Amber 12/14 allowed for 
the addition of hydrogen atoms to the protein and three Na+ counter ions for neutralization.   
The system was suspended within a TIP3P51 water box such that all protein atoms were within  
8 Å of any box edge.   After energy minimization, a 1,000 step restraint gradient minimization 
was performed.   Selective boundary conditions were enforced concurrently with the particle-
mesh Ewald method,52 a component of Amber 12/14, with set parameters of direct space and a 
van der Waals cut-off of 12 Å.   This would be conducive to the treatment of long-range 
electrostatic interactions.   The system passed through an initial energy minimization with 
2,500 steps of steepest descent and a restraint harmonic potential of 500 kcal/mol Å2 being 
applied to the solute.   After this, an additional 1,000 step unrestrained conjugate gradient 
energy minimization was carried out on the complete system, i.e., protein, ligand, solvent 
molecules, and added ions.   Gradual heating of the MD simulation from 0 to 300 K was 
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executed for 50 ps, such that the system maintained a fixed number of atoms and a fixed 
volume, i.e., a canonical (NVT) ensemble.   The solutes within the system were imposed with 
a potential harmonic restraint of 10 kcal/mol Å2 and a collision frequency of 1.0 ps-1.   
Superseding the heating input, a final equilibration estimating 500 ps of the systems was 
required.   The operating temperature was kept constant at 300 K, accompanied by the number 
of atoms and pressure, mimicking an isobaric-isothermal (NPT) ensemble.   The systems 
pressure was maintained at 1 bar using the Berendsen barostat.53  The total time for each MD 
simulation was 20 ns, and five trajectories for each of the eight systems were generated.   In 
each simulation, the SHAKE algorithm54 was employed to constrict the bonds of the hydrogen 
atoms.   The time step of each simulation was 2 fs and a single-precision floating-point 
precision model55 was used.   The simulations coincided with randomized seeding of the NPT 
ensemble.   It was accompanied by constant pressure of 1 bar maintained by the Berendsen 
barostat, a pressure coupling constant of 2 ps, with a temperature of 300 K and Langevin 
thermostat with a collision frequency of 1.0 ps-2.   Co-ordinates were saved every 1 ps and the 
trajectories were analysed every 1 ps using the PTRAJ module implemented in Amber 12.0 
and CPPTRAJ module in Amber 14.0. 
Post-dynamic analysis 
Thermodynamic calculations 
An implicit solvent model was employed to describe the thermodynamic free binding energies 
of oseltamivir bound to WT and mutant H1N1 and H5N1 neuraminidase in this study.   The 
molecular mechanics/generalized Born surface area method was used to evaluate the ligand-
protein complex binding affinities.56–59  To calculate the free binding energy contributions, 
1,000 snapshots were extracted from each of the 20 ns trajectories.   The following set of 
equations describes the calculation of the binding free energy:  
 
∆Gbind = Gcomplex − Greceptor − Gligand                    (1) 
∆Gbind = Egas + Gsol − TS                                              (2) 
Egas = Eint + Evdw + Eele                                               (3) 
Gsol = GGB + GSA                                                               (4) 




Where Egas represents the gas-phase energy, Eint is the internal energy, Eele is the Coulomb 
energy, and EvdW is the van der Waals energy.   The term Egas is directly measured from the 
FF99SB force field terms.   The solvation energy (Gsol) is the summation of contributions from 
polar and nonpolar states.   The polar solvation energy contribution, GGB, is derived from 
solving the GB equation.   The term GSA corresponds to the non-polar solvation energy 
contribution, which is estimated from the SASA determined using a water probe radius of 1.4 
Å.   The temperature and total solute entropy are represented by T and S, respectively.60 
Principal component analysis 
PCA reveals the structure of atomic fluctuations, and describes the motion of the system in 
terms of eigenvectors (planar of motion) and eigenvalues (magnitude of motion).61  The 
individual MD trajectories were stripped of solvent and ions using the PTRAJ and CPPTRAJ 
modules in Amber 12.0/14.0.   The resulting trajectories were aligned against a fully minimized 
structure.   PCA was performed on a Cα backbone with 1,000 snapshots taken every 20 ps.   
The first two eigenvectors (PC1 and PC2) corresponding to the first two modes of PCA 
covariance matrices were generated using in-house scripts.   An average of the PC1 and PC2 
for the 5×20 ns trajectories of the H1N1 and H5N1 WT and mutant systems was generated.   
The corresponding PCA scatters were plotted using Origin software 
(http://www.originlab.com/) and structural postscript diagrams were created using visual 
MDs.62  Porcupine plots of the first and second modes developed by the normal mode wizard 
using the ProDy interface of visual MDs were sketched for each of the systems.63 
Results and discussion 
MD simulations and system stability 
RMSD and potential energy plots in the Supplementary materials (Figures S1–12 of H5N1 and 
H1N1 neuraminidase, respectively) graphically monitor the convergence of the studied 
systems.64  All the systems of H5N1 and H1N1 influenza viruses converge at approximately 
5,000 ps by both RMSD and potential energy calculations. 
Post-dynamic analysis 
RMSF and radius of gyration analysis was used to relate conformational changes and plasticity 





Root mean square fluctuation 
The RMSF captured the fluctuation of each residue, providing insight into the flexible regions 
of the protein that correspond to crystallographic β (temperature) factors.65  Figure 4 illustrates 
the fluctuations of systems WTH5N1 and H274YH5N1.   The crystal structure of the WT 
neuraminidase consists of three α-helices and 24 β-strands.   Evidence from the graph 
demonstrates an unfolding of the protein helix at residue 28 in H274YH5N1 in comparison with 
the WT, shortening the cardinal α-helix and β-strand by one and three residues, respectively.   
Closer inspection revealed a distinct change in fluctuation corresponding to region 108–144, 
possibly due to the presence of a hydrogen bond between Lys125 and Thr131.   A similar effect 
was observed through β-strands 156–162 and 170–177 which share a hydrogen bond between 
amino acids Thr161 and Tyr171.   The residue region 260–320 containing the compensatory 
mutation did not demonstrate large variations in fluctuations. 
As depicted in Figure S13, by interacting with residues in the active site, the role of residue 
222 appeared to shift from a structural one to a functional one.   The Lys222 mutation contains 
a second amino group that acts as an electrophile at physiological pH; this prompts an 
interaction with the active site residues.   Mutation I222KH5N1 caused a change in orientation 
of Gly332, promoting a disulphide link between parallel cysteine residues 339 and 364 and 
causing a shift in the β-strand orientation.66 
Analysis of Figure S14 revealed a migration from a system of high flexibility (H274YH5N1) to 
one of low flexibility (H274Y-I222KH5N1).   The change from a hydrophobic residue, His, to 
the aromatic Tyr274, which contains an ionisable phenolic group, introduced instability in a 
previously predominant hydrophobic region.   Therefore, it is plausible to assume that the 
presence of mutation I222K in system H274Y-I222KH5N1 restricts interaction with the external 
solvent, thus minimizing flexibility throughout the protein. 
In the H274YH1N1 system (Figure 5), an increase in fluctuation at positions 58–65, 246–260, 
284, and 301–305 occurred in comparison with WTH1N1.   The H274Y mutation introduced a 
new hydrogen bond, and the aromatic group imposed a steric bulk disrupting previous 
hydrophobic interactions within that region.   A considerable fluctuation was observed in the 
latter regions of the protein.   There is only a single mutation in the I222KH1N1 system (Figure 
S15), which induced an increase in protein flexibility because Lys enhances solvent interaction.   
An overlay of the RMSF plots for systems H274Y-I222KH1N1 and H274YH1N1 (Figure S16) 
revealed no distinct difference between the two systems, indicating that no potential 
compensatory effect occurred to accommodate the double mutant species of protein H274Y-




Figure 4: RMSF comparison of WTH5N1 and H274YH5N1: T1, T2, T3, T4, T5 and Tavg 
presenting the 5 individual 20 ns MD trajectories and overall average, respectively. 






















































































































































Figure 5: RMSF comparison of WTH1N1 and H274YH1N1: T1, T2, T3, T4, T5 and Tavg 
presenting the 5 individual 20 ns MD trajectories and overall average, respectively. 
 



























































































































































Radius of gyration 
Radius of gyration demonstrates the compactness of protein structures, providing insight into 
complex changes in the molecular shape.67,68  It is evident that systems WTH5N1 and H274YH5N1 
(Figure 6) share a similar arrangement of amino acids in secondary and tertiary structures with 
an almost identical initial compactness.   Although both systems share a close resemblance, the 
H274YH5N1 system showed a distinguishable increase in its radius of gyration over time, 
transmutating to a less compact structure. 
System comparison of WTH5N1 and I222KH5N1 (Figure S17) unveiled the I222K mutation as 
the more compact protein complex.   Condensation of the structure created a semipermeable 
complex that prevented unwarranted solvent exposure of interior amino acid residues 
stabilizing the mutation I222KH5N1.   Comparative analysis of systems H274YH5N1 and H274Y-
I222KH5N1 (Figure S18) proposed an increase in flexibility of system H274Y-I222KH5N1.   The 
compactness of system H274Y-I222KH5N1 attempts to preserve the enzymes bioactivity whilst 
inferring resistance against oseltamivir.   Both systems H274YH5N1 and H274Y-I222KH5N1 
share a similar radius of gyration profile, which suggests that both have a similar complex 
compactness. 
System H274YH1N1 showed a larger radius of gyration than the parent protein WTH1N1, 
indicating that H274YH1N1 is less tightly packed (Figure 7).   Solvent interaction within the 
amino acid sequence perpetuated partial protein unfolding, facilitating a less compacted 
structure.   The single mutation I222KH1N1 (Figure S19) shared a similar trend by way of 
possessing a large radius of gyration value as compared with the WTH1N1 system.   However, 
isoleucine expels solvent, and when Lys was introduced, an ionisable species was generated, 
which, much like the Tyr residue at position 274, was capable of interacting with the 
surrounding solvent, relieving steric strain.   The H274Y-I222KH1N1 system has a folding 
profile similar to that of H274YH1N1, which is indicative of an undisturbed compaction of 
structure.   The H274Y-I222KH1N1 system (Figure S20) appeared unaffected by the mutation 
at position 222.   This could be due to the presence of the solvent-interacting amino acid species 
Tyr having previously rendered the inner folding’s of the protein susceptible to solvation.   The 






























































































































Figure 6: Radius of gyration average comparison across the 20 ns MD simulation of WTH5N1 and 






































































































































Figure 7: Radius of gyration average comparison across the 20 ns MD simulation of WTH5N1 and 

















Calculation of MM/GBSA binding free energy 
 
Evaluation of the free binding energies provides a thorough insight into the total energy of each 
of the systems.   Table 2 summarizes the average molecular mechanics/generalized Born 
surface area (MM/GBSA) thermodynamic energy contributions elicited from the structural 
data of the five 20 ns MD simulations for the H5N1 and H1N1 systems. 
The terms ΔEele and ΔEvdW represent the electrostatic and van der Waals intermolecular 
interacting components, respectively, between the protein and inhibitor.69–70 Systems WTH5N1 
and I222KH5N1 showed a difference of -6.1302 kcal/mol (ΔEele) and -2.5055 kcal/mol (ΔEvdW).   
H274YH5N1 and H274Y-I222KH5N1 showed a difference of -21.2395 kcal/mol (ΔEele) and -
4.1821 kcal/mol (ΔEvdW).   The energy differences advocate a more stable protein–ligand 
interaction of WT and H274YH5N1.   This was measured in terms of effective binding distance 
and positioning of amino acid residues for optimum interaction between charged entities.   The 
ΔGsol, difference defined between systems WTH5N1 and I222KH5N1 was estimated to 1.2626 
kcal/mol and for systems H274YH5N1 and H274Y-I222KH5N1 was estimated to be 13.3466 
kcal/mol.   The change to polar amino acids (e.g.  from Ile to Lys and from His to Tyr) in 
systems I222KH5N1 and H274Y-I222KH5N1 contributed to an improved ΔGsol energy difference.   
Closer inspection of the free binding energy, ΔGbind, quantified the interaction between the 
protein and ligand.   The difference in free binding energy between systems WTH5N1 and 
I222KH5N1 was -7.1732 kcal/mol, and that between systems H274YH5N1 and H274Y-I222KH5N1 
was -11.0751 kcal/mol.   The trend in binding free energy difference was observed to be as 
follows: WTH5N1, I222KH5N1~H274YH5N1, H274Y-I222KH5N1, indicating that the protein-ligand 
interaction became progressively thermodynamically unfavourable in the presence of 
mutations. 
Table 3 corresponds to the calculated energies for the H1N1 neuraminidase systems.   The 
amine group of oseltamivir was kept positively charged during the MD simulation.   According 
to the literature, binding of drug in a positively charged state to the active site residues is falsely 
represented by an ameliorated free binding energy when comparing the mutant sequence with 
the WT sequence.71  Based on a study by Le et al it was proposed that a predominantly 
negatively charged column of residues at the binding pocket electrostatically funnels 
oseltamivir to the active site of N1 neuraminidases.1 This greatly impacts the binding pose, 
whereby a positively charged drug is drawn toward the epicentre of the active site.   The energy 
contribution ΔGGB of H274YH1N1 and I222KH1N1 is testament to the proposed binding 
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instruction as both systems highlighted an improved binding, with an energy difference from 
the WT of -4.1784 kcal/mol and -2.4447 kcal/mol, respectively.   Surprisingly, the double 
mutation species H274Y-I222KH1N1 demonstrated a similar energy profile trend to WTH1N1.   
The electrostatic energy of the I222KH1N1 and H274YH1N1 species differed significantly from 
the WTH1N1 system by -8.3000 kcal/mol and –15.9730 kcal/mol, respectively.   However, a 
remarkable drop in electrostatic energy was observed in the H274Y-I222KH1N1 system 
compared with H274YH1N1.   This phenomenon could relate to the conformation of the double 
mutant system, as the residues interacting with the solvent direct themselves inwardly, 
interacting with neighbouring amino acid residues.   The ΔEvdW and ΔGsol differences between 
H274YH1N1 and double mutation H274Y-I222KH1N1 confirm the funnelling mechanism, as both 
shared an improvement in the ΔEvdW value over the WT.   However, a significant decline in 
ΔGsol of 37.4933 kcal/mol indicated a lack of solvent interaction.   The van der Waals 
contributions for I222KH1N1 suggested a slight decline in hydrophobic interaction, with an 
energy difference from WT of -1.0594 kcal/mol.  A ΔGsol difference between the systems of 
4.7960 kcal/mol implied enhanced solvent interaction of the I222KH1N1 complex.  The 
H274YH1N1 offered a similar van der Waals contribution to WTH1N1, as the aromatic group 
replaced a linear hydrocarbon chain.  Despite this structural feature, a solvation energy 
difference of 13.1386 kcal/mol indicated that the hydroxyl group of Tyr imposed an increased 
solvent exposure. 
 
Table 2: Energy contribution derived from MM/GBSA technique corresponding to structural 
entities of H5N1 system 
Complexes Trajectory ΔGbind ΔEele ΔEvdW ΔGgas ΔGsol 
H274 T1 -27.80 ± 6.57 -54.97 ± 15.38 -30.25 ± 3.27 -85.21± 17.19 57.42 ± 12.03 
T2 -28.56 ± 3.63 -57.65 ± 7.07 -33.19 ± 2.43 -90.85 ± 7.05 62.29 ± 6.22 
T3 -38.19 ± 4.36 -71.84 ± 6.42 -36.14 ± 2.87 -107.97 ± 6.83 69.79 ± 7.34 
T4 -29.29 ± 7.13 -60.08 ± 8.79 -31.52 ± 3.71 -91.63 ± 10.82 61.34 ± 6.48 
T5 -31.89 ± 5.17 -62.10 ± 10.66 -33.42 ± 2.90 -95.52 ± 11.96 63.64 ± 7.78 
Tavg -31.14 ± 4.34 -61.33 ± 9.16 -32.91 ± 4.59 -94.24 ± 8.70 62.89 ± 7.45 
I222K T1 -24.22 ± 6.65 -59.82 ± 11.74 -28.20 ± 4.20 -88.03 ± 12.78 63.80 ± 7.97 
T2 -23.98 ± 5.44 -41.06 ± 12.39 -31.92 ± 3.75 -72.98 ± 14.35 48.99 ± 9.56 
T3 -23.08 ± 4.42 -56.77 ± 11.18 -31.16 ± 3.60 -87.93 ± 12.45 64.85 ± 9.48 
T4 -26.51 ± 7.93 -69.03 ± 8.79 -31.44 ± 3.22 -100.47 ± 9.68 73.96 ± 7.84 




Table 3: Energy contribution derived from MM/GBSA technique corresponding to structural 
entities of H1N1 system 
Tavg -23.97 ± 4.89 -55.20 ± 11.68 -30.40 ± 6.44 -85.60 ± 14.61 61.63 ±8.71 
H274Y T1 -30.80 ± 4.62 -60.00 ± 8.22 -31.74 ± 2.66 -91.75 ± 8.57 60.95 ± 5.98 
T2 -28.53 ±3.97 -56.79 ± 8.77 -29.99 ± 3.23 -86.78 ± 9.48 58.24 ± 7.31 
T3 -30.80 ± 4.62 -60.00 ± 8.22 -31.74 ± 2.66 -91.75 ±8.57 60.95 ±5.98 
T4 -28.53 ± 3.97 -56.79 ± 8.77 -29.99 ± 3.23 -86.78 ± 9.48 58.24 ± 7.31 
T5 -28.53 ± 3.97 -56.79 ± 8.77 -29.99 ± 3.23 -86.78 ± 9.48 58.24 ± 7.31 
Tavg -29.44 ± 3.44 -58.07 ± 6.90 -30.69 ± 4.11 -88.76 ± 8.68 59.33 ± 6.11 
H274Y-
I222K 
T1 -16.86 ± 4.85 -39.61 ± 9.57 -28.15 ± 3.75 -67.76 ± 9.47 50.90 ± 8.06 
T2 -19.70 ± 5.25 -45.19 ± 11.75 -24.53 ± 3.98 -69.72 ± 13.85 50.02 ± 9.90 
T3 -15.41± 6.14 -21.27 ± 8.69 -25.64 ± 7.34 -46.91 ± 13.87 31.50 ± 9.50 
T4 -20.22 ± 3.68 -50.65 ±8.41 -23.39 ± 2.77 -79.04 ± 8.68 58.83 ± 7.00 
T5 -19.63 ± 3.26 -27.45 ± 9.69 -30.82 ± 2.68 -58.27 ± 9.66 38.64 ± 8.05 
Tavg -18.36 ± 3.98 -36.84 ± 9.32 -26.51 ± 5.51 -64.34 ± 10.78 45.98 ± 7.54 
Complexes Trajectory ΔGbind ΔEele ΔEvdW ΔGgas ΔGsol 
H274 T1 -20.30 ± 4.34 -144.88 ± 10.13 -31.31 ± 2.52 -176.19 ± 10.21 155.90 ± 9.36 
T2 -16.48 ± 9.03 -137.06 ± 22.53 -28.17 ± 5.26 -165.22 ± 24.78 148.74 ± 17.50 
T3 -25.81 ± 4.11 -151.45 ± 8.54 -32.68 ± 3.16 -184.14 ± 8.37 158.32 ± 6.69 
T4 -30.52 ± 4.24 -167.85 ± 10.35 -30.61 ± 3.50 -198.46 ± 10.11 167.94 ± 8.49 
T5 -23.27 ± 4.21 -148.70 ± 12.83 -30.35 ± 2.82 -179.04 ± 12.23 155.78 ± 9.73 
Tavg -23.28 ± 5.19 -149.99 ± 12.88 -30.63 ± 3.45 -180.61 ± 13.14 157.34 ± 10.35 
I222K T1 -28.43 ± 4.90 -171.09 ±13.93 -31.26 ± 3.42 -202.34 ± 13.73 173.91 ± 11.24 
T2 -20.18 ± 6.53 -144.76 ± 15.31 -25.08 ± 4.85 -169.84 ± 16.07 149.66 ± 12.94 
T3 -27.13 ±6.00 -156.67 ± 14.22 -31.64 ± 3.28 -188.31 ± 15.30 161.18 ± 11.58 
T4 -26.87 ± 6.57 -165.80 ± 19.73 -31.10 ± 3.41 -196.90 ± 20.91 170.04 ± 16.10 
T5 -26.01 ± 5.15 -153.12 ± 12.22 -28.76 ± 3.28 -181.88 ± 13.21 155.88 ± 10.14 
Tavg -25.72 ± 5.83 -158.29 ± 15.08 -29.57 ± 3.65 -187.85 ± 15.84 162.13 ± 12.40 
H274Y T1 -26.22 ± 3.25 -131.63 ± 16.23 -32.37 ± 2.62 -164.00 ± 15.71 137.78 ± 14.03 
T2 -36.56 ± 4.76 -175.26 ± 15.34 -34.47 ± 3.93 -209.72 ± 14.01 173.16 ± 13.30 
T3 -27.71 ± 3.24 -179.67 ± 11.45 -31.25 ± 2.58 -210.91 ± 11.38 183.21 ± 10.88 
T4 -24.26 ± 5.61 -173.30 ± 16.41 -31.80 ± 2.60 -205.10 ± 16.83 180.84 ± 13.83 
T5 -22.52 ± 5.12 -169.94 ± 22.45 -29.96 ± 2.93 -199.91 ± 21.39 177.39 ± 19.32 




Hydrogen bond formation between amino acid residues 
 
The dimensionality of a protein is a vector metric governed by the direction of interaction and 
number of hydrogen bonds.  Comparative analysis of WTH5N1 and H274YH5N1 verified a 
decrease in the overall number of hydrogen bonds in the mutant species (Figure 8).  This 
phenomenon was attributed to a reduction of hydrophobic interactions within the protein, 
evident from the van der Waals energy contribution.  The residues of neuraminidase interact to 
a greater extent with the surrounding solvent, hence a depletion in the number of internal 
protein hydrogen bonds.  System I222KH5N1 showed a similar trend to the H274YH5N1 system 
(Figure S21).  The double mutation H274Y-I222KH5N1 showed an increase in the number of 
hydrogen bonds (Figure S22), offering a more compact structure that is supported by the radius 
of gyration. 
Mutation H274YH1N1 (Figure S23) showed a decline in the overall average of calculated 
hydrogen bonds as compared with the WTH1N1 system.  This finding supports the idea of an 
unfolding of the protein due to depletion of interactions facilitating α-helices or β-strands 
capable of compacting the enzyme.  Similarly, system I222KH1N1 (Figure S24), compared to 
the parent protein, WTH1N1, has a recorded decrease in the number of internal hydrogen bonds.  
A comparison of systems H274YH1N1 and H274Y-I222KH1N1 (Figure S25) revealed a near 
equivalent hydrogen bonding pattern.  This could be due to torsional or steric stress of the 
macromolecule, such that thermodynamically no further unravelling of the protein can be 
accommodated before an irreversible deformation of the protein takes effect. 
H274Y-I222K T1 -20.35 ± 5.40 -139.80 ± 15.52 -27.49 ± 4.01 -167.29 ± 15.07 146.94 ± 12.68 
T2 -24.92 ± 4.13 -126.91 ± 17.15 -32.09 ± 2.96 -158.99 ± 15.94 134.08 ± 13.95 
T3 -25.68 ± 3.55 -112.27 ± 12.68 -33.69 ± 2.87 -145.96 ± 11.80 120.28 ± 10.14 
T4 -26.03 ± 3.60 -115.52 ± 15.64 -32.90 ± 2.48 -148.42 ± 15.24 122.39 ± 13.43 
T5 -20.62 ± 5.29 -132.49 ± 22.51 -29.35 ± 3.11 -161.85 ± 22.20 141.22 ± 19.16 




Figure 8: Averaged no. of hydrogen bonds in WTH5N1 and H274YH5N1 across the 20 ns MD 







Principal component analysis 
 
PCA is used to assess the impact of mutations on the conformational dynamics of 
neuraminidase to solicit an impartial resistance mechanism.72 Collation of systems WTH5N1 and 
H274YH5N1 (Figure 9) associated H274YH5N1 with restricted motion in relation to its α-carbon 
backbone.  The displacements were reduced, minimizing the spatial occupancy of H274YH5N1 
with a covariance of 0.3191.  The magnitude of covariance for WTH5N1 was estimated to be -
3.6367, advocating a more flexible framework with an inversely proportionate motion (Figure 
S26).  System H274YH5N1 has a disproportionate motion of correlation (R2) value of 0.1814 in 
that the vectors commission dynamism in a single cooperative direction (Figure S27).  The R2 
value for WTH1N1 of -0.6526 indicated a more proportionate but antagonistic motion. 
Examination of system I222KH5N1 (Figure S28) suggested that the neuraminidase enzyme 
tolerated an abridged flexibility of its α-carbon backbone in comparison with the WT enzyme.  
This corresponded with the determinations surmised from the RMSF values.  The single 
mutation has a covariance of -3.1127, which is marginally smaller in magnitude than that for 
the WT, with an R2 of -0.3032.  The direction of motion of I222KH5N1 is antiparallel, the 
associations predominate by an antonymous relationship of large and small variables (Figure 
S29).  The double mutation, H274Y-I222KH5N1, has improved flexibility in the α-carbon 
backbone in comparison with H274YH5N1.  This is demonstrated in the PCA scatter and 
covariance value estimated at 0.8148 (Figure S30).  The improvement in flexibility coincided 
with the RMSD values, suggesting a greater number of conformational possibilities of the 
H274Y-I222KH5N1 system.  An improved R2 of 0.2337, in contrast with H274YH5N1, described 
a unified direction of motion of disproportionate magnitude (Figure S31). 
The WTH1N1 enzyme (Figure 10) appeared to have reduced internal motion of its α-carbon 
backbone in comparison with H274YH1N1, a restriction which corresponded to the compactness 
observed from calculation of the radius of gyration.  The covariance and R2 values were 
estimated to be -1.2249 and -0.4616, respectively, suggesting a disproportionate antithetic 
motion of the enzyme (Figure S32).  A similar effect was observed with the double mutation 
system H274Y-I222KH1N1, where the overall flexibility of the protein was rigid in comparison 
with H274YH1N1 (Figure S33).  The covariance and R2 values of -0.4099 and -0.1539 support 
these findings (Figure S34).  System H274YH1N1 demonstrated a more flexible α-carbon 
backbone which moved in a disorganized motion with a covariance of -0.7200 and an R2 value 
of -0.05218 (Figure S35).  System I222KH1N1 exhibited a continuous linear motion along its α-
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carbon backbone, with a covariance of 0.6457 (Figure S36).  This phenomenon was supported 
by an R2 of 0.3271 (Figure S37). 
 
Figure 9: PCA scatter plots of 1000 frames of the distribution along two planes, PC1 and PC2 for; 
WTH5N1 and H274YH5N1 illustrating differences in eigenvectors of T1, T2, T3, T4, T5 and Tavg 
presenting the 5 individual 20 ns MD trajectories and overall average, respectively. 





































































































































Figure 10: PCA scatter plots of 1000 frames of the distribution along two planes, PC1 and PC2 for; 
WTH1N1 and H274YH1N1 illustrating differences in eigenvectors of T1, T2, T3, T4, T5 and Tavg 






























































































































































Solvent accessible surface area 
 
The SASA imparts information relative to the compactness of the structure as well as the extent 
of hydrophobicity in the interior of the folded protein.73  System H274YH5N1 appeared to 
expand over time (Figure S38), whereas WTH5N1 remained unchanged.  Both systems reflected 
a distinct and relatively stable complexed conformation, which is affirmed by the radius of 
gyration estimations.  System I222KH5N1 (Figure S39) and H274Y-I222KH5N1 (Figure S40) 
demonstrated a nominally lower surface area than the WT and H274YH5N1, respectively.  This 
implied that contact between the van der Waals partitions and the solvent was diminished.  A 
dehydron species may be present in systems I222KH5N1 and H274Y-I222KH5N1 due to the 
contributions of ΔEvdW and ΔGsol, resulting in a reduced interaction between the solvent and 
van der Waals region.74  The preservation of the hydrophobic regions results in a loss in volume 
of the active site. 
The WTH1N1 system has a reduced exposed surface area when compared with H274YH1N1 
(Figure S41).  This observation corresponded to the PCA of H274YH1N1, facilitating a structure 
with greater potential for interaction with solvent.  System I222KH1N1 exhibited a slightly 
different trend such that initially both the WT and single mutant shared similar SASA.  Over 
time, at ~10,000 ps onward, a change in conformation occurred, with I222KH1N1 appearing to 
become more accessible to the solvent (Figure S42).  A similar effect was found between 
H274YH1N1 and H274Y-I222KH1N1 (Figure S43).  During the initial 10,000 ps of the simulation, 
there appeared to be a difference in the SASA of the two systems, with H274YH1N1 having 
greater solvent accessibility than the double mutant.  In the later 10,000 ps, both systems begin 
to overlap.  This anomaly suggests a conformational change in the presence of the double muta-
tion H274Y and I222K, whereby these residues pointed outward, encouraging solvent 
interaction and disrupting the three-dimensional compactness. 
Conclusion 
Significant findings emerged in our endeavour to gain insight into the binding mode and origin 
of resistance of oseltamivir in H1N1 and H5N1.  It was noted that the mechanism of resistance 
is entirely dependent on the type of mutation, relative positioning of such occurrences, and the 
repercussions thereof on the active site of the enzyme under analysis.  Our results indicate that 
resistance of neuraminidase was inherited by the expression of H274Y and/or I222K mutations.  
The neuraminidase of H1N1 has known resistance against oseltamivir in the presence of 
mutations H274Y and/or I222K.  Despite originating from the same host by reassortment, 
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H5N1 has proven to be more susceptible to oseltamivir than H1N1 in the presence of mutations.  
Comparatively, neuraminidase of H5N1 appears to experience greater structural fluctuations 
in acquiring resistance against oseltamivir as opposed to the H1N1 system.  H5N1 gains 
resistance by a loss in volume of the active site due to compaction of the neuraminidase, while 
H1N1 develops resistance by solvent exposure of active site residues.  Subsidiary analyses of 
RMSD, RMSF and potential energy confirm the progressive development of resistance from 
WT through to mutants (for both H1N1 and H5N1). 
The free binding energy established from the MM/GBSA algorithm offers the first sign of 
evidence of resistance.  Based on the electrostatic funnel mechanism of neuraminidase (for 
H1N1), an increase in binding energy was observed.  This was an artefact of the active site 
residues and drug interacting with solvent, rather than with one another.  The presence of the 
H274Y mutation has a compensatory effect to ensure the survival of the viral species by 
inhibiting enzyme interaction with the drug, without compromising the integrity of the enzyme.  
Mutation I222K, through distance, transposes a putative constriction in the volume of the active 
site of H5N1, whereas in H1N1 the protein unfolds, promoting solvent interaction.  As a result, 
the active site inherently cannot support the bulky 1-ethylpropoxy hydrophobic moiety of 
oseltamivir.  It is reasonable to suppose that the I222K mutation has a potent effect in 
discriminating between binding of the substrate and binding of the drug oseltamivir.  The 
H274Y-I222K double mutant exhibits even greater drug resistance.  Overall resistance in 
systems H5N1 and H1N1 occurs as a result of loss of hydrophobicity within the binding pocket 
of the active site.  The lack of hydrophobicity leads to structural collapse of the available active 
site, which in turn diminishes the integrity of the binding landscape.  This poses a threat, given 
that H5N1/avian influenza has been found to have an increasing incidence of human 
transmissibility.  The existence of a resistant strain is having a severe negative impact on human 
health.  Therefore, it is imperative to design and identify unique, innovative, and selective 
chemotherapeutic agents to adapt to the newly defined binding pocket. 
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Abstract  
The rapid development of resistance to existing anti-influenza agents has prompted the urgent 
need for the discovery of novel potential neuraminidase inhibitors.    The use of computer-
aided drug design has changed remarkably the perspective on the discovery and development 
of new drug candidates.    In this report, we propose an improved pharmacophore modelling 
based on the binding free energy contributions from the amino acid residues that are critically 
involved in drug binding rather than arbitrary set of amino acid residues as widely adopted in 
literature.   The robustness of this approach lies in the fact that the calculated Molecular 
Mechanics/ Generalised Born Surface Area (MM-GBSA) per-residue binding free energies 
used to map the pharmacophoric features were obtained from molecular dynamics ensembles 
as opposed to docking scores as commonly adopted.   Prototype Influenza A Neuraminidase 
Inhibitors, oseltamivir, zanamivir, laninamivir and peramivir were used to validate our 
approach.   A wide range of simulation and analytical protocols such as, but not limited to, 
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ligand-based and structure-based pharmacophores, molecular dynamics and per-residue free 
energy footprints were also reported herein to substantiate the proposed approach.    
We believe that the enhanced pharmacophore-modelling approach presented in this report 
would serve as a useful tool in drug discovery workflows.     
 
Keywords 
Virtual screening, neuraminidase, free binding energy, molecular dynamics, influenza virus A, 
ligand-based pharmacophore, structure-based pharmacophore 
 
1.   Introduction 
The natural evolution of the influenza virus presents a continuous challenge to the human 
immune system.    Evolution of the virus occurs primarily via antigenic variations through two 
distinct mechanisms: 1) antigenic shifts, and 2) antigenic drifts.    Antigenic drifts are the result 
of point mutations that occur as the virus replicates and is often the cause of seasonal flu.    
Antigenic shift occurs when two different strains of the influenza virus combine to create a 
novel influenza subtype, which can lead to epidemics and pandemics 1-3. 
Genetic mutations, together with viral compensatory evasion mechanisms in response to 
current therapeutic agents, have led to the rapid build-up of resistance.    Influenza A is a prime 
example of natural selection through an adaptive survival mechanism.    It has been documented 
throughout history as contributing to high fatality rates.    The most significant incidence of 
influenza infection in the past century include the ‘Spanish flu’ pandemic which extended from 
1918 – 1919 with an estimated mortality of 50 million worldwide 4.    In more recent times, the 
2009 pandemic strain of H1N1 claimed the lives of approximately 284,500 people 5.    To date, 
there have been accounts of outbreaks of the newer influenza strains including swine (H1N1) 
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flu and the highly-pathogenic avian (H5N1) flu 6-8.    These strains have already shown 
resistance to current antivirals; oseltamivir (Tamiflu®) 9, zanamivir (Relenza®) 10, peramivir 
(Rapivab®) 11 and laninamivir (Inavir®) 12.    These drugs work by neuraminidase inhibition.     
Figure 1: 2-D Chemical structure of sialic acid (substrate) and active inhibitors (oseltamivir, 
zanamivir, laninamivir and peramivir) 
Neuraminidase is one of three surface antigens which has become the primary target for 
potential pharmacological interventions 13-16.    It is an exosialidase enzyme responsible for the 
cleavage of the α-ketosidic bond between sialic acid and its adjacent sugar residue from the 
viral envelope.    Cleavage occurs during the final stage of infection resulting in the release of 
virus progeny from the host cell 17-18.    It has been suggested that in the early stages of infection, 
neuraminidase may catalyse the removal of “decoy” receptors on mucins, cilia and cellular 
glycocalyx present on human airway epithelium thus promoting access to target cells 19-20.    
There are nine neuraminidase subtypes (N1-N9).    The group 1 neuraminidase enzymes i.e.   
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N1, N4 and N8; are phylogenic subtypes which share a conserved active site 21-24.    The 
appearance of resistance to current neuraminidase inhibitors has emphasized the urgency in the 
discovery, design and development process of alternate chemotherapeutic agents to prevent 
future pandemics 25-30. 
 
Figure 2: 3-D Structure of unbound H1N1 neuraminidase enzyme (PDB ID: 3TI6) 
 
Classical methods of drug development against specified targets estimate a turnaround time 
(i.e.   time from the initiation of work to final registration) of 12 – 15 years 31.   The use of 
computational methodology such as virtual screening (VS) can vastly improve efficiency.    It 
is also more cost-effective by being less resource and labour intensive 32.    Pharmacophores 
can be used as a filtering tool in virtual screening.    The pharmacophore model is generated 
from a three dimensional (3-D) scaffold, mapping critical chemical and functional moieties, 
such as; hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), negatively and 
positively ionisable species, metal chelating groups and hydrophobic areas 33-34.    There are 
two main classes of pharmacophore VS models 1) Ligand-based, and 2) Structure-based 33.     
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Ligand-based pharmacophore modelling is based on known actives.    The bioactive 
conformation allows for library generation of pharmacophore models through similarity 
searches.    A number of 3-D inhibitors are aligned to isolate common pharmacophoric 
descriptors in order to build a pharmacophore model 32.    Structure-based pharmacophore 
modelling exploits a high resolution 3-D structure of a drug-protein complex for the 
assimilation and construction of common interaction patterns of a number of chemically 
diverse and similar functional moieties.    Structural/feature mapping can be used directly to 
conceptualise a pharmacophore ensemble 35.    A disadvantage of ligand-based pharmacophore 
modelling is that the molecules discovered are strictly based on information derived from 
existing ligands (i.e.   templates), which result in limited scaffold diversity in comparison to 
structure-based pharmacophore modelling 32-33, 36-37.    
In this study we wish to propose an additional step to ligand-based pharmacophore VS by using 
information derived from molecular dynamic simulations of actives complexed with their 
respective receptors, to build a conformationally-enhanced pharmacophore model.    The 
design strategy centres on obtaining a binding free energy profile of high contributing active 
site residues and their corresponding interacting ligand chemical features.    Our proof of 
concept implements molecular dynamics (MD), where a thermodynamically favourable 
ensemble (i.e.   energetically optimised drug-protein complex) is used to map pharmacophoric 
regions.    This method proves highly advantageous as the MD ensemble closely mimics a 
biological environment.    MD is a more dependable tool compared to receptor-ligand docking 
as it utilizes improved force fields and scoring functions 38.    The chemo-structural bias of the 
pharmacophore is reduced as the selection criteria of chemical features is governed by common 
interaction patterns of bioactive conformers with active site residues exhibiting a high free 
binding energy contribution.    The free binding energy takes into account more chemical details 
in structural design, such as: local molecular interactions and environmental effects (e.g.   
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Protonation states).    Our ligand-based pharmacophore selection is three-pronged: 1) biological 
activity, 2) structural diversity/similarity and 3) energetically favourable interactions.    There 
have been previous energy based ranking studies to determine the significance of lead 
compounds using the ligand- and structure-based models.    However, the modus operandi 
utilized docking energies 39-43.    Unfortunately, the use of docking energies incurs artefacts, 
which could reflect inflated ligand-protein interactions.    MD would therefore give a more 
accurate depiction. 
The energy mapping of chemical features for the pharmacophore corresponding to critical 
ligand-protein interactions can be used to limit false positives.    Our methodology proposes 
reduced randomisation by the generation of a more focussed library.    Coupled with the 
validation of MM-GBSA results against experimentally active compounds, this technique can 
prove a useful tool in the discovery of potential hits/leads of innovative and unique 
neuraminidase inhibitors.    
 
2.   Methods 
The flow chart in Figure 3, offers a basic overview of the critical steps in this study.    Each 




Figure 3: Pipeline of processes involves in the in silico screening of the generated MD 
ensemble pharmacophores 
2.1 System preparation 
Crystallographic structures of H1N1 neuraminidase bound with sialic acid (PDB ID: 2BAT) 
44, oseltamivir (PDB ID: 3TI6) 45, zanamivir (PDB ID: 3TI5) 45, laninamivir (PDB ID: 3TI3) 
45 and peramivir (PDB ID: 2HTU) 22, were obtained from the RCSB Protein Data Bank (PDB).    
Using the Chimera 1.8.1 software package 46-47 a monomer was selected followed by the 
correction of protonation states of amino acid residues as well as the removal of water, heavy 





2.2 MD simulation 
Amber 14.0 GPU version of the PMEMD engine was used to perform a 20 ns molecular 
dynamics simulation.    The protein was described with the FF99SB variant force field.    The 
LEaP module embedded within Amber was use for the addition of hydrogen atoms and 
neutralisation of the protein by the addition of Na+ counter ions.    The system was suspended 
within a TIP3P 48484848 water box such that all protein atoms were within 8 Å from the box 
edge.    The drug-protein complex was energetically minimised in three stages; 1) 1000 step 
restraint gradient minimisation with selective boundary conditions of the particle-mesh Ewald 
method which has a parameter of direct space and a van der Waals cut-off of 12 Å.    Stage 2, 
a 2500 of deepest descent step with a solute harmonic potential of 500 kcal/mol.   Å2; and stage 
3, a 1000 step unrestrained conjugate gradient energy minimisation of the complete system.    
The system was heated using a canonical ensemble (NVT) from 0 K to 300 K over 50 ps.    The 
collision frequency of solutes was 1.0 ps-1 with a harmonic potential of 10 kcal/mol.Å
2
.    A final 
equilibration step of 500 ps was performed using the SPFP precision model of the SHAKE 
algorithm to constrict hydrogen bonds at 2 fs intervals.    The simulations were conducted in a 
randomised seeding of an isobaric-isothermal ensemble (NPT).    A constant pressure of 1 bar 
was maintained by the Berendsen barostat with a pressure coupling constant of 2 ps.   A 
temperature of 300 K was set using a Langevin thermostat with collision frequency of 1.0 ps-
2.    Co-ordinates were saved every 1 ps and the trajectories were analysed every 1 ps using a 
CPPTRAJ module in Amber 14.0. 
2.3 Pharmacophore model  
The construction of the models was a multi-step process and encompassed the principles of 
structure-based pharmacophore modelling.    Pharmacophore generation is reliant primarily on 
the quality of 3-D molecules used in the training set.    The choice of complexes was based on 
good crystallographic and activity data.     
114 
 
2.3.1 Per-residue free binding energy profiling 
∆𝑮𝒃 = ∆𝑬𝑴𝑴 + ∆𝑮𝒔𝒐𝒍𝒗 + ∆𝑮𝑺𝑨 
The study emphasizes the specific interaction pattern of the ligand complexed with protein, 
highlighting constructive per-residue energy contributions.    The per-residue free binding free 
energy is a post-dynamic calculation estimated from the Molecular Mechanics, Generalised 
Born, Surface Area (MM-GBSA) algorithm embedded within the Amber package.    MM-
GBSA method is capable of accurately ranking inhibitors based on binding free energies.    The 
term ΔEMM is the difference in energy between the protein-ligand complex and the unbound 
receptor and free ligand.    ΔGsolv is the difference in the solvation energies.    ΔGSA is the 
estimated difference in the surface area energies of the unliganded receptor and free ligand.    
The critical binding site amino acid residues corresponding to defined chemical moieties of the 
ligand are profiled in Figure 4 and the Supplementary Information.    
 
Figure 4: High contributing per-residue binding free energy interaction pattern of sialic 









































2.3.2 Ligand-based pharmacophore 
The Espresso algorithm of LigandScout 3.12 software was used to generate the pharmacophore 
from the 3-D training set containing oseltamivir, laninamivir, sialic acid, peramivir and 
zanamivir.    The model was predicted from the alignment of the five ligands and the overlap 
of similar chemical features.    A three-feature limit was used for the creation of the model. 
2.3.3 Structure-based pharmacophore 
LigandScout is capable of interpreting critical interactions between the binding site residues 
and ligand.    The predicted model was generated using the automated LigandScout pipeline 
which considers the 3-D macromolecular structure of the complexed ligand.    The 
pharmacophoric ensemble is a culmination of the four active inhibitor complexes: oseltamivir 
(PDB ID: 3TI6), laninamivir (PDB ID: 3TI3), peramivir (PDB ID: 2HTU) and zanamivir (PDB 
ID: 3TI5).    The minimum feature requirement was set at three.    The model was a measure 
of dihedral angles and complementary chemical features with specific distance interaction 
filters as well as exclusion volumes. 
2.4 Pharmacophore & Docking selectivity and evaluation 
2.4.1 Pharmacophores 
The pharmacophore models obtained from the ligand- and structure-based techniques were 
evaluated for the ability to detect actives from inactives (decoys).    A decoy test set of 698 
molecules was extracted from the electronic directory of useful decoys (E-DUD) 49.    The 
molecules exhibit similar physical properties but dissimilar chemical topology to the inhibitors.    
The active set contained 17 compounds, ranging from high (0.1 nM) to moderate activity (20 





2.4.2 Docking system 
AutoDock Vina version was used to carry out docking.    Validation of the docking software 
was conducted by re-docking of ligands back into their respective binding pockets and cross-
docking of ligands peramivir, laninamivir, sialic acid and zanamivir into the receptor of the 
oseltamivir (PDB ID: 3TI6).    The crystal structure of PDB ID: 3TI6 (resolution: 1.69 Å) was 
selected for the virtual screening as it had the best overall crystallography data.    The docking 
software was further assessed for its ability to pick out actives from inactives using decoy 
molecules. 
2.5 In silico virtual screening  
Two in silico screening methodologies were employed, 1) pharmacophore screening and 2) 
molecular docking.    LigandScout version 3.12 was used for the pharmacophore screen.    The 
predicted ligand- and structure-based pharmacophores models were screened against a library 
of 5189 drug-like compounds obtained from the ZINC database.    A hit list of 23 compounds 
and five compounds was retrieved from the ligand-based and structure-based pharmacophore 
models, respectively.    A combined hit list of these 28 potential inhibitors was further docked 
into the receptor of PDB ID: 3TI6 using Autodock Vina employing an enhanced loop docking 
protocol.    Autodock uses a Lamarckian algorithm to predict docked conformations.    Prior to 
docking, MGL tools were used to define atom types and assign Gasteiger partial charges.    The 
files were then converted to a pdbqt format using the Raccoon version software.    A gridbox 
of dimensions of 34 x 24 x 36 (nm3) was used.    The docking calculations were performed in 
triplicate. 
 3.   Results and Discussion 
The use of CADD strategies proved to be an invaluable tool in the landmark discoveries of 
antiviral neuraminidase inhibitors (zanamivir, oseltamivir and peramivir).    By the construction 
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of a 3-D model using per-residue binding free energies, our work serves to provide an enriched 
perspective on pharmacophore generation. 
Alignment of receptors N1 and N8, confirm a conserved active site with similarity of sequence 
and structure of 0.54 and 56%, respectively.    This allowed the inclusion of peramivir 
complexed with an N8 receptor, in the construction of the pharmacophores.    The catalytic 
cleavage of sialic acid occurs at pH 4.    The system was therefore optimised to mimic the 
slightly acidic biological environment by protonation of the arginine residues.    
Neuraminidase’s mechanism of action occurs in four distinctive steps.     The first step referred 
to as the ‘binding event’ is solvent-mediated.    A charge-charge interaction (i.e.   salt bridge) 
between the pseudo-equatorial carboxylate moiety and Arg 37, 212, 287 ensues.    The 
conformation creates a steric constraint which is accommodated by residue, Tyr 321.    The 
next step is the catalytic reaction, in which hydrogen bond donation from the cationic ligand to 
the solvent and enzymatic residues is facilitated.    A network of interactions with residues Asp 
70, Arg 71 and Glu 196 and Glu197 stabilizes the cationic intermediate 4. 
The active site of N1 neuraminidase can be divided into four critical binding pockets, Figure 
5 50.    Pocket C1 (Figure 5, green residues) encompasses the positively charged guanidino 
groups of Arg 37, Arg 212 and Arg 287 which interact with the carboxylate group of substrate 
and inhibitor.    Residue Arg 71 in the C5 (Figure 5, orange residues) pocket functions as a 
hydrogen bond donor and comprises residues Trp 98, Arg 144 and Ile 142 which create a small 
hydrophobic region.    In the C4 (Figure 5, cyan residues) pocket, a guanidine or amine group 
of the substrate or inhibitor participates in a charge-charge interaction and hydrogen bonds to 
Glu 38, Asp 70 and Glu 147.    Within the C6 pocket (Figure 5, yellow residues), Glu 197, the 
side chain of Arg 71, the amidic carbonyl of Trp 98 and Asp 70 forms a new hydrophobic 




Figure 5: Outlining the residues of the four binding site pockets; (Pocket C1: green), (Pocket 
C4: cyan), (Pocket C5: orange), (Pocket C6: yellow) 
3.1 Ligand-protein interaction pattern and per-residue free binding energy profile 
Post-dynamic analysis of the substrate (sialic acid) and active inhibitors (oseltamivir, 
laninamivir, peramivir and zanamivir) complexed with neuraminidase, revealed that each 
system achieved convergence (see RMSD and potential energy plots in Supplementary 
Information, S1 and S2).    The MM-GBSA algorithm was used to describe the per-residue 
binding free energies.    The ranking of contributions of interacting residues highlighted critical 
pharmacophoric features of each inhibitor used in this study; see Table 1.    A noticeable trend 
in the system energetics of all complexes was observed.    Hydrogen bond donation from 
protonated arginine residues 37, 71, 144, 212 and 287; to the ligand had unfavourable energy 
contributions, whereas the hydrogen bond acceptor residues have an appreciable per-residue 
binding free energy contribution.    A possible explanation for this occurrence is that salt 
bridges have a distinct dual function: participating in both hydrogen bonding and ionic 
interactions.    The energy term for residues engaged in salt bridges, is largely unfavourable 
due to desolvation, as the interaction endures significant entropic loss.    The ubiquitous nature 
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of hydrogen bonds in an aqueous environment sometimes requires desolvation of the donor 
and acceptor prior to formation.    Thus, the per-residue free binding energies of hydrogen bond 
donors of the enzyme, reflected in the MM-GBSA profiles are in a positive scale due to 
enhanced polar solvation properties. 
Table 2: Common active site residues in the binding pattern of each inhibitor 
 Common Residues 


























Oseltamivir √ √ √ √ √ √   √ √ √ √ √ 
Zanamivir  √ √ √ √ √ √ √ √ √ √  √ 
Laninamivir √ √ √  √ √ √ √ √ √ √ √ √ 
Peramivir √ √ √ √ √ √ √ √ √ √ √ √ √ 
 
The interaction pattern of crystallographic structures of the four inhibitors corresponds with 
reported interactions in literature.    Table 1, lists the common interactions observed in the 
inhibitor complexes.    Residues Glu 38, Asp 70, Arg 71, Trp 98, Ile 142, Glu 147, Glu 196, 
Glu 197 and Tyr 321 of Table 1; represent residues with a high binding free energy 
contribution.    The two-dimensional binding of inhibitors and substrate; oseltamivir (Figure 
6), zanamivir (Figure S3), laninamivir (Figure S4), peramivir (Figure S5) and sialic acid 










Figure 6: 2-D interaction profile of oseltamivir with residues of high binding free energies 
3.2 Pharmacophore model construction, evaluation and database screening 
3.2.1 Ligand-based pharmacophore model 
The Espresso algorithm, a built-in heuristics modelling tool of LigandScout was used to predict 
the ten hypothesised models, as shown in Table 2.    The calculation implements a parallel 
Glu 38 Asp 70 Arg 71 Trp 98 Ile 142 Ser 166 Glu 196 Glu 197 Asn 214 Tyr 321
vdW -33,987 -56,585 23,435 -3,195 -0,468 0,277 -16,868 -35,655 -0,198 0,845
Elec. 32,627 53,143 -22,601 3,318 0,492 0,222 17,132 35,713 0,663 -1,155








































alignment of pharmacophoric moieties of the training set molecules.    This was done by the 
automatic assignment and overlaying of distinct binding modes of the ligands until a 
geometrically adequate representation of all five training set molecules was achieved.    
Boolean minimisation refined the pattern matching resulting in a near optimal solution of all 
possible conformations.    Each model was evaluated using two screening sets: 1) active set 
and 2) decoy set of molecules, as described in Section 3.4.1.    This methodology properly 
assesses the ability of the pharmacophore models to adequately detect active compounds over 
decoys.    Pharmacophore model 1 expressed the greatest specificity for detecting actives over 
inactives.    The predicted model also aligned well with the profile of the per-residue binding 
free energy pharmacophoric pattern.    The LigandScout package calculates the area under the 
curve (AUC) as well as the enrichment factor (EF), which was estimated at 0.82 and 35.1% 
respectively.    The pharmacophoric model qualities are represented in the receiver operating 
characteristic (ROC) curve, Figure 7.     
Table 3: Hypothesised models 1-10 
Model number Scoring function Pharmacophoric Features 
1 0.8342 5 x HBA, 4 x HBD, NI, PI 
2 0.8301 4 x HBA, 3 x HBD, NI, PI 
3 0.8251 5 x HBA, 3 x HBD, PI 
4 0.8242 5 x HBA, 3 x HBD, PI 
5 0.8224 5 x HBA, 3 x HBD, PI 
6 0.8017 5 x HBA, 4 x HBD, NI, PI 
7 0.7997 6 x HBA, 3 x HBD, NI 
8 0.7996 6 x HBA, 3 x HBD, NI 
9 0.7996 6 x HBA, 3 x HBD, NI 
10 0.7774 6 x HBA, 3 x HBD, PI 
















Figure 7: ROC curve of model 1 of the ligand-based pharmacophore 
Validation of pharmacophore model 1 (Figure 8) prompted its use in a ligand based virtual 
screen.    A library of molecules with drug-like properties was extracted from the ZINC 
database for use in the in silico screening against the selected ligand-based pharmacophore 
model.    The minimum feature requirement was set to three and possible hits were detected 
using the best matching conformation method and scored based on their pharmacophore-fit.    
A total of 5879 compounds was screened of which only 23 compounds satisfied the predicted 
pharmacophore model.    These molecules were then subjected to a structure based virtual 






















Figure 8: 2-D and 3-D representations of Model-1 with; A) sialic acid, B) oseltamivir, C) 
zanamivir, D) peramivir and E) laninamivir overlay. 
3.2.2 Structure-based pharmacophore model 
A dynamic pharmacophore was generated by superimposing four hypothesised models of each 
inhibitor.    With the aid of LigandScout software the interactions between protein and ligand, 
as well as some of the excluded volume spheres corresponding to 3-D protein structures, were 
interpreted.   The protein-ligand complexes of laninamivir, peramivir, zanamivir and 
oseltamivir displayed a significant overlap in their binding patterns.    Common interaction 
patterns were observed with catalytic residues Arg 37, Arg 70, Arg 71, Arg 212 and Arg 286.    
Glu 196 was also highlighted and it is known to facilitate the electrostatic funnelling of ligands 
into the active site 4.    Other important residues included amino acids: Glu 38, Arg 75, Trp 98, 
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Ile 142, Arg 144, Glu 147, Glu 197, Arg 287, Tyr 321; all of which contribute to the 3-D 
integrity of the binding pockets. 
Overlapping the chemical features of the complexed inhibitors resulted in a structure-based 
pharmacophore model with four HBA’s, a PI and NI species as well as exclusion volumes, as 
seen in Figure 9.    The inclusion of exclusion volumes allows the pharmacophore to accurately 
describe the spatial interface of the ligand bound in the binding pocket, such that steric regions 
that are not occupied by the active ligand are mapped.    The model generated was in close 
approximation to the high per-residue contributors of binding free energy described in Section 
3.1.    Enrichment metrics of the model estimated 0.7 (AUC) and 47.1 % (EF), (Figure 10).     
The predicted model was screened against the 5879 drug-like molecules from the ZINC 
database.    The resulting hit-list of five molecules which suitably satisfied the model’s criteria 
was subjected to further study by molecular docking. 
 
Figure 9: 3-D and 2-D representations of the hypothesised model with; A) oseltamivir, B) 




































Figure 10: ROC curve of the structure-based pharmacophore 
3.3 Molecular Docking 
The crystallographic structure of oseltamivir (PDB ID: 3TI6) complexed with neuraminidase, 
was selected for the molecular docking study.    Validation of the docking system by a re-
docking (see Table S2) and cross-docking (refer to Table S3) procedure established that the 
docking software was capable of placing the ligand in the correct conformation within the 
binding site.    Docking a combined library of known inhibitors with decoy compounds 
established that AutoDock was capable of selecting actives from inactives.    The list of hit 
compounds detected from the screening against the two predicted pharmacophore models was 
docked into the neuraminidase binding site.    A total of 28 molecules was docked and ranked 
according to binding free energy values.    The five highest ranked ligands from each of the hit 
lists of the ligand-based pharmacophore and structure-based pharmacophore, were analysed to 
interpret their significant ligand characteristics and binding interaction patterns with the 
receptor.    Table 3, lists the selected compounds for further analysis.    
 
Specificity (% selected decoys)  
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Table 4: Top five docked ligands of LB and SB pharmacophore hit lists 
Ligand-based 











































































These ligands were further subjected to a 20 ns MD simulation.    The root mean square 
deviation (RMSD) and potential energy plots of ligands 1-10 confirmed the convergence of the 
MD protein-ligand complexes at approximately 25 ns.    See supplementary information 
(Figure S7 to S10).    The root mean square fluctuation (RMSF) plots closely resemble the 
residue contribution profile of inhibitor oseltamivir. 
Based on the predicted binding free energy (ΔGbind), ligand 1 is ranked as having the most 
favourable binding interaction with the receptor followed by ligands 6, 7, 8, are comparable to 
the binding free energy of active inhibitor oseltamivir.    Ligands 2, 3, 4, 5, 9 and 10, however, 
exhibit weaker interaction contributions with the receptor.    However, the correlation of the 
docked energies with calculated binding free energies of the ligand-based pharmacophore hits 
are better than the structure-based pharmacophore.    The total binding free energy was further 
decomposed into its components.    The four inhibitors (oseltamivir, zanamivir, laninamivir 
and peramivir), shared a similar energy contribution trend, the electrostatic energy (ΔEele) 
contribution was counter-balanced by the polar solvation energy (ΔGGB) contribution.    A 
significant proportion of the binding free energy comes from the van der Waals energy (ΔEvdW) 
contributor.    The same trend is observed for the ligands extracted from the virtual screen.    
Structurally the ligands are different to the current drug inhibitors and, as previously 
mentioned, the more basic the ligand, the more potent it is in inhibiting the enzyme 50.      
The binding pattern of ligand 1 displayed significant hydrophobic interactions between the 
conjugated ring and residues Arg 71, 144 and Ile 142, Table 3.    The hydrogen bond donation 
from the protein receptor residues Arg 75, 144, 212 with the sulphonyl amide group, was 
similar to the substrate and active inhibitors.    Further to this, Arg 71 expressed a weak π -
cation interaction between the face of the electron rich π-system of the aromatic ring.    The 
total binding free energy of ligand 1 is -26.68 (kcal/mol), Table 4.    The molecule has three 
distinctive structural features surrounding the phenyl anchor.    The cyano group is 
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accommodated in the C4 pocket.    The sulfamoylcarbamate and tert-butyl group extends from 
the C1 to the C6 binding pockets.    Overall, the molecule offers many electron pairs which can 
attribute to the basicity of the ligand.    The quasi-harmonic entropic approximation (ΔS) of 
ligand 1 comprised of three aspects translational, rotational and vibrational contributions.    The 
measure of disorder for each estimated -12.80, -10.10 and -49.54 (kcal/mol), respectively.    
Collectively giving a ΔS of -72.43 (kcal/mol) suggesting an ordered compact three-dimensional 
protein complex.    Hydrophobic interactions of ligand 2 were observed between Asp 70 and 
Arg 144 with the hydroxyl linker and aromatic ring functionalities, respectively.    The ligand 
structure appears to be interlocked and rigid due to the fused ring complement, resulting in a 
restricted hydrogen bond network with residues Glu 197, Arg 212 and Arg 287.    The unique 
ringed structure of 1,3-dioxolane sits in the C1 pocket, decanol occupies the C6 and C4 pockets 
and a chlorophenyl group resides in the C5 pocket with an overall ΔGbind of -19.05 (kcal/mol).    
The estimated ΔS of the system was measured to be -71.84 (kcal/mol).    With a translational 
contribution of -12.87 (kcal/mol), a rotational contribution of -10.14 (kcal/mol) and a 
vibrational contribution of -48.83 (kcal/mol).    This suggests an ordered three-dimensional 
protein complex.    Ligand 2 acts as a weak acid i.e.   a hydrogen bond donor, but has improved 
lipophilicity compared to ligand 1.     
Ligand 3 is an electronegative rich molecule with a hydrophobic interaction between Glu 197 
and the trifluoromethyl moiety.    The hydrogen bond network observes significant hydrogen 
bond donation from residues Ser 166, Arg 212 and Tyr 321, whilst Glu 197 accommodates a 
hydrogen interaction by donation from the amide group.   A bridging water molecule mediates 
an interaction between Arg 287 and the trifluoromethyl group.    The predicted ΔGbind for ligand 
3 estimated -16.79 (kcal/mol).    The compound comprises four substituents extending from a 
central phenyl ring.    There are two oxohydroxylammonium groups that occupy the C1 and 
C5 pockets as hydrogen bond acceptors.    A hydroxyl group sits in the C6 pocket which acts 
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as an HBA and HBD, and a trifluoroacetamido ethyl group which contains a range of HBA and 
HBD moieties, is accommodated in the C4 pocket.    The compound has an overall acidic 
profile.    The entropic contribution estimated -42.00 (kcal/mol) comprising -12.80 
(translational quasi-harmonic approximation (qha)), -10.29 (rotational qha) and -18.91 
(vibrational qha) (kcal/mol), respectively.    The trifluoromethyl moiety of ligand 4 expressed 
an electrostatic interaction with Lewis base residues Arg 71 and Trp 98.    The dipole created 
by opposing side chain group’s i.e.   the trifluoromethyl group and acetohydrazide, is supported 
by Asp 70 via a bridging water and a hydrophobic interaction.    Asp 70 also functions as both 
a HBA and HBD.    Additional hydrogen bond contributions from Arg 212 and Arg 287 were 
established.    Ligand 4 has two defined structural features attached to the phenyl anchor, the 
first being the HBA, trifluoromethyl group which partially occupies the C5 and C6 binding 
pocket, and the HBD, acetohydrazide which is accommodated in the C1 pocket.    The molecule 
is observed to have a weak Lewis acid chemical profile with a predicted ΔGbind of -12.62 
(kcal/mol).    Ligand 4, has a total entopic quasi-harmonic approximation of -65.37 (kcal/mol), 
translational qha of -12.61 (kcal/mol), vibrational qha of -9.87 (kcal/mol) and vibrational qha 
measuring -42.89 (kcal/mol).    Ligand 5 reflected a defined hydrogen bond interaction pattern 
with acetohydrazide functional group and residues: Asp 70, Arg 71, Arg 212, and Arg 287.    
The structure of ligand 5 comprises three identical methyl ethers and are chemically recognised 
as HBA’s that occupy and overlap with the binding pockets C4, C5 and C6.    The molecule 
also contains an acetohydrazide that possesses an HBA and HBD moiety which interacts with 
residues of the C1 binding pocket.    The compound has an overall basicity with a calculated 
binding free energy estimating -8.80 (kcal/mol).    The measured ΔS reflects an ordered protein 
profile of -43.14 (kcal/mol), and a translational, rotational and vibrational qha of -12.52, -9.51 




 Table 5: Calculated binding free energies based on the MM-GBSA method 
System ΔEele ΔEvdW ΔGSA ΔGGB ΔEgas ΔGsol ΔGbind 




































































































































































































*the energy values reported are measured in kcal/mol: ΔGbind = ΔEgas + ΔGsol - TΔS; ΔEgas = ΔEint + ΔEvdW + ΔEele; 
ΔGsol = ΔGGB + ΔGSA. 
An extensive hydrogen bonding network of ligand 6 with HBD’s: Arg 37, Asp 70, Arg 75, Ser 
99, Arg 212, Arg 287 and HBA’s: Glu 38, Trp 98, Glu 147 and Tyr 321 exists.    A water bridge 
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created by Arg 287 supplements an electrostatic interaction.    Ligand 6 was ranked with the 
most favourable ΔGbind measuring -24.08 (kcal/mol).    The ligand has three key structural 
features; 1) the pyridine anchor, 2) the hydroxamic acid, and 3) the hydroxycarbamimidoyl.    
The hydroxamic acid acts as an HBA, residing in the C1 binding pocket.    The 
hydroxycarbamimidoyl group’s interaction is shared with the C4 and C6 pockets.    The 
molecule assumes a very weak acid profile perceiving it to be a potential inhibitor.    Ligand 7 
had a more conserved binding pattern, with a hydrophobic interaction between Ile 142 and tert-
butyl group.    Arg 212 and Tyr 321 are delegated as a hydrogen bond donor and acceptor, 
respectively.    Salt bridges exerted by Arg 37 and Arg 287 allow for the accommodation of 
the carboxylate group.    Ligand 7 comprises a keto-cyclopropanecarboxylic acid which 
interacts with the C1 binding pocket residues.    A piperazine moiety anchors the molecule and 
engages in a charge-charge interaction in the C4 binding pocket.    The C5 pocket 
accommodates the tert-butoxycarbonyl group.    The molecule has an overall ΔGbind of -23.45 
(kcal/mol).    Ligand 8 shared a similar binding profile to ligand 7.    A distinct hydrophobic 
interaction with residue Arg 144 exists.    A hydrogen bond network between residues Glu 38, 
Arg 75 and Arg 287 and the carboxylate group exists.    Salt bridges created by Arg 37, Asp 
70 and Glu 197 provide valuable contributions to electrostatic interactions.    The composites 
of ligand 8, contrast with its counterparts.    It is composed of piperazine with a tert-
butoxycarbonyl group that facilitates an HBA interaction with the C1 pocket.    The C4, C5 
and C6 binding pockets promote an interaction with the carboxylic acid linker, HBA and 
phenyl ring.    The molecule mimics weak acid properties with a total binding free energy of -
23.30 (kcal/mol).    The complexation of ligand 9 offered three distinct salt bridges: Arg 37, 
Arg 212 and Arg 287 to the carboxylate group.    Ligand 9 has an estimated ΔGbind of -20.00 
(kcal/mol).    It has steric bulk attributed by the chain of two phenyl rings and two piperadine 
groups which reside in the C1 and C5 binding pockets.    The carboxylic acid group is a 
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significant HBA contributor that interacts with the C6 pocket residues.    The composition of 
ligand 10 incorporates a pyridine, morpholine and a carboxylic acid which reside in the C6, C4 
and C1 binding pockets, respectively.    The ligand has a strong affinity predicted ΔGbind of -
17.66 (kcal/mol).    The aromatic ring on ligand 10 demonstrated appreciable hydrophobic 
interactions between residues Asp 70, Arg 71, Ile 142 and Arg 144.    Arg 71 formed a π-cation 
interaction with the face of the benzene ring electron cloud.    Hydrogen bond donation from 
residues Arg 212 and 287 with the pyridine rings was observed.     
3.4 Similarity 
The novelty of the ligands identified was confirmed using PubMed.    Ligand 1 and 3 share no 
similarity with any reported inhibitor in literature.    Ligand 2 displayed no biological activity 
in literature, although the 2,4-dinitrophenolate group has become the basis of the design of 
innovative anti-cancer agents (CID 229329).    Ligand 5, has not been previously reported as a 
potential neuraminidase inhibitor.    However, analogues of the 2-phenylacetohydrazide have 
been evaluated for their inhibition of Microbial tyramine oxidase (AID: 215960).    The 2-
(3,4,5-trimethoxyphenyl)acetohydrazide of ligand 4, serves as an important framework for 
active inhibitors against human AChE and human plasma BChE.    Ligand 6 (5-
[amino(hydroxyimino)methyl]-N-hydroxy-2-pyridinecarboxamide), 7 (2-{[4-(tert-
butoxycarbonyl)piperazino]carbonyl}cyclopropanecarboxylic acid) and 8 (3-[4-(tert-
butoxycarbonyl)piperazino]-2-phenylpropanoic acid), share no similarity.    The piperazine of 
ligand 7 and 8, is a heterocycle which influences the biological activity by conferring metabolic 
stability and potentiating interactions with macromolecules 51-53.    The compound, 6-
morpholinonicotinic acid (ligand 10) has previously been tested in six bioassays 
(SID11536988); 1) influenza A RNA, 2) DnaK protein chaperone, 3) homo sapien peptidyl-
prolyl cis-trans isomerase FKBP1A isoform, 4) influenza A virus M2 ion channel, 5) homo 
sapien ubiquitin-conjugating proteasome E2, and 6) the FRB domain of mTOR.    The molecule 
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has demonstrated no activity in each of these systems.    The 1-benzylpiperidine structure of 
ligand 9 serves as a template for human betaine/GABA transporter 1 inhibitor N-(1-benzyl-4-
piperidinyl)-2,4-dichlorobenzamide (BPDBA) 54.    
4.   Conclusion 
The emergence of resistance in neuraminidase of the influenza A virus has encouraged research 
methods incorporating high-throughput screening.    Current methodologies propose that the 
structure-based pharmacophore predicted model as being superior to the ligand-based 
pharmacophore.    Our proof of concept in using per-residue binding free energies obtained 
from an MD ensemble using the MM-GBSA calculation to generate the ligand-based 
pharmacophore, has proven to be an invaluable additional technique for the generation of a 
suitable pharmacophore model.    The structure-based pharmacophore generated in the study 
has six pharmacophoric features, whereas, the ligand-based pharmacophore has 11 
pharmacophoric features that overlap with the interaction pattern mapped by favourable 
contributions of per-residue binding free energy.    The greater number of pharmacophoric 
features expands the screen for similar structured molecules.    It also introduces improved 
selectivity with greater structural diversity.    The five highest ranking molecules of the ligand-
based pharmacophore hit-list demonstrated a better correlation of its docking energies with the 
calculated MM-GBSA binding free energy.    Despite the predicted ΔGbind of the ligand-based 
docked complexes having a reduced affinity, a defined interaction of the chemical specific side-
chains with the specific binding pockets is observed.    The ease of drugability of these 
compounds based on lipophilicity makes them even more attractive as potential inhibitors. 
Introducing MD simulation into the workflow in pharmacophore generation, creates an 
energetically enhanced 3-D profile of the ligand-protein complex.   The interactions are thus 
based on an optimised conformation.    The decomposition of the binding free energy into the 
per-residue contributions using MM-GBSA calculations allows us to organise and rank the 
136 
 
interacting residues and subsequent chemical features, by their favourable energetics.    The 
potential inhibitors filtered through LBP virtual screens are more structurally specific for the 
target.    Thus the use of this technique would vastly improve the efficacy of in silico screening 
methods which, in turn expedites the design and development of innovative inhibitors to 
prevent future disease.    The results of this study form a strong basis for further investigation 
of the identified high ranking ligands 1-10 from the ligand- and structure-based virtual screen 
as potential inhibitors of influenza neuraminidase. 
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Abstract 
The threat of impending influenza pandemics, due to the rapid development of resistance of 
the influenza virus toward existing chemotherapeutic defences, expedites the need for 
innovative and effective drugs against selective targets.  In this study, we provide a 
comprehensive molecular dynamics perspective of the bonding mode of a designed inhibitor 
in the active site of the 2009 pH1N1 endonuclease.  Using computational techniques we were 
able to decipher the capacity of the active site by comparing the conformations of a bound 
enzyme to an apo-enzyme.  Inhibitors of endonuclease require three features: 
1) a greater number of hydrophilic moieties which are situated on terminal ends of the 
inhibitor, 
2) long, flexible planar side-chains which are anchored to a hydrophobic or neutral base, 
3) steric bulk, to block the binding pocket. 
The structural features outlined will offer tremendous insight when constructing and 





The influenza virus is an important human pathogen, being the primary cause of many 
epidemics and pandemics worldwide.  There have been several documented pandemics, such 
as the ‘1918’ Spanish flu which claimed approximately 40 million lives 1, in 1957 and 1968 
the Asian and Hong Kong influenza viruses were reported each claiming about one million 
lives 2.  The most recent pandemic identified by the World Health Organisation (WHO) was 
the 2009 H1N1/swine flu, however, the virus still maintains its pathogenicity across the eastern 
border specifically in India.  The unpredictable nature of H1N1 to gain resistance to current 
chemotherapies through rapid evolution and its ease of human-human transmissibility poses an 
eminent threat of a new pandemic, to which, the human population has no defence3-5.  Thus it 
is crucial to understand the mechanism of resistance of influenza A viruses, as well continually 
research the development and design of new effective anti-viral agents.   
Influenza vaccines are the most widely used prophylactic measure, however, due to the rapid 
spread of infection the need for effective antiviral drugs is imperative 6.  The influenza A virus 
genome is comprised of eight segments each being viable drug targets.  These include: 1) the 
antigen haemagglutinin 7; 2) the M2 ion channel which, has two main active inhibitors that are 
commercially available Symmetrel/amantadine and Flumadine/rimantadine 8; and 3) 
neuraminidase which, has four main active drug candidates; Relenza/zanamivir, 
Tamiflu/oseltamivir, Rapivab/peramivir and laninamivir 9.  However, the rapid development 
of resistance of the influenza A virus toward available prophylaxis is of growing concern.  
Resistance is often acquired by mutation in the target protein, thus making our efforts to try 
and keep up with evolution more difficult.  Therefore it is essential to explore and investigate 
alternate targets.  An example would be to target the viral replication process. 
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The mechanics of viral replication lie in eight negative-stranded RNA segments which encode 
at least 17 viral proteins, a major component of these segments is the RNA-dependent RNA 
polymerase (RdRp) 10.  The crystal structure of the RNA polymerase reveals a large protein 
complex (~250 kDa) composed of three subunits, which are highly conserved among influenza 
A and B viruses; these include polymerase basic protein 1 and 2 (PB1 and PB2), and 
polymerase acidic protein (PA) 11, 12.  During viral transcription, the RdRp cleaves host pre-
mRNA’s at a distance of 10-13 nucleotides from their 5`-capped terminus 13.  The binding of 
the cap is performed by PB2, whilst the endonuclease activity resides in the N-terminal domain 
of PAN (PA-Nter; containing residues 1 to ~195).  After endonuclease cleavage, the short 5`-
capped RNA serves as primer for the initiation of viral mRNA synthesis, performed by the PB1 
unit with viral mRNA’s being subsequently translated by the host cell machinery 14.  The 
process of binding and cleavage of the 5`-cap i.e. ‘cap snatching mechanism’, is not a normal 
cellular function thus it remains an exclusive and essential step in the influenza virus lifecycle 
13, 15. 
There has been further evidence to suggest the existence of an alternate encoded protein, PA-
X, which has an overlapping sequence and similar enzymatic activity as PAN, may contribute 
to the host protein shutdown observed during influenza A infection 16.                                                                          
Thus the acidic component of the polymerase offers a viable strategy to inhibit the influenza 
viral replication.  Over the last 20 years several structurally diverse small molecule PA 
inhibitors have been discovered to have strong activity toward the PA-Nter enzyme.  Such as 
flutimide and its structural analogues, tetrameric acids, green tea catechins, N-hydroxamic acid, 
epigallocatechin gallate, N-hydroxypyridazinones and hydroxypyri(mi)dinones.  (most potent 
antiviral L-742,001) 17-20. 
The catalytic site of endonuclease is similar to the (P)DXN(D/E)XK nuclease motifs formed by 
D108, E119, a proline (influenza A) or alanine (influenza B) at position 107, and K134 or 
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K13721.  It comprises a histidine (H41) and a cluster of three acidic residues (E80, D108, E119), 
which are conserved in all influenza viruses and coordinate (together with I120) to one, two or 
three divalent metal ions (Mg2+ or Mn2+, with Mg2+ being the prominent cofactor in vivo) 22-24.  
There are approximately 35 crystal structures related to the influenza virus PA endonuclease 
deposited in the RCSB Protein Data Bank, with over 20 enzymes in complex with an inhibitor.  
Multiple biochemical studies reveal critical information of the structural composition of the 
enzyme17, 25.  The PAIs identified inhibit the PA endonuclease through chelation of its metal 
cofactor(s) with the active site.  The architectural characterisation of PAN allows the design 
and development of novel and rational PAI chelating structures and enhanced enzyme binding 
properties to improve antiviral activity in cell culture. 
Bauman et al, created a new class of influenza endonuclease inhibitors via structure-based drug 
design26.  It was identified that (compound 7’s) had the greatest antiviral potency amongst the 
endonuclease inhibitors.  In our study we wish to supply a molecular dynamic comparative 
perspective of the apo-enzyme of endonuclease as well as a bound ligand.  This will provide 
significant structural binding markers that will allow us to via in silico screening identify an 
expanded class of endonuclease inhibitor.  In turn, highlight critical features to be considered 
for de novo drug synthesis. 
Methods 
Preparation of System 
Crystallographic structure of H1N1 endonuclease unbound (PDB ID: 4M5Q) and bound with 
inhibitor (compound 7) (PDB ID: 4M4Q), were obtained from the RCSB Protein Data Bank 
(PDB)26.  Using the Chimera 1.8.1 software package a monomer was selected followed by the 
correction of protonation states of amino acid residues as well as the removal of water, polar 
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hydrogens and non-bonding species 27, 28.  The specific van der Waals radius and molecular 
mass of the Mn metal was accommodated for in mol2 format in preparation of the ligand.  
Molecular Dynamics Simulation 
Amber 14.0 GPU version of the PMEMD engine was used to perform a 100 ns molecular 
dynamics simulation.  The protein was described with the FF99SB variant force field 29.  The 
LEaP module embedded within Amber was use for the addition of hydrogen atoms and 
neutralisation of the protein by the addition of Na+ counter ions.  The system was suspended 
within a TIP3P 303029 water box such that all protein atoms were within 8 Å from the box edge.  
The drug-protein complex was energetically minimised in three stages; 1) 1000 step restraint 
gradient minimisation with selective boundary conditions of the particle-mesh Ewald method 
which has a parameter of direct space and a van der Waals cut-off of 12 Å.  Stage 2, a 2500 of 
deepest descent step with a solute harmonic potential of 500 kcal/mol. Å2; and stage 3, a 1000 
step unrestrained conjugate gradient energy minimisation of the complete system.  The system 
was heated using a canonical ensemble (NVT) from 0 K to 300 K over 50 ps.  The collision 
frequency of solutes was 1.0 ps-1 with a harmonic potential of 10 kcal/mol.Å
2
.  A final 
equilibration step of 500 ps was performed using the SPFP precision model of the SHAKE 
algorithm to constrict hydrogen bonds at 2 fs intervals.  The simulations were conducted in a 
randomised seeding of an isobaric-isothermal ensemble (NPT).  A constant pressure of 1 bar 
was maintained by the Berendsen barostat with a pressure coupling constant of 2 ps. A 
temperature of 300 K was set using a Langevin thermostat with collision frequency of 1.0 ps-
2.  Co-ordinates were saved every 1 ps and the trajectories were analysed every 1 ps using a 





Binding free energy calculation 
An implicit solvent model was employed to describe the thermodynamic free binding energies 
of the bound conformation of endonuclease enzyme.  The Molecular Mechanics/Generalised-
Born Surface area method was used to evaluate the ligand-protein complex binding affinities.31-
34  To calculate the free binding energy contributions 10000 snapshots were extracted from the 
100 ns trajectory.  The following set of equations describe the calculation of the binding free 
energy: 
∆Gbind = Gcomplex − Greceptor − Gligand                    (1) 
∆Gbind = Egas + Gsol − TS                                              (2) 
Egas = Eint + Evdw + Eele                                               (3) 
Gsol = GGB + GSA                                                               (4) 
GSA = γSASA                                                                       (5) 
The term Egas represents the gas-phase energy, and is directly estimated from the FF99SB force 
field terms which comprises the energy contributor’s internal energy (Eint), van der Waals 
energy (EvdW) and Coulomb energy (Eele).  The solvation energy, Gsol is estimated by the 
contribution of energies from polar states, GGB and non-polar states, GSA.  The non-polar 
solvation energy is determined from the solvent accessible surface area (SASA) using a water 
probe of 1.4Å.  The temperature and total solute entropy are represented by T and S, 
respectively35.  
Principle Component Analysis (PCA)   
PCA reveals the structure of atomic fluctuations.  PCA describes the motion of the system in 
terms of eigenvectors (planar of motion) and eigenvalue (magnitude of motion) 36.  
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The individual MD trajectories are stripped of solvent and ions using the PTRAJ and CPPTRAJ 
modules in Amber 12.0/14.0.  The resulting trajectories were aligned against a fully minimised 
structure.  PCA was performed on C backbone with 5000 snapshots taken every 20 ps. The 
first two Eigen vectors (PC1 and PC2) corresponding to the first two modes of PCA covariance 
matrices were generated using in-house scripts.  The corresponding PCA scatters were plotted 
using Origin software (http://www.originlab.com/), structural postscript diagrams were created 
using VMD 37.  Porcupine plots of the first and second modes developed by the normal mode 
wizard (NMW) using the ProDy interface of VMD were sketched for each of the systems 38. 
 
Results and Discussion 
The crystal structure of the apo- influenza endonuclease (4M5Q) and ligand-bound (4M4Q) 
enzymes contain a residue complement of 196 and 200 amino acids, respectively.  The 
difference in the amino acid sequence lies in the N-terminus of the enzyme and is dependent 
on the resolution of the crystal structure.  The difference of four amino acids does not alter the 
secondary or tertiary structures of the metalloprotein as is observed from the secondary 
structure analysis of the systems (see Supplementary information S1 to S5).  The root mean 
square deviation (RMSD) and potential energy plots attained convergence in both systems at 
10 ns for the apo-enzyme and 25 ns for the ligand-bound PA.  With a measured average RMSD 
of 1.5 Å and 1.2 Å, respectively.  The energy difference between the systems estimates 10 000 
kcal/mol in favour of the ligand-enzyme complex. 
The intention of this study is to highlight the critical binding features of the unique inhibitor.  
Each PAN, comprises two divalent Mn metal centers which are essential to the binding of the 
inhibitor in the active site.  The binding mode of the highly potent molecule is unlike the 
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binding of other endonuclease inhibitors in the active site.  The metal cofactor exists as +2 
cation, which, governs the architecture of the potential chemotherapeutic.   
According to the online protein-ligand interaction profiler (PLIP) 39, PAN has an alpha-beta 
construction with five-mixed beta-strands forming a twisted plane surrounded by seven alpha-
helices.  A negatively charged cavity surrounded by helices α2-5 and strand β3 house the metal 
ion.  The geometry of metal co-ordination is square planar and square pyramidal.  Metal 
chelation occurs via amino acid interactions: Ile120, acidic residues Glu80, Asp108, three 
water molecules stabilised by residue H41, Glu119 and the carbonyl oxygens of Lys106 and 
Pro107.  The co-ordinating residues have been found to be highly conserved between influenza 
A, B and C viruses. 
The root mean square fluctuation no observable perturbations between the apo-enzyme and the 
ligand-metalloprotein complex of the residues implicated in the binding of the metal (Figure 
1).  Residues 50 to 75 of both systems, which, are assembled in a coil exert a high frequency.  
The ligand of system 4M4Q expresses two prominent hydrophobic interactions of the α-helix.  
The first being between with β-carbon of Ala42 and C10 of the ligand cyclohexyl group at a 
distance of 3.79 Å.  The second non-polar interface occurs between the γ-carbons (i.e. Cγ1 and 
Cγ2) of Ile43 and C9 and C26 of the cycloheyl (3.78 Å) and fluorocyclohexenyl (3.69 Å) groups 
of the ligand, respectively.  A hydrogen bond network exists between the ligand and catalytic 
residues.  These include interactions of hydrogen bond donors of the protein; ε-amino group of 
Lys39 (H-acceptor distance = 3.01  Å, donor-acceptor distance = 3.97 Å) and Lys139 (H-
acceptor distance = 1.80 Å, donor-acceptor distance = 2.58 Å), as well as the δ-guanidino group 
of Arg129 (H-acceptor distance = 2.77 Å, donor-acceptor distance = 3.76 Å) with N14 and N15 
of the aromatic pyran ring and C5 para to the nitrogen of pyridine ring.  The ε-O of the carboxyl 
group of residue Glu85 and the hydroxyl group of Tyr135 accept hydrogens from the ligand 
via C20 of the fluorocyclohexenyl group (H-acceptor distance = 2.27 Å, donor-acceptor 
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distance = 3.01 Å) and C5 of the pyridine ring (H-acceptor distance = 3.06 Å, donor-acceptor 
distance = 3.65 Å). 
 
Figure 1: RMSF of the bound and unbound system of endonuclease enzyme 
An estimation of the number of hydrogen bonds throughout the simulation affirmed that the 
apo-enzyme (4M5Q) and ligand-protein complex (4M4Q) were similar averaging between 90 
– 130 hydrogen bonds (Figure 2).  However, it was observed that the molecular dynamics of 
the apo-enzyme predisposes the enzyme to greater solvent exposure which leads to a 4-5 
hydrogen bond difference of apo-enzyme and complex systems at any given point during the 
simulation.  This is exacerbated in the apo-enzyme due to the high concentration of histidine 
residues which readily interact with adjacent residues in the α-helices and β-strands, as well as 
the metal centers.  Binding of the ligand in the active site pocket is mediated by the divalent 
metal cations and specific hydrophobic interactions.  Thus the number of hydrogen bonds when 
comparing the bound and unbound systems of the PA subunit remain essentially the same. 




























Figure 3: Solvent accessible surface area (left) and volume (right) analysis of the proteins 
bound (4M4Q) and unbound (4M5Q) over 100ns 
Solvent accessible surface area (SASA) refers to the relative area exposed to solvent taking 
into consideration, the composition of van der Waals surface of the protein.  The SASA for the 











































































ligand-protein complex, 4M4Q is slightly larger that of the apo-enzyme, 4M5Q (Figure 3).  The 
Mn+2 metal centers in their unbound state are co-ordinated to three waters.  In the bound state 
the waters are extruded to accommodate the ligand.  The structural moieties of the ligand are 
accommodated in the active site, the structure displays a significant number of hydrophilic 
pharmacophoric features.  The metal-ligand interaction co-ordination geometry is by a square 
planar arrangement.  The molecular size of the ligand is much larger than that of the three water 
molecules combined, which causes the binding cavity to expand.  The overall volume of 4M4Q 
the system increases significantly (Figure 3).  This distortion in conformation may be key to 
the inhibition of the endonuclease activity of the PA subunit. 
The radius of gyration describes the dynamic motion of the amino acid residues bound in their 
secondary structure in relation to the α-carbon backbone.  It indirectly quantifies the amount of 
energy required to overcome inertia.  System comparison of 4M5Q and 4M4Q reveal that the 
apo-enzyme is more tightly bound than the ligand-metalloprotein complex (Figure 4).  System 
4M4Q achieves a stabilised conformation only after ~40 ns at which point the protein complex 
is least compact.  This phenomenon is in line with the multiple biological functioning of the 
RNA-dependent enzyme.  PAN has been implicated in cap-binding, endonuclease activity, viral 
RNA binding and replication.  The volume of the ligand-protein complex is considerably larger 
than the apo-enzyme.  This proposes a constricted and relaxed conformation of the enzyme, 
where when selectively bound to the inhibitor the overall structure of the protein is more 




Figure 4: Radius of gyration of systems 4M4Q and 4M5Q over 100ns 
Principal component analysis explores the dynamics of protein folding in terms of the diffusive 
properties of the polypeptide chain.  System 4M5Q has a more compact three-dimensional 
structure than the ligand-protein complex, 4M4Q (Figure 5).  With a correlation of -0.011 
which is close to zero indicating that principal component 1 (PC 1) and principal component 2 
(PC2) are independent of one another and the direction of motion is antithetic.  The degree of 
motion although inversely proportional is also disproportionate in either direction.  This is 
supported by a covariance value of -0.62.  The correlation value of the bound complex 4M4Q, 
measured 0.0091 and the covariance value estimated 1.17.  This indicates that the fluctuation 
of the α-carbon backbone of PC1 and PC2 is independent of one another and occurs in a 
uniform disproportionate direction.   































Figure 6: Normal mode analysis of system 4M5Q (left) and 4M4Q (right) 


















Figure 6, describes the elastic motion of the alpha-carbon backbone of the PA subunit for both 
the 4M4Q and 4M5Q systems.  The normal mode analysis demonstrates a greater disorder in 
the bound conformation of 4M4Q eigenvector to the order ~0.001. 
Using MM/GBSA calculation it was found that the binding free energy of the bound 
conformation revealed significant contribution from the Evdw of -29.64 (kcal/mol) to the total 
ΔG measuring -20.54 (kcal/mol).  Van der Waals interactions are non-bonding entities and 
occur largely by the aggregation of non-polar residues forming hydrophobic pockets.  The 
contribution from electrostatics and solvent are included in table 1. 
 
Table 1: Energy contributions of the binding free energy term (ΔG) 
Energy component Energy contribution/ (kcal/mol) 
Eele -6.70  +/- 8.12 
GGB 19.68 +/- 7.43 
Egas -36.35 +/- 8.46 
GSA -3.88 +/- 0.46 
Gsol 15.81 +/- 7.23 
 
The quasi-harmonic approximation of entropy (ΔS) describes the disorder in the protein 
sequence which impacts the folding of the protein.  The composites of ΔS, include the effects 
of translation, rotation and vibration.  In the bound conformation, system 4M4Q, these were 
estimated to be -12.93, -10.68 and -21.01 (kcal/mol) respectively.  The overall measured 





The molecular dynamics analysis of bound and unbound endonuclease enzyme provided 
insight in the conformational change of the protein.  Subtle changes in the active site are 
amplified in the overall protein folding structure.  Using molecular dynamics simulation we 
were able to observe the effect of the inhibitor binding on the overall PA subunit.  It is clear 
that in order for a molecule to inhibit or bind to the active site components and chelate to metal, 
the inhibitor would have to exhibit an inherently hydrophilic nature.  Hydrophilic features 
would also need to be adaptive, in that the functional moiety would need to be ionisable.  The 
co-ordination of the ligand to the metal centers is required to be resilient against any 
fluctuations in pH.  The molecule should have two adjustable “arms” or side-chains in order to 
chelate to the metal center in a square planar geometry. 
The study offered insight into the expandable limitations of the PA subunit.  Thus future design 
of inhibitors may be constructed by active binding feature as well as steric bulk to block the 
active site. 
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8. General conclusions 
8.1 Conclusion 
 
The study had three distinct aims: 
4. To determine, differentiate and distinguish the mechanism of resistance of 
neuraminidase in influenza A; 2009-pandemic H1N1 (2009-pH1N1) and H5N1 
subtypes in the presence of mutation/s H274Y and I222K. 
5. To propose potential neuraminidase scaffolds for new and innovative prophylactic 
chemotherapies via the aid of in silico technique ligand-based virtual screening (LB-
VS) and structure-based virtual screening (SB-VS). 
6. To identify the binding mode of the polymerase endonuclease of H1N1 and isolate 
potential drug therapies to selectively inhibit enzyme activity, using LB-VS and SB-
VS. 
Overall, each aim was achieved.  Molecular dynamics proved an invaluable tool, specifically 
the multiple MD simulations.  The enriched MD simulation offered improved resolution of the 
protein conformation and three-dimensional structure.   
The comparative study of the wild type and mutant species of neuraminidase of the 2009-
pH1N1 and the highly pathogenic H5N1 strains, described a change in the active site of the 
enzyme.  It was found that a single point mutation of H274Y compared to the point mutation 
I222K influenced the structure of the active site to a greater extent by lowering the binding 
affinity of the drug, oseltamivir.  The binding affinity of the drug was further reduced in the 
presence of the double mutation, i.e. H274Y-I222K.  However, the 2009 pandemic swine flu-
H1N1 exhibited greater susceptibility to oseltamivir than the highly pathogenic avian flu-
H5N1.  This urged a closer inspection of the different neuraminidase binding landscapes.  
Evidence suggested a structural collapse of the active site of the wild type influenza A virus in 
the mutant species.  The contributions to the binding free energy term, the solvent accessible 
surface area analyses and radius of gyration analyses proposed a loss in hydrophobicity in the 
systems.  However, the volume ratio of the active site and overall compactness of the ligand-
protein complex of H5N1 mutants and mutants of H1N1 when compared to their wild type 
structures, was significantly altered.  Furthermore, when comparing the H5N1 systems to those 
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of the H1N1, the H5N1 ligand-protein complexes were found to exhibit a greater folding 
capacity which ultimately led to decreased surface solvent exposure. 
The difference in the binding site of the influenza viruses offers an explanation into the 
discrepancy in the mechanism and extent of resistance in the H1N1 and H5N1 systems.  
However, this only reiterates the need for new and innovative anti-viral agents.  Using ligand-
based and structure-based pharmacophore techniques, in the construction of three-dimensional 
models a set of 10 discriminant compound scaffolds was isolated.  These were preferentially 
screened for their ability to bind to the transmutated active site of the H1N1 mutant species.  
The in silico investigation of the H1N1 species containing the mutations H274Y and/or I222K, 
revealed pertinent information about the pharmacophoric features of potential inhibitors.  With 
the binding site volume being larger in the H274YH1N1 and I222KH1N1 systems than in the 
WTH1N1, it could accommodate: 
1) a larger profile inhibitor; 
2) an inhibitor with increased hydrophilic property  
3) structurally the inhibitor should have a longer hydrophobic ‘tail’ to be accommodate in 
the binding region which held the bulky group of oseltamivir.  
The binding mode study of endonuclease revealed that co-ordination of two divalent metal 
centers to a potential inhibitor, is required for the selective impair enzyme activity.  The binding 
of the inhibitor in the active site of endonuclease is indirect.  The interaction profile of the 
ligand-to-protein comprises: 
1) salt bridges; 
2) water bridges;  
3) metal chelation; and 
4) electrostatic interactions predominantly with Arg, Asp and Glu residues. 
The designed drug should exhibit hydrophilic properties and functional moieties capable of 
ionising at a pH range of 5 – 7 whilst retaining its stability.  The binding affinity of the inhibitor 
to the imperative active site residues and metal ions should improve with the drop in pH. 
The therapeutic targets neuraminidase and endonuclease, are exceptional focal points in the 
effort to treat influenza A viral infections.  The evolutionary capability of neuraminidase 
remains a conundrum, which requires constant vigilance and monitoring to prevent future 
pandemics.  Endonuclease inhibition is an ideal target being responsible for initiating the ‘cap-
163 
 
snatching’ mechanism in protein synthesis.  Furthermore, the enzyme shares a conserved 
protein sequence identity in the different types and subtypes of influenza viruses.  Thus 
potential inhibitors would have a broad spectrum anti-viral activity. 
8.2 Future work  
 
The World Health Organisation has been on high alert since the 2006 outbreak of the highly 
transmissible and infectious H5N1, avian flu.  The virus stoked the fears of the world as natural 
evolution of the strain overcame cross-species barriers, infecting both birds and humans alike 
with detrimental consequences.  The realisation of the human population being vulnerable to 
such infections heightened the urgency for new chemoprophylaxis 1.   
In order for this pre-emptive effort to be successful, researchers must be able to predict possible 
antigenic variations of influenza strains.  The drawback of this technique lies in the fact that 
not all highly resistant, highly transmissible and highly virulent strains of the influenza virus 
have been expressed.  Drug design relevant to these potential strains seems a never ending 
game of “cat and mouse”.  This study has accentuated the reliability, usefulness and dynamic 
capacity that computational techniques lend to the pharmaceutical, medicinal, biological and 
biochemical industries.   
Molecular dynamics simulations, binding free energy calculations and other post-dynamic 
analyses have demonstrated their ability to provide insurmountable evidence in explaining the 
resistance mechanisms of complex systems 2.  Three-dimensional detail of protein structures, 
such as protein folding can be elucidated.  Further to this, the structural and conformational 
effects mutations have on protein complexes can also be determined 3.  The potential success, 
effectiveness and design of drugs based on prerequisite structure-based or ligand-based 
pharmacophore anomalies, can timeously and easily be interpreted.  Going forward, 
computational studies would be an indispensable tool in reducing resources by: 
1) understanding the mode of action and resistance mechanism of critical enzyme targets; 
2) acting as a preface to screen the design and efficacy of drugs prior to synthesis; 
3) providing an atomistic perspective of the structural and conformational detail of 
proteins bound or unbound; and  
4) being used as a reliable and accurate comparative tool. 
164 
 
With regard to the systems evaluated in this thesis, a purely computational perspective was 
used.  Further investigation into the synthesis of the scaffold of compounds isolated from the 
in silico studies of potential drug candidates of neuraminidase can be performed.  Enhancement 
and pharmacophore expansion of the scaffolds into a family of compounds may lead to the 
discovery of more potent chemotherapeutic agents of influenza.    
Endonuclease inhibitors, as mentioned earlier have exhibited duality in their therapeutic 
activity as anti-cancer agents.  Comparative research in: 
1) understanding the mode of action; and 
2) structural similarities, of endonuclease and the therapeutic targets of cancer would offer 
exceptional insight into the behaviour of the proteins and provide possible 
pharmacophoric features in the design and development of new drug candidates 4. 
Further research should be invested in targeting hemagglutinin and the M2 ion channels.  The 
computational software tool, Discovery Studio maybe used to model the glycoprotein structure 
and proton channel 5.  In doing so, the mode of action of each protein may be described and a 
possible mechanism of inhibition may be suggested.  The software is further capable of 
designing and screening potential drug candidates which would adhere to the pharmacophore 
outlined from determining the mechanism of inhibition.  ESI/Q-tof hybrid techniques can be 
employed to test the design of the M2 ion channel inhibitors.  This is achieved by constructing 
a bilipid layer resembling the endosome, with an induced potential difference across the bilayer 
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